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Community	development	and	activity	is	critically	dependent	on	communication	
between	individuals.	Likewise,	proper	growth	and	functioning	of	multicellular	
organisms	requires	communication	between	cells.	In	this	process,	extracel-
lular	stimuli	that	trigger	the	correct	cellular	responses	through	the	activation	of	
specific	intracellular	signalling	pathways	play	a	pivotal	role.	A	key	mechanism	in	
cellular	signal	transduction	is	the	reversible	tyrosine	phosphorylation	of	
proteins,	exerted	by	the	concerted	action	of	two	classes	of	enzymes:	protein	
tyrosine	kinases	(PTKs)	that	catalyse	the	addition	of	a	phosphate	group	to	a	
tyrosine	residue,	and	protein	tyrosine	phosphatases	(PTPs)	that	remove	that	
phosphate	group	again.	Although	the	number	of	genes	in	the	human	genome	
that	encode	PTPs	roughly	equals	that	of	PTK-encoding	genes,	our	knowledge	
on	products	of	PTP	genes	is	lagging	behind	that	on	PTK	genes	[1,	2].	Partly		
this	can	be	explained	by	the	fact	that	PTKs	were	discovered	earlier	than	PTPs.	
In	addition,	immediately	after	their	discovery,	the	role	of	PTKs	was	coupled		
to	disease.	Mutant	forms	of	PTKs	were	found	encoded	by	the	genomes	of	tumour	
viruses	and	PTK	signalling	pathways	appeared	constitutively	activated	in		
malignant	cells.	In	contrast,	around	the	time	of	their	first	identification	[3]		
PTPs	were	merely	regarded	as	“housekeeping”	proteins	that	served	to	terminate	
intracellular	signalling	initiated	by	PTKs.	This	view	has	changed	considerably		
over	the	past	decade.	Nowadays,	PTPs	are	known	as	downstream	counter-
actors	but	also	as	upstream	activators	of	PTKs.	Furthermore,	we	now	know	
that	PTP	activity	is	subjected	to	regulatory	principles	as	well	and,	importantly,	
mutations	in	PTP	genes	are	causative	or	directly	involved	in	several	develop-
mental	and	acquired	disorders,	including	several	forms	of	cancer	[4].	Thus,	
PTPs	perform	much	more	complex	roles	in	intracellular	signalling	than	initially	
anticipated.	However,	the	physiological	function(s)	of	most	PTPs	still	
remain(s)	to	be	disclosed.
	 This	thesis	provides	an	overview	of	our	studies	on	PTPs	that	belong	to	the	
protein	tyrosine	phosphatase	receptor-type	R	(PTPRR)	isoform	family.	Using	
cell	and	animal	models,	information	about	the	function	of	these	proteins	in	
 • General introduction
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cellular	signalling	and	control	of	locomotion	was	obtained.	Before	presenting	
this	work,	I	will	first	introduce	the	reader	to	signalling	mechanisms	and	
components	that	are	generally	relevant	for	studies	described	in	the	upcom-
ing	chapters.
Receptor tyrosine kinase signalling
Many	fundamental	cellular	processes	like	cell	growth,	differentiation,	meta-
bolism	and	survival	are	regulated	by	extracellular	growth	factors	or	cytokines.	
Since	these	factors	are	unable	to	pass	the	hydrophobic	cell	membrane,	they	
exert	their	effects	via	binding	to	cell	surface	receptors.	One	such	receptor	
family	consists	of	the	so-called	receptor	tyrosine	kinases	(RTKs)	that	have	an	
intrinsic	protein	tyrosine	kinase	activity	[5].	RTKs	are	single	membrane	
spanning	proteins	consisting	of	an	intracellular	kinase	domain	and	an	extra-
cellular	ligand-binding	domain	that	is	usually	glycosylated.	This	extracellular	
part	often	contains	one	or	multiple	copies	of	Ig-like,	fibronectin	type	III-like,	
EGF-like	or	cysteine-rich	domains	[6].	In	general,	ligand	binding	to	RTKs	
induces	dimerisation	of	these	receptors	resulting	in	autophosphorylation	of	
two	different	classes	of	tyrosine	residues	in	their	cytosolic	domains.	Auto-
phosphorylation	of	tyrosine	residues	within	the	kinase	domain	increases	the	
kinase	activity	and	precedes	phosphorylation	of	other	tyrosine	residues	that	
are	localized	outside	the	kinase	domain	[7,	8].	These	latter	phosphotyrosines	
function	as	binding	sites	for	SH2	(Src	homology	2)	or	PTB	(phosphotyrosine	
binding)	domain-containing	proteins.	Binding	provides	a	mechanism	for	the	
assembly	and	recruitment	of	downstream	signalling	complexes.	Depending		
on	the	type	of	RTK	that	is	activated,	many	different	signalling	pathways	(e.g.		
the	STAT,	PLCγ,	MAPK,	PI3-K	or	Cdc42	cascade)	can	be	switched	on	[5].		
As	an	example	of	RTK	signalling,	the	working	mechanism	of	the	TrkA	signal	
transduction	cascade	will	be	described	in	detail.	
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The signalling cascade initiated by TrkA neurotrophin receptor 
The	neurotrophin	receptor	family	is	comprised	of	the	tropomyosin-related	
kinases	TrkA,	TrkB	and	TrkC	and	plays	an	important	role	in	neuronal	signal	
transduction	[9].	The	first	discovered	neurotrophin,	the	nerve	growth	factor		
(NGF),	was	shown	to	bind	to	and	activate	the	complex	glycosylated	TrkA	receptor	
[10].	Like	for	other	RTKs,	N-linked	glycosylation	of	the	extracellular	domain	is		
necessary	to	prevent	TrkA	from	ligand-independent	activation.	Glycosylation	
also	aids	in	the	targeting	of	the	receptor	to	the	plasma	membrane	[11].	Ligand-
induced	TrkA	activation	(Figure	1)	results	in	the	phosphorylation	of	several	
different	tyrosine	residues	inside	and	also	outside	the	activation	loop	within	the		
kinase	domain.	Site-specific	binding	of	adaptor	proteins	to	these	newly	formed	
phosphotyrosine	residues	enables	the	activation	of	the	PLCγ,	PI3-K	and	ERK1/2	
cascade,	respectively	[9].	The	activation	of	the	ERK1/2	signalling	cascade	
following	NGF-induced	TrkA	dimerisation	will	be	described	below	in	more	
detail.	Studies	in	neuroendocrine	PC12	cells	of	rat	demonstrated	that	TrkA	sig-
nalling	promotes	survival	as	well	as	differentiation	in	these	cells.	Distinction	
between	these	two	responses	is	governed	by	receptor	endocytosis	[12].	The	
NGF-stimulated	survival	response,	mediated	through	the	PI3-K	cascade,	is	
blocked	when	endocytosis	is	absent	[13].	Thus,	TrkA	can	activate	different	
signalling	cascades	depending	on	whether	it	is	internalised	or	whether	it	
remains	at	the	plasma	membrane.	
Mitogen-activated protein kinases
Mitogen-activated	protein	kinase	(MAPK)	signalling	pathways	are	amongst	the		
most	extensively	studied	communication	cascades	in	cells.	MAPK-mediated		
signalling	is	instrumental	in	the	transduction	of	external,	mostly	growth	factor-
derived,	signals	into	processes	like	cell	growth,	migration,	proliferation,	
differentiation,	and	survival	[15,	16].	MAPK	pathways	are	organised	into	three	
layers	of	consecutive	acting	kinases	comprising	a	MAP	kinase	kinase	kinase	
(MAPKKK),	a	MAP	kinase	kinase	(MAPKK)	and	the	effector	MAP	kinase	itself	
(Figure	2).	MAPKs	are	serine/threonine	kinases	that	are	highly	conserved	
throughout	all	eukaryotic	cells	and	continuously	shuttle	between	the	nucleus	
and	the	cytoplasm.	Once	activated,	they	can	phosphorylate	a	wide	range	of	
cytosolic	and	nuclear	substrates.	MAPKs	are	classified	into	conventional	and		
atypical	enzymes,	based	on	their	ability	to	be	activated	by	MAPKKs.	Conven-
tional	MAPKs	comprise	the	extracellular	signal-regulated	kinases	1,	2	and	5	
(ERK1/2	and	ERK5),	the	c-Jun	amino-terminal	kinases	(JNK1/2/3)	and	the	p38	
proteins	(p38α/β/γ/δ)	(Figure	2).	These	MAPKs	all	contain	the	signature		
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Figure 1 • TrkA receptor-mediated 
signal transduction pathways. 
Binding of NGF to TrkA leads to re-
ceptor dimerisation and activation 
through autophosphorylation.Sub-
sequent recruitment of adaptor 
proteins to the different phospho-
tyrosine residues within the TrkA 
molecules results in the activation  
of PI3-K, PLCγ and MAPK signalling 
cascades. Adaptor protein Shc 
activates Ras/Rap1 through Grb-2 
and Sos. Subsequent activation of 
Raf, MEK1/2 and ERK1/2 ultimately 
leads to changes in gene expression 
due to the phosphorylation of down-
stream transcription factors [14].
C
h
a
p
te
r1
1
28 • Yao Z, Seger R: The mole-
cular mechanism of MAPK/ERK 
inactivation. Curr Genomics 2004, 
5(4):1-9.
29 • Stork PJ: Directing NGF’s 
actions: it’s a Rap. Nat Cell Biol 
2005, 7(4):338-339.
30 • Andersen JN, Mortensen OH, 
Peters GH, Drake PG, Iversen LF, 
Olsen OH, Jansen PG, Andersen 
HS, Tonks NK, Moller NP: 
Structural and evolutionary 
relationships among protein 
tyrosine phosphatase domains. 
Mol Cell Biol 2001, 21(21):7117-7136.
31 • Ducruet AP, Vogt A, Wipf P, 
Lazo JS: Dual specificity protein 
phosphatases: therapeutic 
targets for cancer and 
Alzheimer’s disease. Annu Rev 
Pharmacol Toxicol 2005, 45:725-750.
32 • Chirivi RG, Dilaver G,  
van de Vorstenbosch R, 
Wanschers B, Schepens J,  
Croes H, Fransen J, Hendriks W: 
Characterization of multiple 
transcripts and isoforms derived 
from the mouse protein tyrosine 
phosphatase gene Ptprr.  
Genes Cells 2004, 9(10):919-933.
33 • Braithwaite SP, Paul S,  
Nairn AC, Lombroso PJ: Synaptic 
plasticity: one STEP at a time. 
Trends Neurosci 2006, 29(8): 
452-458.
34 • Sallee JL, Wittchen ES, 
Burridge K: Regulation of cell 
adhesion by protein-tyrosine 
phosphatases: II. Cell -cell 
adhesion. J Biol Chem 2006, 
281(24):16189-16192.
35 • Burridge K, Sastry SK,  
Sallee JL: Regulation of cell 
adhesion by protein-tyrosine 
phosphatases. I. Cell -matrix 
sequence	TxY	in	their	so-called	activation	loop	[17].	Phosphorylation	on	both	
the	tyrosine	and	the	threonine	residue	within	the	signature	sequence	is	
essential	for	MAPK	activation	and	this	is	achieved	through	the	dual	kinase	
specificity	of	MAPKKs.	These	MAPKKs	in	turn	need	to	be	phosphorylated	and	
activated	by	upstream	serine/threonine	kinases,	the	MAPKKKs.	However,	
not	all	MAPKs,	notably	ERK3/4/7	and	NLK	are	regulated	in	this	way.	The	
regulation	and	physiological	function	of	these	atypical	MAPKs	has	recently	
been	reviewed	[18]	and	is	a	topic	which	is	beyond	the	scope	of	this	thesis.	
	 ERK1	and	ERK2	are	ubiquitously	expressed	MAPKs	that	are	involved	in	cell	
proliferation	and	differentiation.	Many	different	stimuli	-	including	growth	
factors,	neurotrophic	factors	and	environmental	stress	-	can	activate	ERK1/2,	
which	then	phosphorylate	cytosolic	(e.g.	p90RSK)	or	nuclear	(e.g.	Elk-1,	c-
Myc)	proteins	[19,	20].	In	vivo	experiments	demonstrated	an	important	role	for	
these	MAPKs	in	mesoderm	formation	and	synaptic	plasticity	[16].	ERK5,	also	
known	as	Big	MAPK1	(BMK1),	is	activated	in	cells	after	oxidative	stress	or	
treatment	with	growth	factors.	This	protein	can	phosphorylate	substrates	
including	MEF2	and	c-Fos.	Like	ERK1/2,	ERK5	is	also	involved	in	cell	prolifera-
tion	and	in	neuronal	differentiation,	albeit	at	later	stages	of	neural	develop-
ment	[21].	The	p38	MAPKs	are	activated	in	immune	cells	by	inflammatory	
cytokines	and	play	an	important	role	in	the	control	of	cytokine	expression.	In	
non-immune	cells,	p38	proteins	can	be	activated	by	other,	stress-related,	
stimuli	such	as	osmotic	shock	and	heat	shock	[22].	The	JNKs	were	character-
ised	as	stress-activated	protein	kinases	and	as	the	enzymes	involved	in	
phosphorylation	of	the	transcription	factor	c-Jun.	Nowadays,	many	other	
substrates	are	known	to	be	phosphorylated	by	JNKs,	implicating	these	MAPKs	
in	the	regulation	of	cellular	processes	like	apoptosis,	transformation	and	
differentiation	[15,	23].
	 Spatio-temporal	control	of	MAPK	signalling	activity	is	well	recognised	as		
a	key	determinant	of	the	final	cellular	response	triggered	by	the	ligand-induced	
activation	of	an	RTK.	Elegant	studies	in	the	paradigm	PC12	cell	model	(Figure	3)		
have	provided	some	insight	into	this	type	of	regulation	[25,	26].	Epidermal	
growth	factor	(EGF)	signalling	via	its	receptor	(EGFR),	for	example,	induces	a		
rapid	and	transient	ERK1/2	activation	in	the	cytosol	of	PC12	cells	mediated	via		
the	small	G	protein	Ras.	This	sequence	of	events	will	culminate	in	cell	pro-
liferation.	NGF-induced	activation	of	TrkA,	on	the	other	hand,	leads	to	differen-
tiation	of	PC12	cells	into	sympathetic	neurons	and	involves	a	slower,	sustained,	
activation	and	subsequent	translocation	of	ERK1/2	to	the	nucleus.	An	explana-
tion	for	this	difference	in	EGF	and	NGF-induced	MAPK	activation	is	provided	by	
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Figure 2 • The conventional MAPK 
pathways. 
MAP kinases can be activated by  
a wide variety of extracellular stimuli 
through a cascade of upstream 
kinases that ultimately leads to the 
dual phosphorylation of a tyrosine (Y) 
and a threonine (T) residue in the 
activation loop of the MAPKs. Once 
phosphorylated, MAPKs phospho-
rylate cytoplasmic and nuclear 
proteins, which then control a wide 
variety of cellular processes.  
Adapted from reference [24].
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the	fact	that	activated	TrkA,	in	sharp	contrast	to	EGFR,	not	only	signals	through		
Ras	but	-	upon	being	endocytosed	and	retrogradely	transported	towards	the		
cell’s	interior	-	also	activates	the	small	G	protein	Rap1.	When	this	latter	
signalling	cascade	is	switched	on	it	causes	the	sustained	activation	and	nuclear	
translocation	of	ERK1/2.	In	conclusion,	not	only	the	kinetics	but	also	the	
subcellular	localisation	of	MAPK	activity	determines	the	biological	outcome	of	
signalling	events.	This	imposes	an	important	regulatory	role	on	proteins	that	
can	bind	and/or	inactivate	MAPKs.
	 Since	phosphorylation	of	both	regulatory	residues	within	the	MAPK	
signature	sequence	(pT-X-pY)	is	required	for	activation,	dephosphorylation	of	
either	one	already	suffices	for	inactivation.	Thus,	in	principle,	termination	of	
MAPK	signalling	can	be	achieved	by	phosphatases	that	are	either	serine/thre-
onine-specific	(PP	phosphatases),	tyrosine-specific	(classical	PTPs)	or	of	the	
dual-specificity	type	(dual	specificity	phosphatases;	DSPs)	[24,	27,	28].
Protein tyrosine phosphatases
Both	the	classical	PTPs	and	the	DSPs	belong	to	the	PTP	protein	superfamily	
that	is	defined	by	the	active	site	signature	motif	within	the	catalytic	core	of	
these	enzymes	(HCX5R;	the	cysteine	residue	is	essential	for	catalysis)	[2,	30].		
The	DSPs	represent	a	very	heterogeneous	group	of	phosphatases	with	regard		
to	their	preferred	substrates.	Some	members	are	phosphotyrosine/phospho-
threonine-specific,	whereas	others	target	phosphoserine	residues	or	even	
non-protein	phospholipid	substrates.	This	group	of	phosphatases	has	been	
reviewed	by	others	[31]	and	will	not	be	further	discussed	here.	Classical	PTPs		
are	strictly	phosphotyrosine-specific	enzymes	and	the	corresponding	genes	
are	usually	subdivided	in	receptor-type	and	non-receptor-type	PTP-encoding	
ones	(Figure	4).	This	is	not	an	absolute	distinction,	however,	because	alterna-
tive	promoter	use	and	alternative	splicing	events	make	that	several	PTP	genes	
(e.g.	Ptprr	and	Ptpn5	in	mice)	give	rise	to	receptor-type	as	well	as	non-receptor-
type	PTP	isoforms	[32,	33].
	 Receptor-type	PTPs	(RPTPs)	have	a	single	transmembrane	domain	and	
variable	extracellular	domains	which	very	often	display	features	of	cell-
adhesion	molecules.	Several	of	these	RPTPs	indeed	have	been	implicated	in	
cell-cell	and	cell-matrix	adhesion	events	[34,	35].	The	intracellular	segment	
of	most	RPTPs	harbours	two	tandem	PTP	domains.	Enzymatic	activity	resides	
mainly	in	the	first,	membrane-proximal,	domain	(D1).	The	membrane-distal	
D2	domain	is	mostly	catalytically	inactive	and	rather	serves	in	the	regulation	
of	activity,	specificity	and	stability	of	the	entire	RPTP	[36-38].	About	one	third	
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Figure 3 • Different kinetics of ERK 
activation in PC12 cells. 
EGF treatment results in a rapid 
transient activation of ERK in the 
cytoplasm that involves Ras, and  
will lead to proliferation of the neuro-
endocrine PC12 cells ( left part). NGF 
stimulation induces a sustained ERK 
activation that can be viewed as the 
sum of the short-term Ras-mediated 
effects and a long lasting signal 
exerted via Rap1. The subsequent 
translocation of ERK into the 
nucleus leads to PC12 cell diffe-
rentiation into sympathetic neurons 
(right part). Nuclear and cytoplasmic 
ERK activity is displayed as gray 
colourings within the cells. Adapted 
from references [25] and [29].
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of	the	RPTPs	has	only	a	single,	active	PTP	domain	(Figure	4).	IA2	and	IA2β	form	
exceptions	to	this	rule	because	non-conservative	substitutions	in	their	single	
PTP	domain	preclude	any	phosphatase	activity	[39].	Non-receptor-type	PTPs	
all	contain	a	single,	catalytically	active	PTP	domain	that	is	flanked	(in	most	
cases	at	the	N-terminal	side)	by	regulatory	sequences	which	control	the	
subcellular	distribution,	substrate	specificity	and	enzymatic	activity	of	the	PTP	
in	a	direct	or	indirect	way	(Figure	4).	The	wide	variety	of	additional	protein	
domains	as	present	within	these	non-receptor-type	PTP	enzymes	is	viewed	as	
evidence	for	their	highly	diverse	and	specialised	roles	in	cellular	functioning	
[40-44].	
Tyrosine-specific MAPK phosphatases
In	humans	a	subset	of	eleven	DSPs,	collectively	known	as	MAP	kinase	phospha-
	tases	(MKPs),	were	found	to	be	especially	suited	to	bind,	dephosphorylate	and	
thus	inactivate	MAPKs	(reviewed	in	[46]).	In	addition,	three	genes	have	been	
identified	in	man	that	encode	classical,	tyrosine-specific	PTPs	capable	of	
binding	and	inactivating	MAPK	family	members:	PTPN5,	PTPN7	and	PTPRR	[47].	
	 Alternative	splicing	of	PTPN5	transcripts	gives	rise	to	the	STEP	(striatal-
enriched	phosphatase)	family	of	enzymes	that	comprises	membrane-associated	
(STEP61)	and	cytosolic	(STEP46)	isoforms	[33].	Proteolytic	cleavage	of	STEP61	
after	hypoxia	or	glutamate	stimulation	generates	an	additional	isoform,	STEP33		
[48,	49].	As	the	name	indicates,	STEP	isoforms	are	brain-specific	with	highest		
expression	levels	in	striatum	[50,	51].	Intriguingly,	STEP	proteins	also	recog-
nize	substrates	other	than	MAPKs,	namely	the	Src-family	kinase	Fyn	and	NMDA-
	receptor	subunits	[52,	53].	The	current	belief	is	that,	by	regulating	MAPK,	Fyn	
and	NMDA	receptor	phosphorylation	status,	STEP	activity	opposes	the	
development	of	synaptic	plasticity	[33].	
	 PTPN7	encodes	a	38kDa	cytosolic	protein	that	is	mainly	expressed	in	the		
thymus,	spleen	and	all	hematopoietic	lineages.	This	product	has	been	named	
HePTP	(Hematopoietic	PTP)	or	LC-PTP	(Leukocyte-phosphotyrosine	phospha-
tase)	[54,	55].	The	use	of	cell	and	animal	models	has	revealed	that	HePTP	
performs	a	negative	role	in	T-cell	signalling	by	down-regulating	MAPK	activity	
[56-58].
	 PTPN5,	PTPN7	and	PTPRR-encoded	PTPs	all	have	in	common	the	presence	
of	a	16	amino	acids	kinase	interaction	motif	(KIM)	that	is	located	just	N-terminal	
of	the	phosphatase	domain	and	is	required	for	the	association	with	MAPKs.		
In	part	the	KIM	sequence	also	determines	the	binding	specificity	of	a	given	PTP	
towards	the	various	MAPKs	[59,	60].	Association	specificity	is	also	influenced	
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Figure 4 • The phosphotyrosine-
specific PTP superfamily. 
Schematic diagrams of represen- 
tative members for each classical 
receptor-type and non-receptor- 
type PTP subfamily, as classified by 
the features of their non-catalytic 
domains. For each of the 38 
mammalian PTP genes a single cor-
responding protein is listed except 
for the genes PTPN5 (STEP61 and 
STEP46) and PTPRR (PTPBR7,  
PTP-SL and PTPPBSγ, in bold). 
Adapted from references [45] and 
[30].
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by	a	small	sequence,	the	so-called	kinase	specificity	sequence	(KIS),	that	is	
located	in	between	the	KIM	and	the	PTP	domain	[61].	KIM-mediated	binding	to		
the	docking	site	on	a	MAPK	enables	the	active	site	in	the	phosphatase	to	interact		
with	the	phosphorylated	activation	loop	of	the	MAPK,	leading	to	the	dephos-
phorylation	of	the	regulatory	tyrosine	residue	and	inactivation	of	the	MAPK		
[62,	63].	As	a	substrate,	the	tyrosine-specific	MAPK	phosphatases	(MAPK-PTPs)	
prefer	ERK1/2/5	and	p38	over	JNK	[60,	61,	64].	Intriguingly,	overexpression	of		
MAPK-PTPs	demonstrated	that	they	not	only	are	able	to	inactivate	MAPKs	but		
that	their	binding	also	prevents	the	translocation	of	the	MAPKs	into	the	nucleus	
[60,	65,	66]	(Figure	5).	Furthermore,	upon	binding	to	activated	MAPKs,	the		
MAPK-PTP	itself	first	becomes	phosphorylated	by	the	MAPK	(on	a	threonine		
residue	just	outside	the	KIM	domain)	before	it	act	to	dephosphorylate	the	
protein	[59].	Importantly,	the	interaction	between	the	two	proteins	is	regulated	
by	PKA.	Phosphorylation	of	a	conserved	serine	residue	within	the	KIM-domain,	
which	can	be	reversed	by	PP1	[67,	68],	abolishes	the	binding	and	subsequent	
dephosphorylation	of	MAPKs	and	results	in	the	release	of	MAPKs	to	the	nucleus	
[65,	69]	(Figure	5).	This	PKA-mediated	regulatory	principle	also	holds	for	most	
of	the	dual-specificity	MKPs	that	contain	a	KIM-like	domain	[46].	
Regulation of PTP activity
Regulation	of	PTK	activity	has	been	extensively	studied,	especially	for	the	RTKs,	
but	until	a	decade	ago	very	little	was	known	about	regulatory	mechanisms	
controlling	PTP	activity.	Since	then	several	different	mechanisms	that	may	
regulate	PTP	activity	have	been	put	forward	[44].
	 Like	for	RTKs,	it	has	been	proposed	that	RPTP	activity	is	regulated	via	
dimerisation.	For	a	number	of	RPTPs	it	was	indeed	found	that	their	ectodo-
mains	have	the	potential	to	interact	with	homophilic	and	heterophilic	ligands	
[41].	Yet,	only	the	binding	of	pleiotrophin	to	RPTPζ	thus	far	serves	as	a	natural	
example	for	ligand-dependent	RPTP	dimerisation,	in	this	case	resulting	in	
inactivation	of	the	phosphatase	[70,	71].	Artificial	ligand-induced	dimerisation	
of	the	RPTPs	CD45	and	DEP-1	leads	to	a	decreased	or	an	increased	activity,	
respectively	[72,	73].	Dimerisation	of	the	RPTP	Sap-1	through	the	formation	of		
an	intermolecular	disulfide	bridge	in	the	extracellular	domain	was	found	to	sig-
nificantly	reduce	its	phosphatase	activity	[74].	A	study	on	isolated	RPTP	
transmembrane	(TM)	domains	demonstrated	that	also	TM	homodimerisation	
could	contribute	to	RPTP	regulation	[75].	For	CD45	and	RPTPα	it	has	even	
been	shown	that	the	transmembrane	domain	by	itself	is	sufficient	to	cause	
their	constitutive	dimerisation	[76-78].	
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Figure 5 • Regulation of MAPKs  
by tyrosine-specific MAPK 
phosphatases. 
Extracellular stimuli lead to the acti-
vation of MAPKs. Inactivation of 
MAPKs in the cytosol, and the pre-
vention of their nuclear transloca-
tion, is regulated in part through 
binding to the KIM-domain of MAPK-
PTPs and subsequent dephosphory-
lation of the phosphotyrosine residue 
within the MAPK. The association  
of the two proteins is regulated via 
reversible phosphorylation of a  
serine residue within the KIM-
domain by the concerted action  
of cAMP-dependent protein kinase 
(PKA) and Ser/Thr-protein phos-
phatase-1 (PP). 
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Intracellular	regions,	like	the	PTP	domains	D1	and	D2,	may	also	contribute	to	
RPTP	dimerization	[38].	Intra-	and	intermolecular	interactions	that	result	
from	binding	of	D2’s	to	D1’s	were	found	to	either	inhibit	or	increase	the	catalytic	
activity	of	the	latter	[79,	80].	Interestingly,	also	homodimerisation	of	RPTP	D1		
domains	has	been	noted.	The	first	report	stems	from	a	crystallographic	study		
on	RPTPα−D1	domains,	where	a	wedge-like	motif	in	one	D1	domain	was	found	
to	bind	and	sterically	block	the	catalytic	site	of	the	other,	and	vice	versa,	there-		
by	abrogating	all	catalytic	activity	[81].	However,	crystallographic	data	on		
recombinant	LAR,	CD45	and	RPTPµ	PTP	domains	did	not	reveal	such	intermole-
cular	interactions.	This	suggests	that	regulation	of	phosphatase	activity	by		
dimerisation	involving	a	wedge-like	structure	is	not	a	general	phenomenon		
[82-84].
	 The	catalytic	site	cysteine	residue	in	PTPs	is	extremely	reactive	and	as	a		
consequence	very	vulnerable	to	oxidation.	Susceptibility	to	reactive	oxygen	
species	(ROS)	thus	represents	the	Achilles’	heel	of	PTP	signalling.	The	pro-
duction	of	ROS	(e.g.	O2ˉ. and	H2O2)	is	induced	by	many	physiological	stimuli	
including	growth	factors	and	cytokines	and	evidence	is	accumulating	that	this	
production	is	mediated	by	the	nicotinamide	adenine	dinucleotide	phosphate	
(NADHP)	oxidase	protein	complex	[85,	86].	Elevation	of	ROS	levels	in	response	
to	RTK	activation	can	indeed	temporally	and	locally	inhibit	PTP	activity	[87,	88].	
For	example,	PDGF	receptor	activation	induced	a	transient	oxidation	of	the	
active	site	cysteine	in	SHP-2,	rendering	it	inactive	[89].	It	is	important	to	note	
that	this	oxidation-induced	inactivation	of	PTPs	by	generating	a	sulfenic	acid	
(PTP-S-OH)	is	in	general	perfectly	and	rapidly	reversible.	The	PTP	domain	
protects	its	core	cysteine	from	being	irreversibly,	multiply	oxidised	by	rapidly	
converting	the	sulfenic	acid	in	a	cyclic	sulphenamide	intermediate.	This	
product	can	than	easily	be	reduced	to	the	catalytically	active	state	again	by	
redu-cing	agents	like	glutathione	[90,	91].	Interestingly,	also	the	conserved	
cysteine	within	the	PTP	signature	sequence	in	inactive	D2	domains	can	be	
exploited	to	regulate	D1	PTP	activity	in	a	redox-dependent	fashion.	Cellular	
oxidative	stress	was	found	to	induce	a	conformational	change	in	RPTPα	D2	
that	resulted	in	the	stabilisation,	and	wedge	domain-mediated	inactivation,		
of	RPTPα	dimers	[92,	93].	
	 It	will	come	as	no	surprise	that	also	phosphorylation	itself	may	represent	
a	way	to	regulate	PTP	activity.	The	activated	insulin	receptor,	for	example,	
phosphorylates	tyrosine	residues	within	PTP1B	that	result	in	an	increase	of	its	
phosphatase	activity	[94].	Phosphorylation	of	a	serine	residue	within	the	KIM-
domain	of	MAPK-PTPs	(e.g.	STEP	and	PTPRR),	on	the	other	hand,	impairs	the	
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binding	to	their	substrate	and	thus	effectively	reduces	their	MAPK-PTP	activity	
(Figure	5)	[33,	65].	Very	recently	also	sumoylation,	a	process	that	primarily	
occurs	in	the	(peri)nuclear	region,	has	been	demonstrated	to	modulate	PTP	
activity.	Insulin-induced	PTP1B	sumoylation	was	found	to	reduce	its	catalytic	
activity,	probably	by	altering	the	conformation	in	such	a	way	that	the	catalytic	
domain	is	blocked	or	is	non-functional	[95].
	 In	contrast	to	the	reversible	processes	mentioned	above,	also	the	irrever-
sible	action	of	proteases	is	involved	in	regulating	PTP	activity.	For	example,	
proteolytic	cleavage	of	PTP1B	by	calpain	in	platelets	results	in	an	increased	
enzymatic	activity	and,	in	addition,	causes	its	subcellular	relocation	from	the	
ER	membrane	into	the	cytosol	[96].	Release	of	RPTP	catalytic	domains	into	the	
cytoplasm	by	intracellular	cleavage	has	been	proposed	as	a	mechanism	to	
protect	membrane-associated	substrates	from	dephosphorylation	by	RPTPs	
[97].	Likewise,	the	extracellular	proteolytic	cleavage,	or	ectodomain	shedding,	
that	is	observed	for	multiple	RPTPs	may	well	serve	to	downtune	ligand-induced	
RPTP	signalling,	perhaps	by	competing	for	ligands	by	the	shedded	‘decoy-
receptor’	[98-100].
Protein tyrosine phosphatase receptor-type R isoforms
One	of	the	three	human	genes	that	encode	KIM-containing	tyrosine-specific	
PTPs	is	the	PTPRR	gene	on	chromosome	12,	band	q15.	Orthologues	have	been	
found	in	many	vertebrate	species,	including	mouse	and	rat.	Homologous	genes		
can	still	be	found	in	distant	species	like	Drosophila	(Table	1)	[101-104].
Table 1 PTPRR nomenclature
Species Homo S. Mus M. Rattus N. Drosophila M.
Gene PTPRR Ptprr Ptprr PTP-ER
Chromosome 
(position)
12q15 10A2 7q22 2(57F)
Protein isoform
PTPPBSα
PTPPBSβ
PTPPBSγ
PTPPBSδ
PTPBR7
PTP-SL
PTPPBSγ-42
PTPPBSγ-37
PCPTP1
PCPTP1-Ce
PTP-ER
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Interestingly,	like	its	human	and	rat	orthologue,	the	mouse	Ptprr	gene	gives	
rise	to	multiple	neuronal	PTPRR	protein	isoforms	(Figure	4)	[32,	100].	Four	
different	transcripts	have	been	identified	in	mouse	(represented	by	PTPBR7,	
PTP-SL,	PTPPBSγ+	and	PTPPBSγ-	cDNAs)	[104-106].	These	products	result	
from	the	differential	use	of	three	distinct	transcription	start	sites	[32,	107]	and	
the	alternative	inclusion	of	a	117	nucleotide	sequence	stretch	in	the	unique	5’	
UTR	of	the	shortest	mRNA	(PTPPBSγ)	[104].	
	 In	situ	hybridization	studies,	Northern	blot	experiments	and	RT-PCR	
analyses	have	yielded	RNA	expression	data	for	these	individual	transcripts.	
PTPBR7	messengers	are	expressed	during	early	embryogenesis	in	spinal	
ganglia	and	Purkinje	cells.	PTP-SL	transcripts	are	not	present	during	prenatal	
development,	but	postnatally	PTP-SL	transcripts	replace	the	decreasing	
PTPBR7	levels	in	Purkinje	cells	[107].	PTPBR7	expression	persists	in	all	other	
brain	regions	after	birth.	Trace	amounts	of	PTP-SL	messengers	are	present	in	
midbrain,	brainstem	and	cortex,	but	high-level	expression	is	exclusively	found	
in	adult	cerebellar	Purkinje	cells.	Intriguingly,	this	cell-specific	expression	
pattern	is	also	observed	in	adult	rat.	The	PTPBR7	orthologue,	PCPTP1,	is	abun-
	dant	in	cerebellum,	midbrain,	cerebral	cortex	and	hippocampus	whereas	the		
PTP-SL	orthologue,	PCPTP1-Ce,	is	exclusively	expressed	in	Purkinje	cells	of		
the	cerebellum	[101,	102].	Mouse	PTPPBSγ	variants	are	expressed	at	extremely	
low	levels	throughout	the	brain.	In	fact,	they	represent	the	only	Ptprr	tran-
scripts	in	non-neuronal	tissues;	trace	amounts	have	been	detected	in	the	
gastrointestinal	tract	and	in	developing	bone	[32,	104].	Unfortunately,	cell	
lines	in	culture	do	not	express	PTPRR-encoding	transcripts.	Thus	far,	only	in	
rat	PC12	cells	a	Ptprr-derived	transcript	has	been	detected,	namely	the	largest	
one	that	encodes	the	receptor-type	protein	isoform	PCPTP1	[101,	108].
	 As	to	be	expected,	the	above	Ptprr	transcripts	give	rise	to	multiple	PTPRR	
protein	isoforms.	Mutagenesis	studies	revealed	exactly	which	AUG	start	codons		
are	being	used	in	the	various	Ptprr	mRNAs.	The	first	startcodon	is	used	in		
PTPBR7	transcripts	but	it	is	primarily	the	second	one	that	is	used	in	the		
PTP-SL	mRNA.	Intriguingly,	the	second	as	well	as	the	third	start	site	in	the		
two	types	of	PTPPBSγ	mRNAs	are	preferred	by	the	ribosomes,	yielding	
isoforms	PTPPBSγ-42	and	PTPPBSγ-37	with	sizes	of	42	and	37	kDa,	respec-
tively.	PTPBR7	and	PTP-SL	are	72	and	60	kDa	in	size,	respectively.	All	four	
isoforms	are	identical	in	their	C-terminal	part,	which	harbours	the	KIM	and		
the	catalytically	active	PTP	domain.	Thus,	the	four	isoforms	differ	in	the	length	
of	their	N-terminal	part	and,	consequently,	have	distinct	subcellular	localiza-
tions	(Figure	6)	[32].	The	receptor-type	PTPBR7	is	a	classical	type-I	trans-
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Figure 6 • Subcellular localisation 
of the different mouse PTPRR 
isoforms. 
The transmembrane proteins PTPBR7 
and PTP-SL are both localised at  
the Golgi apparatus and in late endo-
cytotic compartments. PTPBR7 is 
also present in early endosomes and 
at the plasma membrane, where it 
is subjected to proteolytic cleavage. 
The PTPPBSγ-42 and PTPPBSγ-37 
isoforms are cytosolic proteins. Grey 
arrows indicate general protein 
transport routes, but these are not 
per se the routes followed by the 
PTPRR proteins.
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membrane	protein.	It’s	functional	signal-peptide	is	cleaved	of	in	the	ER	and	a	
second	hydrophobic	segment	further	on	in	the	protein	functions	as	transmem-
brane	anchor.	PTPBR7	is	localized	at	the	cell	membrane,	the	Golgi	apparatus	
and	at	early	and	late	endosomes	[107,	109-111].	PTP-SL	is	also	localized	at		
the	Golgi	and	late	endosomes,	but	it	is	not	present	at	the	cell	surface	or	early	
endosomes	[107,	110,	111].	This	isoform	contains	two	hydrophobic	regions	in		
the	N-terminal	part,	which	led	originally	to	the	prediction	that	PTP-SL	would	be	
a	type-I	transmembrane	protein	also	[105].	However,	subsequent	studies	
revealed	that	the	protein	lacked	a	functional	signal	peptide	sequence	and,	
hence,	PTP-SL	was	suggested	to	be	a	membrane-associated	protein	[107].		
To	clarify	this	issue,	a	direct	assessment	of	PTP-SL’s	membrane	topology	is	
eagerly	awaited.	The	two	smallest	isoforms,	PTPPBSγ-42	and	PTPPBSγ-37,	
are	located	in	the	cytosol	and	essentially	consist	of	the	KIM	and	PTP	domain.	
	 All	four	isoforms	have	a	rather	short	half-life,	of	several	hours,	and	appear	
constitutively	phosphorylated	at	the	serine	residue	within	the	KIM	domain	and/or	
the	threonine	residue	in	between	KIM	and	PTP	domain.	In	addition,	PTPBR7	was	
found	to	be	subjected	to	N-terminal	proteolytic	processing	at	the	cell-surface,	
resulting	in	yet	another,	65-kDa	transmembrane	PTPRR	isoform	[100].	
Biological activities of the PTPRR proteins
As	outlined	above,	PTPRR	isoforms	are	KIM-containing	PTPs.	Transfection	
experiments	indeed	disclosed	their	potential	to	bind,	dephosphorylate	and	
thereby	inactivate	the	ERK1/2/5	and	p38α	MAPKs	[59,	64,	109]	(Figure	5).	
Contrary	to	the	other	two	MAPK-PTPs,	STEP	and	HePTP,	PTP-SL	was	found	to	
bind	ERK1/2	much	more	efficiently	than	p38α.	The	KIS	region	adjacent	to	the	
KIM-domain	turned	out	important	for	this	differential	recognition	of	MAPKs.	
Furthermore,	the	association	of	ERK1/2	and	p38α	to	STEP	or	HePTP	was	found		
to	be	impaired	under	reducing	conditions,	whereas	PTP-SL	binding	to	MAPKs		
appeared	insensitive	to	reducing	agents	[61].	Interestingly,	swapping	experi-
ments	with	the	KIM	domains	of	PTP-SL	and	the	MAPKK	MEK1	yielded	a	
chimaeric	protein,	consisting	of	the	MEK1	kinase	domain	and	the	PTP-SL	KIM,	
which	associated	strongly	with	ERK2	and	displayed	gain-of-function	activity	
towards	this	MAPK.	This	observation	indicates	that	the	PTPRR	KIM	has	a	
higher	affinity	towards	ERK2	than	the	KIM	of	its	upstream	kinase	[112].	It	should	
be	noted	here	that	most	studies	addressing	the	regulation	of	MAPK	signalling	
by	PTPRR	isoforms	actually	made	use	of	a	truncated,	cytosolic	version	of	
PTP-SL	that	closely	resembles	PTPPBSγ-42.	Furthermore,	these	studies	mostly	
involved	ectopic	expression	in	non-neuronal	cells.	Studies	under	more	physi-
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ological	conditions	are	required	in	order	to	shed	light	on	the	actual	regu-
latory	potential	of	PTPRR	isoforms	on	MAPK	signalling	pathways.	Thus	far,		
only	the	effect	of	the	PTPBR7	isoform	on	ERK1/2	activity	has	been	studied	in		
‘a	natural	context’,	i.e.	in	the	PC12	cell.	Analyses,	however,	were	indirect,	using	
the	activity	of	a	MAPK	substrate	as	a	readout,	and	they	required	artificial	
stimuli	such	as	the	co-expression	of	a	constitutively	active	MEK1	mutant	[109].	
Findings	obtained	pointed	to	a	suppressive	effect	on	MAPK	signalling	follow-
ing	PTPBR7	overexpression,	corroborating	the	regulatory	potential	of	PTPRR	
isoforms	on	this	paradigm	signalling	cascade.
	 Crystallographic	and	biochemical	studies	on	the	PTPRR	phosphatase	domain	
provided	evidence	that	this	moiety	functions	as	a	monomeric	structure	[113].		
A	close	comparison	of	the	catalytic	activity	of	the	PTPRR	phosphatase	domain	
with	the	D1	domain	of	another	RPTP,	RPTPµ,	revealed	that	it	has	a	rather	low		
catalytic	efficiency	[113].	This	may	well	be	explained	by	the	observation	that		
the	PTPRR	catalytic	loop	appears	relatively	rigid	and	stable	when	compared	to		
that	of	RPTPµ.	This	arrangement	may	hinder	the	switch	from	the	‘open’	to	the		
‘closed’	conformation	of	the	loop	upon	substrate	binding.	Although	the	KIM		
region	is	not	included	in	the	3D	structure	of	the	PTPRR	PTP	domain,	the	spatial	
information	was	also	used	to	derive	a	hypothetical	model	for	the	interaction	
with	ERK2.	Based	on	this	model,	it	was	concluded	that	the	phosphorylation	of	
PTPRR	is	accomplished	first,	and	only	after	a	conformational	rearrangement	
the	subsequent	dephosphorylation	of	ERK2	takes	place	[113].	The	data	also	
suggest	a	possible	enhancement	of	PTPRR	catalytic	efficiency	upon	binding	to		
the	MAPK	which	would	be	in	line	with	findings	for	MKP-3,	a	dual-specificity	
MAPK	phosphatase	that	demonstrates	a	35-fold	increase	in	activity	upon	ERK2	
binding	[114].	Binding	to	ERK5	indeed	increased	the	catalytic	activity	of	a	
cytosolic	version	of	PTP-SL	[64],	but	PTPRR	activation	due	to	ERK1/2	binding	
has	not	yet	been	reported.
	 Knowledge	on	the	putative	roles	of	PTPRR	isoforms	in	health	and	disease		
is	currently	limited	to	two	reports.	The	first	study	addressed	a	potential	role	
for	the	PTPPBSγ	isoform	in	cartilage	formation	[115].	Using	an	embryonic	
mandibular	explant	culture	model	system	and	antisense	oligodeoxynucleo-
tides,	evidence	was	provided	that	PTPPBSγ	may	regulate	the	rate	of	chondro-
blast	proliferation	in	early	skeletal	development.	The	second	study	implicated	
the	human	PTPRR	gene	in	the	pathogenesis	of	inv(12)-type	leukaemia	[116].	
Exon	4	of	the	TEL	gene	was	found	to	be	fused	to	exon	7	of	the	PTPRR	gene	
resulting	in	a	TEL/PTPRR	chimeric	gene.	This	fusion	gene	generates	10	
different	transcripts	of	which	only	one	encodes	a	chimeric	product	consisting	
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of	the	TEL	transcriptional	repressor	fused	to	a	large	part	of	the	PTPRR	
phosphatase	domain.	This	TEL-PTPRR	fusion	protein,	however,	lacks	
catalytic	activity,	indicating	that	it	is	probably	through	interference	with	the	
functioning	of	wild-type	TEL	that	this	chimera	causes	the	leukaemia	pheno-
type	[116].	
Outline of this thesis 
The	principle	aim	of	my	Ph.D.	research	was	to	elucidate	the	signalling	role	of		
the	PTPRR	subfamily	of	tyrosine-specific	phosphatases.	The	finding	that	a		
PTPRR-encoding	messenger	is	temporally	up-regulated	after	NGF-induced	
sustained	ERK1/2	activation	in	PC12	cells	[108]	and	the	potency	of	PTPRR	
isoforms	to	associate	with	these	MAPKs	[59,	60,	65]	prompted	for	an	investi-
gation	of	the	role	of	this	protein	family	in	the	spatial	and	temporal	control	of	
MAPK	signalling.	Rat-derived	PC12	cells,	in	which	PTPRR	proteins	were	
overexpressed	or	depleted,	were	used	as	the	paradigm	cell	model	for	these	
studies	(chapter	2).	As	an	alternative	approach	to	gain	more	insights	in	the	
physiological	role	of	PTPRR	isoforms,	we	decided	to	generate	PTPRR	deficient	
mice	via	homologous	recombination	in	embryonic	stem	cells	(chapter	3).	We	
monitored	the	phosphorylation	levels	of	several	different	proteins	involved	in	
MAPK	signalling	and	looked	at	the	brain	morphology	of	the	PTPRR	deficient	
brain	as	well.	Behavioural	studies	were	performed	with	these	Ptprr-/-	mice	to	
test	their	motor	coordination	and	balance	skills.	In	addition,	we	investigated	
possible	regulatory	mechanisms	that	may	act	on	PTPRR	activity	(chapter	4).	
We	first	elucidated	the	membrane	topology	of	PTP-SL	using	a	selective	cell-
permeabilisation	method	in	combination	with	dedicated	antisera	directed	
against	PTPRR	domains.	We	next	investigated	whether	the	PTPRR	isoforms	
were	able	to	form	homo-	and	hetero-multimers	and	which	PTPRR	domains	are	
responsible	for	this	phenomenon.	Possibly	altered	PTPRR	activities	caused		
by	multimerisation	were	also	tested.	In	chapter	5	we	examined	the	association	
of	the	PTPRR	proteins	with	the	neurotrophic	receptor	TrkA	and	investigated		
the	role	of	these	PTPs	in	TrkA	maturation	and	signalling.	Finally,	all	results	
described	in	the	various	chapters	are	discussed	in	a	broader	context	in	
chapter	6.
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 • Abstract
Spatio-temporal control of extracellular signal-regulated kinase (ERK) 
activity, a critical determinant of the cell’s response to growth 
factors, requires timely dephosphorylation of its regulatory tyrosine 
and/or threonine residue by MAPK phosphatases. We studied the 
physiological role of kinase interaction motif (KIM)-containing protein 
tyrosine phosphatases (PTPs) in the control of EGF- and NGF-induced 
ERK activity in neuroendocrine PC12 cells. We found a single KIM-
containing PTP to be endogenously expressed in rat PC12 cells: the 
transmembrane PTPRR isoform termed PCPTP1. Protein knock-down  
of PCPTP1, or fourfold overexpression of its mouse orthologue, PTPBR7, 
left EGF- and NGF-induced ERK1/2 activity in PC12 cells unaltered. 
Ectopic expression of cytosolic PTPRR isoforms, however, resulted in 
reduced EGF-induced ERK1/2 activity, an effect that was dependent 
on the phosphatase activity and the KIM-domain of these PTPs.  
The finding that robust changes in tyrosine-specific MAPK phosphatase 
expression levels have minor effects on temporal ERK1/2 activity 
control in PC12 cells suggests that dual-specificity MAPK phosphatases 
may act as major regulators of growth factor-induced ERK1/2 signalling 
in these cells.
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One	of	the	best-studied	cellular	signalling	relays	is	the	mitogen-activated	
protein	kinase	(MAPK)	signalling	cascade,	the	central	mechanism	by	which	
growth	factors	steer	cellular	key	decisions	such	as	proliferation	and	differen-	
tiation	[1].	It	has	become	clear	that	it	is	not	just	the	amplitude	but	also	the	
spatio-temporal	distribution	of	the	MAPK	activity	within	the	cell	that	deter-	
mines	the	final	outcome	of	this	signalling	relay.	For	example,	in	the	rat	PC12	
phaeochromocytoma	cell	line	seminal	studies	have	shown	that	epidermal	
growth	factor	(EGF)-induced	proliferation	relies	on	a	transient	activation	of	
the	extracellular	signal-regulated	kinases	1	and	2	(ERK1/2)	in	the	cytosol,	
whereas	nerve	growth	factor	(NGF)-induced	differentiation	requires	a	sustained	
ERK1/2	activation	and	translocation	to	the	nucleus	[2,	3].	Thus,	not	only	signal-	
ling	molecules	that	activate	these	ubiquitous	MAPKs	but	also	the	ones	that	
inactivate	and/or	localize	them	are	important	for	determining	signalling	speci-	
ficity.	ERK	activation	requires	the	phosphorylation	of	two	closely	spaced	
regulatory	tyrosine	and	threonine	residues	by	the	dual	specificity	MAP	kinase	
kinases	MEK1/2	[4].	Concomitantly,	ERK	inactivation	involves	dephosphorylation	
of	these	residues	by	MAPK	phosphatases.	Although	the	EGF	and	NGF	specific	
pathways	that	lead	to	ERK	activation	have	been	mapped	in	detail	in	PC12	cells	
[3],	the	contribution	of	MAPK	phosphatases	in	this	model	system	has	received	
little	attention.
	 The	dephosphorylation	of	ERK1/2	regulatory	tyrosine	and	threonine	
residues	can	be	achieved	by	three	different	phosphatase	types:	protein	serine/
threonine	phosphatases,	dual	specificity	(serine/threonine/tyrosine)	
phosphatases	(MKPs/DUSPs)	and	classical	phosphotyrosine-specific	protein	
tyrosine	phosphatases	(PTPs)	[5].	The	latter	two	types	have	gained	consider-
able	interest	because	they	contain	a	so-called	kinase	interaction	motif	(KIM)	
that	is	also	present	in	the	upstream	MAPK	kinases	MEK1/2.	The	KIM-domain	
mediates	the	interaction	and	in	part	determines	binding	specificity	towards	
the	different	MAPKs	[6-8].	Importantly,	this	interaction	can	be	regulated	via	
cAMP	because	PKA-mediated	phosphorylation	of	a	serine	residue	within		
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the	KIM-domain	abolishes	binding	and	dephosphorylation	of	MAPKs	[9,	10].		
	 Mammals	contain	three	classical	PTP	families	that	may	regulate	ERK	
activity	by	KIM-dependent	binding	and	dephosphorylation:	HePTP/LC-PTP,	
STEP	and	PTPRR	(Fig.	1A).	The	haematopoietic	HePTP/LC-PTP	was	indeed	
shown,	through	gene	targeting	studies,	to	be	a	physiological	regulator	of	ERK	
in	lymphocytes	[11]	and	the	striatal-enriched	phosphatase	(STEP)	enzyme	
family	was	found	to	regulate	ERK	activity	in	primary	neuronal	cultures	[12].		
For	PTPRR	isoforms	current	data	mainly	reflect	overexpression	studies		
in	non-neuronal	cells	[6,	9,	13].	Given	that	rat	PTPRR	receptor-type	isoform		
treatment	[14],	a	role	in	neuronal	differentiation	induced	by	sustained	ERK	
activity	may	be	expected.
	 In	the	current	study	we	assessed	the	contribution	of	the	KIM-domain-
containing	classical	PTPs	to	the	regulation	of	ERK	activity	in	rat	PC12	cells.	
HePTP	and	STEP	mRNAs	were	not	detectable	in	PC12	cells.	For	the	PTPRR	
gene	a	single	transcript	type,	encoding	the	transmembrane	isoform	PCPTP1,	
was	encountered.	We	exploited	retroviral	transduction	to	increase	or	decrease	
PTPRR	protein	levels	and	monitored	growth	factor-induced	ERK	activation	
using	phosphospecific	antibodies.	Our	results	demonstrate	that	KIM-domain-
containing	tyrosine-specific	PTPs	are	dispensable	for	proper	ERK-dependent	
signalling	in	PC12	cells	and	put	forward	the	dual-specificity	MAPK	phosphatases	
as	the	physiological	regulators	of	ERK	activity	in	these	cells.		
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RT-PCR 
Total	RNA	from	exponentially	growing	PC12	cells,	rat	cerebellum,	mouse	
cerebrum	or	spleen	was	purified	using	RNazol	B	(Campro	Scientific,	Veenendaal,	
The	Netherlands).	RT-PCR	analyses	were	performed	essentially	as	described	
[15].	Briefly,	cDNA	was	synthesized	from	total	RNA	by	random	hexamer	priming	
using	SuperScriptTM	II	RNase	H-	Reverse	Transcriptase	(Invitrogen	Life	
Technologies,	Breda,	The	Netherlands)	and	used	for	PCR.	Amplified	products	
were	analyzed	on	agarose	gels.	Primers	used	are:		PCPTP1-forward	5’-
CCTCAATGCACACACTATGAGG-3’;	PCPTP1-Ce-forward	5’-CTTCAGCTCGCAGG
CTTTC-3’;	PTPPBSγ	(rat)-forward	5’-GTGCAGGACGTGGAGGAAG-3’;	PTPRR-
reverse	5’-TCCTTCTTTGCTCCAGAT-3’;	STEP-forward	5’-GAGGACTACCGGCTGCGAC-3’;	
	STEP-reverse	5’-GGCTCATGGCGTGGTGCAC-3’;	HePTP-forward	5’-CATCTGCT-
CAGTGAACACACC-3’;	HePTP-reverse	5’-GTCTGCTACAGTGTTGGGC-3’;	β-actin-
forward	5’-GCTAGAGCTGCCTGACGG-3’	and	β-actin-reverse	5’-GAGGCCAGGAT-
GGAGCC-3’.
Plasmids
Subcloning	of	a	XhoI-NotI	fragment	from	pIRES2-eGFP	(Clontech)	into	XhoI-NotI	
digested	retroviral	plasmid	pLXSN	(Clontech)	generated	pLXSN-IRES2-eGFP.	
The	BamHI	site	in	pLXSN-IRES2-eGFP	was	subsequently	used	to	insert	the	BglII	
insert	from	pSG5-PTPPBSγ-FL	[16],	rendering	pLXSN-PTPPBSγ-IRES2-eGFP.	
By	inserting	the	N-terminus-encoding	EcoRI	fragment	from	PTPBR7-eGFP	
[17]	into	EcoRI-digested	pLXSN-PTPPBSγ-IRES2-eGFP	we	generated	pLXSN-
PTPBR7-IRES2-eGFP.	Mutant	pLXSN-PTPPBSγ	constructs	were	generated	as	
follows.	First	mutant	PTP-SL	open	reading	frames	were	excised	from	pRK5-
PTP-SL	expression	vectors	([6]	kindly	provided	by	dr.	R.	Pulido,	Valencia,	
Spain)	using	NotI	and	XhoI,	and	ligated	in	between	the	corresponding	sites		
in	pLXSN.	Using	BstBI	we	subsequently	excised	the	mutation-containing	
sequence	parts	from	the	obtained	plasmids	and	inserted	them	into	BstBI-
digested	pLXSN-PTPPBSγ-IRES2-eGFP.	For	siRNA	constructs,	appropriate	
 • Materials and methods
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oligonucleotides	were	annealed	and	ligated	in	the	pSUPER-Retro	vector	pSR	
[18].	Plasmids	pSR-1211	and	pSR-2380	encode	siRNAs	that	target	the	nucleotides	
1211-1229	and	2380-2398	in	the	PCPTP1	mRNA	[Genbank:D38292],	respectively.	
All	constructs	were	verified	by	sequence	analysis.
Cell culture and retroviral transduction 
PC12	cells	(ATCC	#CRL-1721)	were	grown	on	collagen-coated	dishes	in	DMEM	
supplemented	with	10%	FCS	and	5%	horse	serum	(HS)	at	37°C.	Ecotropic	
Phoenix	packaging	cells	[19]	were	cultured	in	DMEM,	10%	FCS.	For	retrovirus	
production,	Phoenix	cells	were	transiently	transfected	by	calciumphosphate	
precipitation.	Twenty-four	hours	after	transfection,	medium	was	replaced		
by	DMEM	containing	10%	FCS	and	5%	HS.	After	10h	retrovirus-containing	medium	
was	collected,	filtered	through	a	0.45-µm	pore-size	filter	and	supplemented	
with	polybrene	(Sigma-Aldrich	Chemie	B.V.,	Zwijndrecht,	The	Netherlands)	to	
a	final	concentration	of	5	µg/ml.	PC12	cells	were	infected	by	replacing	culture	
medium	with	undiluted	polybrene-	and	retrovirus-containing	medium	for	8-16	h.	
After	four	subsequent	rounds	of	infection,	transduced	cells	were	selected		
for	2-3	weeks	in	medium	containing	500	µg/ml	G418	(Gibco	Europe,	Breda,		
The	Netherlands)	or	2.5	µg/ml	puromycin	(Sigma-Aldrich	Chemie	B.V.),	
respectively.
Immunoblot analysis 
Cells	were	seeded	in	six-well	plates	at	a	density	of	1*106	cells/well.	The	next	
day	medium	was	replaced	by	DMEM	without	serum.	After	o/n	serum	deprivation,	
cells	were	treated	with	0.075-100	ng/ml	EGF	(a	kind	gift	of	Dr.	J.	van	Zoelen,	
Nijmegen,	The	Netherlands)	or	50	ng/ml	NGF	(N6009,	Sigma-Aldrich	Chemie	
B.V.)	for	different	time	periods.	Cells	were	washed	twice	with	ice-cold	
phosphate-buffered	saline	(PBS)	before	being	scraped	with	a	rubber	policeman	
in	75	µl	lysis	buffer:	50	mM	Tris-HCl,	pH	7.5;	150	mM	NaCl;	1%	triton	X-100;		
100	mM	NaF;	2	mM	Na3VO4;	20	mM	Na4P2O7;	1	mM	PMSF;	protease	inhibitor	
cocktail	(Roche	Diagnostics	GmbH,	Mannheim,	Germany).	Lysis	was	continued	
on	ice	for	30	min	and	insoluble	components	were	subsequently	pelleted	by	
centrifugation	for	25	min	at	14.000	rpm	and	4°C.	Supernatants	were	stored		
at	-20°C	until	further	use.	Protein	concentrations	were	determined	spectro-
photometrically	[20].
	 Protein	samples	(8	µg)	were	subjected	to	SDS-PAGE	on	10%	PA	gels	and	
blotted	onto	polyvinylidene	fluoride	(PVDF)	membranes.	Blots	were	blocked	
for	30	min	using	3%	non-fat	dry	milk	in	TBS-T	(10	mM	Tris-HCl,	pH	8.0;	150	mM	
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NaCl;	0.05%	Tween-20)	and	incubated	overnight	at	4°C	with	a	1:2000	dilution		
of	a	phospho-ERK1/2	monoclonal	antibody	(#9106,	Cell	Signalling	Technology,	
Beverly,	USA).	Following	three	washes	with	TBS-T,	blots	were	incubated	for		
1h	with	a	1:10,000	dilution	of	peroxidase-conjugated	goat	anti-mouse	IgG		
(Pierce	Biotechnology	Inc.,	Rockford,	IL,	USA)	in	3%	non-fat	dry	milk	in	TBS-T.	
Immunoreactive	bands	were	detected	with	Lumi-LightPLUS	Western	Blotting	
Substrate	(Roche	Diagnostics	GmbH)	using	a	BioChemi	imaging	system	and	
obtained	signals	were	quantified	with	the	Labworks	4.0	program	(UVP	
BioImaging	Systems,	Cambridge,	UK).	Blots	were	then	stripped	for	40	min	at	
60°C	(in	62.5	mM	Tris-HCl,	pH	6.6;	100	mM	β-mercapto-ethanol;	2%	SDS),	
washed	with	TBS-T	and	reprobed	for	1h	with	rabbit	polyclonal	ERK1	(C-16)	
antibody	(sc-93,	Santa	Cruz	Biotechnology,	Inc.,	Santa	Cruz,	USA)	at	a	dilution	
of	1:8000	in	TBS-T	containing	3%	non-fat	dry	milk.	Peroxidase-conjugated		
goat	anti-rabbit	IgG	(Pierce	Biotechnology	Inc.)	was	used	for	detection	and	
quantitation	as	described	above.	Ratios	of	the	phospho-ERK1/2	/	total	ERK1	
signals	were	determined	for	every	sample	and,	to	be	able	to	compare	signal	
ratios	originating	from	different	blots,	a	reference	standard	sample	
(corresponding	to	a	PC12	cell	lysate	following	5	min	treatment	with	EGF)		
was	included	on	each	blot.
	 PTPRR	expression	levels	were	determined	by	subjecting	50	µg	of	total	
protein	to	SDS-PAGE	and	immunoblot	analysis	as	described	above,	using	
monoclonal	antibody	6A6	[16].	Phospho-PTPPBSγ	and	phospho-PTPBR7	levels	
were	determined	by	western	blotting	of	6A6	immunoprecipitates,	performed	
as	described	previously	[16],	from	PTPPBSγ	or	PTPBR7	expressing	cells	which	
had	been	incubated	with	10	ng/ml	EGF,	50	ng/ml	NGF	or	10	µM	forskolin	after	
overnight	serum	starvation.	Blots	were	incubated	simultaneously	with	a	rabbit	
monoclonal	phospho-PKA	substrate	(RRXS*/T*)(100G7)	antibody	(#9624,		
Cell	Signalling	Technology)	and	with	6A6,	both	in	a	1:1000	dilution.	Goat	anti-
mouse	and	goat	anti-rabbit	secondary	antibodies	conjugated	to	Alexa	Fluor	
680	(Molecular	Probes)	or	IRDye800	(Rockland	Immunochemicals)	fluorescent	
dyes	were	used	for	detection	and	quantification	on	an	Odyssey	infrared	imaging	
system	(LI-COR).
Immunofluorescence microscopy 
Cells,	cultured	on	collagen-coated	coverslips,	were	fixed	at	room	temperature	
for	30	min	in	PHEM	buffer	(60	mM	PIPES;	25	mM	HEPES,	pH	6.9;	10	mM	EGTA;	
2	mM	MgCl2)	containing	4%	paraformaldehyde,	and	subsequently	washed	with	
PBS	and	permeabilized	for	5	min	using	0.2%	Triton	X-100	in	PBS.		
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Aspecific	sites	were	blocked	by	incubating	for	30	min	with	4%	BSA	in	PBS	
before	cells	were	incubated	for	1h	with	a	1:500	dilution	of	rabbit	polyclonal		
α-SL	antiserum	[21]	in	PBS	containing	0.4%	BSA.	Following	three	washes	with	
PBS,	cells	were	incubated	for	1h	in	a	1:300	dilution	of	Alexa568-conjugated	
goat-anti-rabbit	IgG	(Molecular	Probes)	in	PBS,	0.4%	BSA.	Following	PBS	
washes	and	methanol	dehydration,	coverslips	were	mounted	on	glass	slides	
using	Mowiol	(Sigma-Aldrich),	and	images	were	collected	using	confocal		
laser	scanning	microscopy	(MRC1024,	Bio-rad).	
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A single classical KIM-containing PTP is expressed in PC12 cells
To	determine	which	of	the	three	KIM-containing	phosphotyrosine-specific	PTPs	
are	endogenously	expressed	in	rat	PC12	cells,	an	RT-PCR	analysis	on	total	
RNA	was	performed.	Expected	amplicons	for	STEP	and	HePTP	were	obtained	
from	mouse	cerebrum	and	mouse	spleen	RNA,	respectively,	but	STEP	and	
HePTP	messengers	remained	undetectable	in	PC12	material	(Fig.	1B),	in	con-	
cordance	with	earlier	reports	[22,	23].	For	the	rat	PTPRR	gene	two	different	
transcripts,	encoding	PCPTP1	and	PCPTP1-Ce,	respectively,	have	been	reported	
[24,	25].	PCPTP1	mRNA	is	present	in	PC12	cells	[14,	24,	26]	but	PCPTP1-Ce	
transcripts	remain	undetectable	in	PC12	RNA,	although	the	amplification	
product	is	readily	obtained	using	rat	cerebellum	RNA	(Fig.	1B).	In	mouse		
the	PTPRR-encoding	gene	generates	a	third	transcript	isoform	which	encodes	
two	additional	protein	isoforms	(PTPPBSγ-42	and	PTPPBSγ-37)	through	the	
use	of	alternative	translation	start	sites	[16].	To	be	able	to	probe	for	the	
presence	of	putative	rat	PTPPBSγ	variants,	we	searched	in	public	databases		
for	the	rat	PTPRR	genomic	region	displaying	very	high	homology	to	mouse	
PTPPBSγ	transcript-specific	sequences	and	designed	primers	for	use	in		
RT-PCR	assays.	Indeed,	the	predicted	PTPPBSγ-type	fragment	was	amplified	
from	rat	cerebellum	RNA,	while	mouse	PTPPBSγ	cDNA	served	as	positive	
control,	but	no	signal	was	obtained	using	PC12	material	(Fig.	1B).	Thus,	in	rat	
PC12	cells	only	the	largest	PTPRR	transcript,	that	encodes	the	receptor-type	
isoform	PCPTP1,	is	expressed.
	 We	next	investigated	PTPRR	isoform	expression	in	PC12	cells	at	the		
protein	level.	Both	Western	blot	analysis	of	PC12	cell	lysates	and	immuno-
precipitation	experiments	revealed	multiple	immunoreactive	bands	(e.g.			
Fig.	2A	and	data	not	shown)	that	compare	well	to	patterns	obtained	with	
expression	constructs	for	rat	PCPTP1	[24].	Proteins	of	around	72	and	65kDa	in	
size	are	detected	that	represent	endogenous	rat	PCPTP1	and	a	post-transla-
tionally	modified	variant,	respectively,	as	is	the	case	for	the	mouse	ortholog	
PTPBR7	[16].	These	data	are	in	line	with	PTPRR	isoform	PCPTP1	to	be	the	only	
 • Results 
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Figure 1 • Tyrosine-specific MAPK 
phosphatases expressed in PC12 
cells. 
A) Schematic diagrams of STEP 
(STEP61, STEP46), HePTP and PTPRR 
(PTPBR7, PTP-SL, PTPPBSγ-42, 
PTPPBSγ-37) protein isoforms. Mouse 
isoform nomenclature is given on the 
right. Signal peptides (SP), prolinerich 
and PEST domains (PP), trans-
membrane segments (TM), kinase-
interacting motifs (KIM), hydrophobic 
regions (HR) and catalytic phospho-
tyrosine phosphatase domains (PTP) 
are indicated. 
B) Assessment of KIM-containing, 
tyrosine-specific PTP expression  
by RT-PCR. Rat protein nomenclature 
is indicated on the left, aligned with 
the diagrams of the mouse orthologs 
depicted in panel A). STEP and HePTP 
transcripts, as detected by RT-PCR 
(+) in mouse cerebrum (CRB) and 
spleen (SPL) RNA, respectively, are 
not found in PC12 cells. For rat 
PTPRR proteins (PCPTP1, PCPTP1-
Ce, PTPPBSγ) isoform-specific primer 
sets were used on rat cerebellum 
(CBL) and PC12 total RNA. Samples 
lacking RT enzyme (-) and appropri-
ate plasmids (p) served as negative 
and positive controls, respectively.  
A β-actin specific RT-PCR served as  
a positive control for the reverse 
transcriptase reactions. 
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detectable	KIM-containing	phosphotyrosine-specific	phosphatase	in	PC12	
cells.	
RNAi-mediated knock-down of PCPTP1
To	assess	whether	dephosphorylation	by	PCPTP1	is	of	relevance	for	the	regu-
lation	of	EGF-	and	NGF-induced	ERK	signalling	in	PC12	cells,	we	aimed	at	
silencing	PCPTP1	expression	via	RNA	interference.	Different	siRNA	sequences	
were	tested	through	viral	transduction	with	pSUPER-Retro	[18]	and	the	one	
targeted	to	nucleotides	2380-2398	of	PCPTP1	resulted	in	an	almost	complete	
ablation	of	PCPTP1	protein	levels	(Fig.	2A).	To	enable	exclusion	of	off-target	
effects	in	these	cells,	knockdown	was	also	rescued	by	introduction	of	a	retroviral	
expression	vector	encoding	PTPBR7,	the	mouse	ortholog	of	PCPTP1.	Effects		
on	ERK	activity	following	EGF	or	NGF	administration	to	serum-starved	PC12	
cells	were	monitored	over	time	by	immunoblot	analysis	of	cell	lysates	using	
phosphospecific	ERK1/2	antibodies.	Reprobing	the	same	immunoblot	with	
antiserum	directed	against	total	ERK1	enabled	us	to	correct	for	loading	diffe-	
rences	between	samples	and	to	express	ERK1/2	activity	as	relative	phosphory-
lation	units.	EGF	administration	to	mock-transduced	PC12	cells	resulted	in		
a	very	rapid	but	transient	ERK1/2	activation	that	peaks	within	the	first	5	min		
(Fig.	2B,	upper	panels).	Upon	NGF	treatment,	ERK1/2	biphosphorylation		
is	maximal	after	some	10	min	and	then	gradually	decreases,	with	sustained	
ERK1/2	activity	still	being	detectable	after	48	h	(Fig.	2B,	lower	panels)	[27].	
Reasoning	that	possible	effects	of	the	altered	PCPTP1	levels	would	be	most	
noticeable	at	time	points	with	maximal	ERK1/2	activation,	we	compared	
relative	phospho-ERK1/2	levels	in	the	transduced	cells	at	2	and	5	min	after	EGF	
addition	(Fig.	2C)	or	at	10,	20,	30	and	60	min	following	NGF	administration		
(data	not	shown).	Depletion	of	PCPTP1,	however,	did	not	result	in	significant	
alteration	of	the	response	to	EGF	or	NGF	administration.	Also	the	use	of		
very	low	EGF	concentrations,	to	ensure	that	ERK1/2	is	not	maximally	phos-
phorylated	and	PCPTP1	knockdown	may	allow	further	increase	of	ERK1/2	
activity,	did	not	reveal	a	significant	difference	in	ERK1/2	activation	between	
mock	transduced	and	PCPTP1	knockdown	cells	(Fig.	2D).	
Effects of PTPRR overexpression on transient and sustained ERK activity
As	an	alternative	way	to	assess	the	relevance	of	PTPRR	activity	for	the	
regulation	of	ERK	signalling,	we	generated	pools	of	PC12	cells	that	stably	
expressed	mouse	PTPRR	isoforms	by	means	of	retroviral	transduction.	
Lysates	of	the	resulting	cell	lines	were	first	analyzed	on	Western	blots		
Figure 2 • ERK activity profile is 
not affected by PCPTP1 depletion.  
A) RNAi-mediated knockdown of 
endogenous PCPTP1 in PC12 cells. 
PC12 cells stably expressing siRNA 
targeted to nucleotides 2380-2398 
in PCPTP1 cDNA  (pSR-2380) were 
generated via retroviral 
transduction. Empty vector (pSR) 
was used as control and PCPTP1 
knockdown was rescued by 
transduction of pSR-2380-con-
taining cells with a retroviral ex-
pression construct for the mouse 
ortholog PTPBR7. Equal amounts  
of protein from the resulting stable 
cell pools were subjected to im-
munoprecipitation using α-SL anti-
serum and captured proteins were 
analyzed on Western blots using 
monoclonal antibody 6A6.  
B) Transient and sustained ERK1/2 
signalling in wild type PC12 cells. 
After overnight serum deprivation, 
cells were stimulated with 100 ng/ml 
EGF (upper panels) or 50 ng/ml NGF 
(lower panels) for the indicated time 
points. Cell lysates were sub-jected 
to Western blot analysis and 
phospho-ERK1/2 signals (pERK1, 
pERK2) were detected using a che-
miluminescence imaging system. 
The same blot was reprobed with 
total ERK1 antibody to correct for 
loading differences.  
C) Transient ERK activity is not af-
fected in PCPTP1 knockdown cells. 
Serum-starved cells were stimulated 
with 10 ng/ml EGF for 2 or 5 min, 
respectively, and harvested. Relative 
phospho-ERK1/2 levels in the pro-
tein lysates, determined as above, 
are presented as mean values ± SEM 
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from three independent experiments. 
D) PCPTP1 knockdown in PC12 cells 
does not significantly alter ERK 
activity at reduced levels of EGF. 
Serum starved cells were stimulated 
with 0.075 ng/ml EGF for the indi-
cated time points and relative 
phospho-ERK1/2 levels were deter-
mined as before. Results are mean 
values ± SEM (n=4).
C
h
a
p
te
r 
2

to	determine	PTPRR	expression	levels	(Fig.	3A).	Transduction	with	mouse	
PTPBR7-encoding	viruses	resulted	in	immunoreactive	bands	that	super-
imposed	on	those	of	endogenous	PCPTP1,	confirming	the	previous	annotation	
of	these	signals.	Ectopic	expression	of	mouse	PTPPBSγ	transcripts	resulted		
in	two	additional	immunoreactive	bands	which	represent	PTPPBSγ-42	and	
PTPPBSγ-37	[16].	Cells	transduced	with	a	construct	encoding	PTP-SL,	the	mouse	
ortholog	of	PCPTP1-Ce,	failed	to	display	appreciable	levels	of	expression		
(not	shown)	and	are	therefore	not	included	in	this	study.	Quantitation	revealed	
that	PTPBR7	expression	exceeds	three-fold	the	endogenous	PCPTP1	level,	
whereas	PTPPBSγ	expressing	cells	show	PTPRR	levels	that	are	some	seventeen-
fold	higher	than	in	non-transduced	controls	(Fig.	3B).	Analysis	of	the	subcellu-
lar	distribution	revealed	that	endogenous	PCPTP1	displayed	a	weak	vesicle-type	
of	staining	in	PC12	cells,	and	only	limited	cell	membrane	localization	(Fig	3C,	
left	panel).	In	line	with	previous	data	[16,	17,	21],	its	mouse	ortholog	PTPBR7		
was	detected	at	the	cell	membrane,	on	vesicular	structures	and	at	the	Golgi	
apparatus	(Fig.	3C,	middle	panel).	Mouse	PTPPBSγ	isoforms	are	cytosolic	
proteins	that	are	excluded	from	the	nucleus,	while	endogenous	PCPTP1	adds		
a	speckled	pattern	(Fig.	3C,	right	panel).	
	 Effects	of	PTPBR7	and	PTPPBSγ	expression	on	ERK1/2	activity	profiles	in	
the	transduced	cells	were	again	determined	through	phospho-ERK1/2	immuno-
blots	(Fig.	4A).	Mean	values	for	six	independent	experiments	were	plotted		
(Fig.	4B,C)	and	identical	results	were	obtained	using	independently	derived	
PC12	stably	transduced	cell	pools.	Ectopic	expression	of	PTPBR7	was	found		
to	have	no	effect	on	EGF-induced	transient	and	NGF-induced	sustained	ERK1/2	
activity.	At	5	min	following	EGF	addition	the	PTPBR7	expressing	cells	display		
a	small	reduction	in	ERK1/2	activity,	but	this	does	not	reach	significance.	
	 Likewise,	at	2	min	following	EGF	administration	and	at	10,	20,	30	or	60	min	
after	NGF	treatment	the	phospho-ERK1/2	levels	in	the	various	cell	pools	
expressing	PTPPBSγ	are	not	different	from	those	in	mock-transduced	cells.	
On	the	contrary,	PTPPBSγ	expressing	cells	show	a	significant	reduction	in	
ERK1/2	activity	levels	5	min	after	EGF	administration	(p<0.008;	Fig.	4B).	
Separate	analyses	of	the	ERK1	and	ERK2	activity	levels	provided	essentially	
the	same	results	(data	not	shown).	Thus,	boosting	PTPRR	activity	in	the	
cytosol	17-fold	results	in	a	significant	~25%	reduction	of	ERK1/2	activity	during	
the	later	phase	of	the	transient	response	to	EGF.
PTPRR effects on ERK activity involve KIM-mediated interactions
The	binding	of	KIM-domain-containing	phosphatases	to	their	MAPK	targets	
27 • Yao H, York RD, Misra-Press 
A, Carr DW, Stork PJ: The cyclic 
adenosine monophosphate-
dependent protein kinase (PKA) 
is required for the sustained 
activation of mitogen-activated 
kinases and gene expression by 
nerve growth factor. J Biol Chem 
1998, 273(14):8240-8247.
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Figure 3 • Expression of PTPRR 
isoforms in PC12 cells.  
A) PC12 cells were retrovirally trans-
duced with expression constructs 
for mouse PTPRR isoforms, or mock-
transduced. Equal amounts of cell 
lysates were subjected to 10% SDS-
PAGE and immunoblotting. Rat 
PCPTP1, mouse PTPBR7 and mouse 
PTPPBSγ ( indicated on the left) were 
detected using 6A6 antibody. Mole-
cular size markers are indicated on 
the right. The arrow indicates a 
cross-reactive ~50kDa background 
band.  
B) Quantitative representation of 
PTPRR expression levels as deter-
mined in A. PTPRR levels were 
corrected for loading differences 
using monoclonal α-tubulin antibody 
E7 immunostaining (not shown) as  
a control. Results are the mean 
values ± SEM of four individual pools 
of cells.  
C) Subcellular localization of stably 
expressed PTPRR protein isoforms in 
the transduced PC12 cells as deter-
mined by fluorescence microscopy 
using polyclonal α-SL antibody. Bar 
indicates 10 μm.
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Figure 4 • PTPRR effect on growth 
factor-induced ERK signalling.  
A) PC12 cells stably expressing 
PTPPBSγ show reduced transient 
ERK1/2 activity. Serum-starved 
pools of mock-transduced, PTPBR7 
expressing or PTPPBSγ expressing 
cells were treated with 100 ng/ml 
EGF for 2 or 5 min before being 
lysed. Proteins were size-separated 
and immunoblotted. Representa- 
tive images of phospho-ERK1/2 
(upper panel) and total ERK1  
( lower panel) immunoreactivity  
are depicted.  
B) Reduced transient ERK activity  
in PTPPBSγ expressing cells. Quan-
titative representation of relative 
phospho-ERK1/2 levels in cells 
stimulated with EGF for two or five 
minutes. Results are presented as 
mean values ± SEM from six inde-
pendent experiments (Student’s t-
test, *p<0.008).  
C) Increased PTPRR levels have no 
effect on NGF-induced ERK1/2 
activity. Serum starved PC12 cell 
pools stably expressing PTPBR7  
or PTPPBSγ were stimulated with  
50 ng/ml NGF for the indicated  
time points ( in min). Cells were then 
lysed and phospho-ERK1/2 were 
analysed on Western blots as in 
panels A-B. Results are the mean ± 
SEM of three independent experi-
ments.
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Figure 5 • Assessment of PTPRR 
KIM domain phosphorylation.  
A) Lysates of PTPPBSγ expressing 
cells after overnight serum star-
vation (t=0) and subsequent treat-
ment with EGF, NGF or forskolin 
were subjected to immunoprecipi-
tation with monoclonal antibody 
6A6, and captured proteins were 
analyzed on blot using a phospho-
PKA substrate antibody (upper 
panel) and 6A6 (lower panel). It  
was ascertained that the phospho-
PKA substrate antibody remained 
unreactive towards PTPPBSγ mutant 
S94A (data not shown).  
B) Quantitative representation of 
phospho-PTPPBSγ levels deter-
mined as in A. Results, expressed  
as the ratio of the signals obtained 
with the phospho-PKA substrate 
antibody and the PTPRR antibody, 
are presented as mean values ± SEM 
(n=3, Student’s t-test, *p<0.02).  
C) Representative image of PTPBR7 
proteins, immunoprecipitated with 
antibody 6A6 from PTPBR7 
expressing cells that received the 
indicated stimuli, as detected with 
phospho-PKA substrate antibody 
(upper panel) or 6A6 (lower panel). 
D) Quantitative representation of 
phospho-PTPBR7 levels as deter-
mined in C. Results are presented  
as mean values ± SEM (n=3). 
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can	be	abrogated	by	the	cAMP-dependent	protein	kinase	PKA,	through	
phosphorylation	of	a	specific	serine	residue	within	the	KIM-domain	[9,	10,	12].	
Intriguingly,	current	models	on	transient	versus	sustained	ERK	activation		
in	PC12	cells	incorporate	an	NGF-induced	PKA-mediated	signalling	pathway	
[27].	To	investigate	whether	this	mechanism	kept	PTPRR	isoforms	from	regu-
lating	ERK	phosphorylation	levels	in	PC12	cells,	we	investigated	the	phosphory-
lation	status	of	the	KIM	domain	serine	residue	in	immunoprecipitated	PTPRR	
proteins	using	an	antibody	directed	against	phosphorylated	PKA	substrates.	
Administration	of	the	PKA	activator	forskolin	was	used	to	determine	maximum	
levels	of	KIM-domain	phosphorylation	[12].	Phosphorylation	levels	of	endo-
genous	PCPTP1	in	PC12	cells	were,	unfortunately,	below	detection	level	(data	
not	shown).	In	PTPPBSγ-expressing	PC12	cells	about	half	of	this	phosphatase	
appeared	phosphorylated	following	overnight	serum	starvation,	and	EGF		
or	NGF	administration	even	led	to	a	significant	decrease	in	the	phosphory-
lation	of	the	regulatory	serine	(Fig.	5A,B).	In	PTPBR7	expressing	cells,	
however,	the	PTPBR7	KIM-domain	seems	maximally	phosphorylated	under		
all	conditions	tested	(Fig.	5C,	D),	which	may	explain	the	negative	findings	
regarding	ERK1/2	activity	modulation	by	this	receptor-type	PTPRR	isoform.		
	 To	determine	whether	the	phosphatase	activity	and/or	MAPK	binding	
potential	of	PTPPBSγ	is	required	for	the	observed	attenuation	of	the	EGF-
stimulated	transient	ERK	activity	(Fig.	4),	PC12	cell	pools	were	generated		
that	stably	express	specific	PTPPBSγ	mutants.	PTPPBSγ	C343S	and	D309A	
mutants	represent	catalytically	impaired	versions	that	still	may	bind	phospho-
tyrosine-containing	substrates	[28].	In	the	∆KIM	mutant	the	KIM-domain	has	
been	deleted,	making	it	unable	to	associate	with	MAPKs	[6].	Furthermore,	
because	phosphorylation	is	known	to	regulate	its	association	with	MAPKs	[9,	
13],	we	also	included	the	PTPPBSγ	S94A/T116A	double	mutant	in	this	series	of	
experiments.	The	PTPPBSγ	mutant-expressing	cell	pools	demonstrated	
expression	levels	that	were	comparable	with	or	even	exceeding	that	of	wild-
type	PTPPBSγ	expressing	cells	(Fig.	6A).	Again,	relative	phospho-ERK1/2	
levels	were	determined	by	phospho-immunoblot	analyses.	Only	in	PC12	cells	
expressing	wild	type	PTPPBSγ	or	PKA-insensitive	PTPPBSγ	S94A/T116A	a	
significant	decrease	in	ERK1/2	activity	at	5	min,	but	not	at	2	min,	following	EGF	
stimulation	is	apparent	(Fig.	6B;	p<0.05).	The	catalytically	impaired	mutants	
as	well	as	the	version	without	the	KIM-domain	have	lost	this	ability,	demon-
strating	the	requirement	of	a	direct	association	with	and	subsequent	dephos-
phorylation	of	the	MAPK	by	the	PTP.	
28 • Blanchetot C, Chagnon M, 
Dube N, Halle M, Tremblay ML: 
Substrate-trapping techniques 
in the identification of cellular 
PTP targets. Methods 2005, 
35(1):44-53.
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Figure 6 • Wild type and non-
phosphorylatable PTPPBSγ affect 
ERK activity. 
A) Expression analysis of wild type 
and mutant PTPPBSγ proteins. Equal 
amounts of protein from PC12 cells 
stably expressing wild type (WT) or 
mutant (ΔKIM, D309A, S94A/T114A, 
and C343S) PTPPBSγ were subjec-
ted to SDS-PAGE and immunoblot 
analysis using antibody 6A6. 
B) EGF-induced ERK1/2 activity  
in PC12 cells stably expressing 
PTPPBSγ protein variants. Serum 
starved cells that stably express 
PTPPBSγ mutants were stimulated 
with 10 ng/ml EGF for 2 or 5 min, 
and lysed. Relative phospho- 
ERK1/2 levels were determined via 
immunoblot analysis as described  
in the legends to Fig. 2. Results  
are presented as mean values ± SEM 
(n=4, Student’s t-test; *p<0.05).
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Kurokawa K, Ohba Y, Nagai T, 
Miyawaki A, Matsuda M: Spatio-
temporal images of growth-
factor- induced activation of Ras 
and Rap1. Nature 2001, 411(6841): 
1065-1068.
The	neuroendocrine	PC12	cell	line	represents	a	paradigm	model	system	to	study	
spatial	and	temporal	aspects	of	growth	factor-induced	MAPK	signalling	[2,	29].	
In	this	study	we	made	an	inventory	of	the	MAPK-associating,	phosphotyrosine-
specific	PTPs	that	are	endogenously	expressed	in	this	cell	system	and	tested	
their	physiological	relevance	for	the	spatio-temporal	control	of	EGF-	and	NGF-
induced	ERK1/2	activity.	The	PTPRR	isoform	PCPTP1	was	the	only	detectable	
KIM-domain	containing	classic	PTP	in	these	cells.	Knockdown	of	PCPTP1	protein	
levels	or	additional	expression	of	its	mouse	ortholog	PTPBR7,	however,	left	
transient	and	sustained	ERK1/2	signalling	in	response	to	EGF	or	NGF,	respec-
tively,	unaltered.	Our	finding	that	in	this	cell	system	PTPBR7	was	constitutively	
phosphorylated	on	a	regulatory	serine	residue	within	the	KIM-domain,	pre-
cluding	its	binding	to	ERK,	provides	a	likely	explanation.	Ectopic	expression		
of	the	cytosolic	PTPPBSγ	isoforms	resulted	in	a	decrease	of	EGF-induced,		
but	not	NGF-induced,	ERK1/2	activation.	This	effect	required	PTPPBSγ	enzy-
matic	activity	and	an	intact	KIM-domain,	pointing	to	a	direct	association	with	
and	dephosphorylation	of	the	MAPK.	In	line	with	this,	only	some	30-50%	of	the	
PTPPBSγ	molecules	was	found	to	be	phosphorylated	on	their	KIM	serine	residue,	
leaving	the	majority	available	for	engagement	in	ERK	binding	and	dephosphory-
lation.
	 It	is	unclear	what	causes	the	differential	effect	by	the	PTPPBSγ	isoforms	
as	compared	to	the	receptor-type	PTPBR7	protein	on	the	amplitude	of	the	
transient	ERK	activity	following	EGF	administration.	It	may	well	be	attributable	
to	the	distinct	subcellular	localizations	of	these	PTPRR	isoforms	or	rather	
could	reflect	the	much	higher	expression	levels	for	PTPPBSγ-42	/	PTPPBSγ-37	
as	compared	to	PTPBR7.	Why	PTPPBSγ’s	ectopic	expression	affects	only	the	
transient	and	not	the	sustained	ERK	activity	profile,	however,	must	have	other	
grounds.	Current	models	incorporate	an	NGF-induced	PKA-mediated	signal-
ling	pathway	in	PC12	cells	[27].	Reasoning	along	these	lines,	PTPPBSγ	proteins	
may	thus	become	hyperphosphorylated	in	the	KIM-domain	upon	NGF	addition.	
 • Discussion
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In	contrast,	we	found	that	treatment	with	EGF	and	NGF	both	resulted	in	
significantly	lower	PTPPBSγ	phosphorylation	levels.	This	may	be	explained		
by	assuming	that	the	initial	boost	of	ERK1/2	activity	following	growth	factor	
addition	results	in	a	rapid	KIM	region-mediated	association	of	PTPPBSγ	and	
ERK1/2,	thereby	protecting	the	regulatory	serine	in	the	KIM	region	from	subse-
quent	phosphorylation.	Irrespective,	the	PKA-mediated	signalling	that	results	
from	NGF	treatment	of	PC12	cells	and	that	is	required	for	the	sustained	ERK	
activity	[27]	does	not	explain	the	PTPPBSγ	selective	effect.	
	 In	line	with	our	findings,	ectopic	overexpression	of	a	cytosolic	version	of	
PTP-SL	(thus	resembling	PTPPBSγ	isoforms)	in	PC12	cells	has	been	reported	
previously	to	result	in	reduced	phospho-ERK5	and	phospho-ERK1/2	levels	
following	EGF	administration	[30].	Those	data,	however,	were	not	quantified	
nor	tested	for	statistical	significance.	In	contrast	with	our	studies,	Ogata		
and	coworkers	did	observe	a	suppressive	effect	of	PTPBR7	on	sustained	ERK	
activity	in	PC12	cells	[26].	Those	experiments,	however,	involved	transient	
transfections	that	likely	result	in	much	higher	PTPBR7	expression	levels,	and	
activation	of	the	PC12	cells	was	done	through	co-transfection	of	constitutively	
active	MEK1	instead	of	NGF	administration.	Furthermore,	not	ERK	phosphory-
lation	status	but	transcriptional	activity	of	its	downstream	substrate	Elk1	was	
used	as	a	read-out,	and	together	this	may	have	caused	an	exaggeration	of	
effects.
	 PCPTP1,	the	rat	homologue	of	mouse	PTPBR7,	is	abundantly	expressed		
in	several	rat	brain	regions,	including	the	cerebellum,	cerebral	cortex	and		
the	hippocampus	[24].	Intriguingly,	PCPTP1	mRNA	levels	are	increased	9-fold	
over	the	initial	8h	of	NGF-induced	differentiation	of	PC12	cells	[14],	in	line	with		
a	role	in	neuronal	differentiation	induced	by	sustained	ERK	activity.	Our	protein	
knockdown	findings,	however,	are	at	odds	with	a	critical	role	for	PCPTP1	in	
ERK1/2-dependent	processes	in	PC12	cells.	Other	KIM-domain-containing	
tyrosine-specific	PTPs	cannot	camouflage	the	impact	of	PCPTP1	signalling	
since	we	excluded	expression	of	other	PTPRR	isoforms,	STEP	and	HePTP/LC-
PTP	in	PC12	cells.	On	the	other	hand,	redundancy	with	KIM-	domain-containing	
dual-specificity	phosphatases	(MKP/DUSP)	may	well	explain	PTPRR’s	modest	
effect	on	ERK1/2	signalling.	In	Drosophila,	for	example,	redundancy	regarding	
ERK	inactivation	was	encountered	for	DMKP3,	a	homolog	of	mammalian		
MKP-3/MKP-4,	and	PTP-ER,	the	Drosophila	homolog	of	PTPRR	[31].	Potential	
candidates	that	could	take	over	the	role	of	the	PTPRR	proteins	in	PC12	cells	
are	MKP-3,	MKP-4,	MKP-X	and	Dusp2,	in	view	of	their	localization	in	the	
30 • Buschbeck M, Eickhoff J, 
Sommer MN, Ullrich A: 
Phosphotyrosine-specific 
phosphatase PTP-SL regulates 
the ERK5 signalling pathway.  
J Biol Chem 2002, 277(33):29503-
29509.
31 • Rintelen F, Hafen E, Nairz K: 
The Drosophila dual-specificity 
ERK phosphatase DMKP3 coope-
rates with the ERK tyrosine phos-
phatase PTP-ER. Development 
2003, 130(15):3479-3490.
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cytoplasm	and	high	specificity	towards	ERK1/2	[5].	We	detected	MKP-3	and	
MKP-X	transcripts	in	PC12	cells	by	RT-PCR	analyses	(data	not	shown)	but	did	
not	observe	alterations	in	growth	factor-induced	ERK1/2	activity	profiles	
following	RNA	interference	strategies	towards	depletion	of	MKP-3	and	MKP-X	
(data	not	shown).	It	should	be	noted	that	verification	of	changes	in	MKP	protein	
levels	was	not	performed	due	to	lack	of	suitable	antibodies.	
	 What	other	substrate	targets	for	PCPTP1	may	exist	in	PC12	cells	to	explain	
its	endogenous	presence?	Besides	ERK1/2,	PTPRR	proteins	were	shown	to	
bind	the	MAPK	family	members	p38α	and	ERK5	[6,	9,	13,	30,	32]	but	these	studies	
were	mostly	performed	in	non-neuronal	cells,	using	either	recombinant	
proteins	or	ectopically	expressed	phosphatases	and	MAPKs.	Further	studies	
towards	the	identification	of	the	physiological	targets	of	PTPRR	isoforms		
are	therefore	needed.	In	addition,	current	in	vitro	studies	might	be	hampered	
by	the	fact	that	potential	ligands	for	the	PCPTP1	/	PTPBR7	extracellular	part,	
which	may	critically	control	the	activity	of	the	phosphatase,	have	not	been	
identified	yet.	Also	in	view	of	the	restricted	expression	pattern	of	the	Ptprr	gene	
[21,	24,	33]	and	its	conserved	potency	to	generate	multiple	protein	isoforms	
through	the	use	of	different	promoters,	alternative	splicing	and	multiple	start	
codons		[16,	25,	33]	it	may	well	be	that	the	tyrosine	phosphatase	PTPRR	family	
members	will	prove	physiological	regulators	of	MAPK	signalling	in	other	cell	
systems	and	following	different	stimuli	than	the	ones	tested	here.	Given	the	
lack	of	endogenous	PTPRR	expression	in	many	neuronal	cell	lines,	studies	in	
PTPRR	deficient	mice	are	eagerly	awaited	to	address	their	functional	signifi-
cance	in	MAPK	signalling	in	vivo.
	 The	PTPRR	isoform	PCPTP1	is	the	sole	tyrosine-specific	PTP	in	PC12	cells	
that	is	able	to	bind	ERK	MAPKs	through	its	KIM-domain	and	it	is	readily	up-
regulated	upon	growth	factor-induced	differentiation	of	these	cells.		
Still,	the	physiological	regulation	of	ERK1/2	signalling	in	PC12	cells	could		
not	be	ascribed	to	this	PTP.	We	conclude	that	other,	dual-specificity	MAPK	
phosphatases	may	act	as	major	regulators	of	EGF-	and	NGF-induced	signal-
ling	pathways	in	these	cells.	
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The neuronal protein tyrosine phosphatases encoded by mouse gene 
Ptprr (PTPBR7, PTP-SL, PTPPBSγ-42 and PTPPBSγ-37) have been impli-
cated in mitogen-activated (MAP) kinase deactivation on the basis of 
transfection experiments. To determine their physiological role in vivo, 
we generated mice that lack all PTPRR isoforms. Ptprr-/- mice were 
viable and fertile, and not different from wildtype littermates regarding 
general physiology or explorative behaviour. Highest PTPRR protein 
levels are in cerebellum Purkinje cells, but no overt effects of PTPRR 
deficiency on brain morphology, Purkinje cell number or dendritic 
branching were detected. However, MAP kinase phosphorylation levels 
were significantly altered in the PTPRR-deficient cerebellum and cere-
 brum homogenates. Most notably, increased phospho-ERK1/2 immuno-
staining density was observed in the basal portion and axon hillock of 
Ptprr-/- Purkinje cells. Concomitantly, Ptprr-/- mice displayed ataxia 
characterized by defects in fine motor coordination and balance skills. 
Collectively, these results establish the PTPRR proteins as physiological 
regulators of MAP kinase signalling cascades in neuronal tissue and 
demonstrate their involvement in cerebellum motor function.
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The	cerebellum	is	the	major	centre	of	fine	motor	coordination	in	the	central	
nervous	system,	and	in	addition	serves	in	cognitive	processing	and	sensory	
discrimination.	These	functions	require	proper	cellular	signalling	through	rever-
sible	phosphorylation	of	proteins.	Neurotrophic	factors,	for	example,	exploit	
phosphorylation	cascades	to	exert	their	effect	on	the	developing	nervous	
system	[1]	and	synaptic	plasticity	and	memory	in	the	adult	brain	relies	heavily	
on	the	mitogen-activated	protein	kinase	(MAPK)	cascade	[2,	3].	Concomitantly,	
abnormal	protein	phosphorylation	is	associated	with	neurological	pathologies	
involving	malformations,	excitotoxicity	and	neuron	loss	[4,	5].	When	occurring	
in	the	cerebellum	this	may	cause	autism,	mental	retardation,	palsy,	epilepsy	
and,	most	notably,	ataxia	[6].	Thus,	signalling	relays	such	as	the	MAPK	signal	-
ling	pathway	must	be	tightly	controlled	to	warrant	proper	functioning.
	 Spatiotemporal	control	of	MAPK	activity	is	exerted	through	docking	and	
scaffolding	interactions	with	activating	upstream	kinases	and	inactivating	
phosphatases	[7,	8].	MAPK	activation	involves	the	dual	phosphorylation	of	a	
threonine	and	a	tyrosine	residue	that	are	close	together	in	the	activation	lip.	
Inactivation	of	MAPKs	thus	can	be	achieved	by	serine/threonine	phosphatases,	
by	tyrosine-specific	phosphatases	(PTPs),	or	by	so-called	dual-specificity	
phosphatases	(DUSPs).	Some	phosphatases	are	specifically	tailored	for	this	
task.	They	contain	a	so-called	kinase	interaction	motif	(KIM)	that	mediates	
selective	binding	to	the	MAPK	common	docking	domain	[8],	thereby	enabling	
retention	and	inactivation	of	the	MAPK	in	the	cytosol.	
	 Three	human	genes	encode	KIM-containing	tyrosine-specific	phosphatases:	
PTPN5,	PTPN7	and	PTPRR.	When	overexpressed	in	cells	they	display	pronounced	
effects	on	MAPK	signalling	cascades,	most	notably	the	extracellular	signal-
regulated	kinases	ERK1/2	relay	[9-15].	Physiological	relevance	has	been	
provided	for	PTPN5	(STEP)	by	pharmacological	studies	in	vitro	and	in	vivo	[15,	
16],	for	PTPN7	(HePTP/LC-PTP)	exploiting	a	knock-out	mouse	model	[17]	and	
for	a	homologous	protein	in	Drosophila,	PTP-ER,	through	mutational	ana-
	lyses	[18].	Here	we	provide	evidence	that	the	protein	products	of	the	neuronal	
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mouse	gene	Ptprr	(i.e.	PTPBR7,	PTP-SL,	PTPPBSγ-42	and	PTPPBSγ-37;	[19])	
also	represent	physiological	regulators	of	MAPK	activities.	We	have	generated	
mice	that	lack	all	four	PTPRR	isoforms	and	found	that	ERK1/2	phosphorylation	
levels	in	Ptprr-/-	brain	tissue	were	increased	as	compared	to	wildtype	
material.	Furthermore,	Ptprr-/-	mice	displayed	fine	motor	coordination	and	
balance	skills	defects	in	multiple	tests,	establishing	a	role	for	PTPRR	proteins	
in	cerebellum	motor	function	and	the	regulation	of	MAPK	signalling	cascades	
in	neuronal	tissue.
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Generation of Ptprr-/- mice
A	replacement-type	targeting	vector	was	constructed	that	contained	a	1.7	kbp	
BglII-BamHI	fragment	from	intron	5	and	a	3	kbp	HindIII-XhoI	fragment	from	
intron	6	of	the	mouse	gene	Ptprr	to	facilitate	homologous	recombination.	Both	
genomic	fragments	where	amplified	by	PCR	from	mouse	129/Ola	genomic	DNA	
using	high	fidelity	polymerase	and	digested	with	the	appropriate	restriction	
enzymes.	In	between	the	Ptprr	homology	regions	a	neomycin	phosphotrans-
ferase	selection	cassette	was	inserted	in	the	opposite	transcriptional	orien-
	tation,	and	at	the	upstream	end	of	the	targeting	vector	a	diphtheria	toxin	
expression	cassette	was	included	to	allow	selection	against	random	insertions.	
The	linearised	targeting	construct	was	introduced	into	mouse	129/Ola	ES		
cells	and	resulting	G418-resistant	colonies	were	scored	for	proper	recombina-
tion	by	Southern	blot	analysis,	exploiting	5’	and	3’	diagnostic	probes	derived	
from	flanking	intronic	sequences,	or	by	allele-specific	PCR	analysis.	Details,	
including	primer	sequences,	are	described	in	the	Supplemental	materials		
and	methods	section.	Successfully	targeted	ES	clones	were	karyotyped	and	
only	purely	diploid	cell	lines	were	used	for	injection	into	blastocysts	and	embryo	
transfer.	Resulting	chimaeric	male	mice	were	used	to	produce	heterozygous	F1	
offspring	with	C57BL/6	females.	F1	animals	were	backcrossed	onto	the	C57BL/6	
genetic	background	for	one	more	generation	and	resulting	heterozygotes	were	
then	intercrossed	to	produce	a	mouse	colony	containing	Ptprr-/-	animals	and	
wildtype	littermate	controls.	Mice	were	kept	at	the	Central	Animal	Facility		
of	the	Radboud	University	Nijmegen	in	a	standard	room	with	a	day/night	rhythm	
of	06:00/18:00h	at	a	temperature	of	21ºC	and	a	humidity	of	50-60%.	Mice	were	
housed	in	Macrolon	cages	and	fed	ad	libitum.	All	procedures	involving	animals	
were	approved	by	the	Animal	Care	Committee	of	the	Radboud	University	
Nijmegen	Medical	Centre,	The	Netherlands,	and	conformed	to	the	Dutch	Council	
for	Animal	Care	and	the	NIH	guidelines.
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RNA analysis
Total	RNA	from	cerebrum	and	cerebellum	of	wildtype,	heterozygous,	and	
homozygous	Ptprr-/-	mice	was	purified	using	RNazol	B	(Campro	Scientific).	
10µg	RNA	samples	were	size-fractionated	on	a	1%	formamide	agarose	gel,	
transferred	to	Hybond-N	membranes	(Amersham)	and	probed	with	a	32P-
labelled	cDNA	fragment	(nucleotide	positions	980	-	3430;	Acc	no	D31898)	
comprising	exons	5	until	14	of	PTPBR7	that	is	present	in	all	Ptprr	RNA	
isoforms.	Overnight	hybridisation,	subsequent	washes	in	40	mM	phosphate	
buffer	containing	0.2%	SDS,	and	exposure	to	Kodak	X-Omat	S1	films	was		
as	described	[20].	
Antibodies
The	rabbit	polyclonal	antiserum	α-SL	(1:5000)	and	the	monoclonal	antibodies	
6A6	(1:16)	and	5E4	(1:16),	all	directed	against	the	phosphatase	moiety	in	PTPRR	
isoforms,	have	been	described	previously	[19,	21].	The	rabbit	antisera	raised	
against	STEP	and	the	extracellular	domain	of	PTPBR7	(α-BR7;	[22])	were		
a	kind	gift	of	drs.	R.	Pulido	and	P.	Ríos	(Valencia,	Spain).	Polyclonal	antisera	
against	total	ERK1	(1:8000),	p38	(1:2000),	and	JNK1	(1:500)	were	obtained		
from	Santa	Cruz	Biotechnology	(sc-93,	sc-535	and	sc-474,	resp.),	antiserum	
against	total	MEK1	(1:1000)	was	from	Biosource	(AH01102),	monoclonal	
antibody	ERK-PT115	(1:500)	against	threonine-phosphorylated	ERK1/2	was	
from	Sigma-Aldrich	(M7802),	antiserum	against	Elk-1	(1:1000)	and	mono–
clonal	phospho-specific	antibodies	against	ERK1/2	(1:2000),	p38	(1:2000),		
JNK1	(1:500),	MEK1/2	(1:1000),	Elk-1	(1:1000)	and	S6	ribosomal	protein	(1:500)	
were	from	Cell	Signalling	Technology	(#9182,	#9106,	#9216,	#9255,	#9121,	
#9186	and	#4856,	resp.).	The	rabbit	polyclonal	28kD-calbindin	antiserum	
(1:500)	was	from	Sigma-Aldrich	(#C7354).	Goat	anti-Rabbit	and	anti-Mouse	
HRP-conjugated	secondary	antibodies	(1:20.000;	Pierce	Biotechnology	Inc.)	
were	used	for	chemiluminescent	detection	on	immunoblots.	Alternatively,	
1:2000	dilutions	of	goat	anti-mouse	and	goat	anti-rabbit	secondary	antibodies	
conjugated	to	Alexa	Fluor	680	(Molecular	Probes)	or	IRDye800	(Rockland	
Immunochemicals)	fluorescent	dyes	were	used	for	detection	and	quantifi-
cation	with	the	Odyssey	infrared	imaging	system	(LI-COR).	Donkey	anti-mouse	
and	anti-rabbit	biotin-conjugated	IgG	(1:250;	Pierce)	secondary	antibodies		
in	conjunction	with	Vector	ABC	Elite	staining	protocols	(Vector	laboratories,	
Burlingame,	CA,	USA)	served	in	immunohistochemical	analyses.
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24 • van der Zee CE, Man TY,  
van Lieshout EM, van der Heijden 
I, van Bree M, Hendriks WJ:  
Delayed peripheral nerve rege-
neration and central nervous 
system collateral sprouting in 
leucocyte common antigen-
related protein tyrosine phos-
phatase-deficient mice.  
Eur J Neurosci 2003, 17(5):991-1005.
Immunoblot analyses
Protein	lysates	of	whole	brain	or	separated	cerebrum	and	cerebellum	from	
individual	wild-type,	heterozygous,	and	knockout	mice	were	prepared	by	
homogenisation	in	lysis	buffer:	100	mM	Na2PO4	pH	8.1,	1%	Triton	X-100,	2	mM	
EDTA,	1	mM	PMSF,	0.1	mM	Na3VO4,	25	mM	NaF,	1mM	Na4P2O7	and	1	protease	
inhibitor	cocktail	tablet	(Roche	Diagnostics)	per	50	ml.	Homogenates	were	
then	incubated	at	4ºC	for	60	min	while	rotating,	followed	by	a	10	min	centri-
fugation	at	16.000	g.	Protein	concentration	in	the	resulting	supernatant	frac-
	tion	was	determined	spectrophotometrically	[23].	Fifty	micrograms	of	protein		
per	sample	was	subjected	to	SDS-PAGE	and	electroblotted	onto	PVDF	
membranes.	Subsequent	blocking	and	chemiluminescent	immunodetection	
was	as	described	previously	[19].	In	some	experiments,	first	immunoprecipi-
tations	with	monoclonal	antibody	6A6	[19]	or	with	rabbit	antiserum	α-BR7		
(2	µl	per	sample;	[22])	from	pre-cleared	lysates	(500µl)	were	performed	prior	
to	the	immunoblot	procedure.	For	the	ratio-imaging	of	relative	phosphory-
lation	levels,	brain	lysates	derived	from	individual	mice	(30	µg	of	protein	per	
sample)	were	subjected	to	10%	SDS-PAGE	and	size-separated	proteins	were	
blotted	onto	PVDF	membranes.	Blots,	containing	six	wildtype	and	six	PTPRR-
deficient	samples	for	a	given	tissue,	were	blocked	for	30	min	using	Odyssey	
blockbuffer	(LI-COR)	and	incubated	overnight	at	4ºC	with	pairs	of	rabbit	and	
mouse	antibodies	directed	against	total	and	phosphorylated	proteins	using	
standard	procedures.	Immunodetection	with	Alexa	Fluor	680	or	IRDye800	
conjugated	secondary	antibodies	enabled	quantifiable	data	acquisition	on		
the	Odyssey	infrared	imaging	system	(LI-COR).	Results	are	expressed	as		
the	ratio	of	the	signal	intensities	detected	by	the	phospho-specific	antibody	
and	the	antibody	that	is	immunoreactive	also	to	the	unphosphorylated		
version	of	the	protein,	respectively.
Immunohistochemistry
Mice,	5-7	months	of	age,	were	anaesthetized	and	perfused,	and	brain	tissue	
cryosections	were	prepared	and	processed	for	immunohistochemistry	essen-
	tially	as	described	[24].	In	brief,	8	µm	coronal	cryosections	were	incubated	
with	monoclonal	antibody	5E4	[19]	and	donkey-anti-mouse-biotin-conjugated	
IgG,	and	immunoreactivity	was	visualised	using	Vector	ABC	Elite	with	AEC	as		
a	substrate.	Subsequently,	sections	were	rinsed	with	water,	incubated	in	0.9%	
NaCl	and	0.5%	CuSO4	for	5	min,	and	counterstained	with	haematoxylin	for	3	
min.	Finally,	sections	were	dehydrated	with	ethanol	and	xylene,	embedded	in	
Eukitt	(Electron	Microscopy	Sciences)	and	examined	by	light	microscopy.		
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For	calbindin	and	biphosphorylated	ERK1/2	immunostaining,	paraformalde-
hyde-fixed	brain	slices	were	prepared	and	used	essentially	as	described	[24].	
In	brief,	sagittal	vibratome	sections	(40	µm	thick)	of	perfusion-fixed	mouse	
cerebellum	were	stained	free-floating	using	28	kD	calbindin	or	phospho-ERK1/2	
rabbit	antibodies	and	biotin-conjugated	donkey-anti-rabbit	secondary	antibody.	
Visualization	was	done	with	Elite	Vectastain	and	DAB-Ni	as	substrate,	resulting	
in	a	black	precipitate.	Haematoxilin/eosin	staining	was	performed	on	the	
alternate	sagittal	40	µm	brain	sections	according	to	standard	procedures.	
Haematoxilin/eosin	and	calbindin-antibody	stained	images	were	collected	
using	a	Dialux	20	microscope	(Leitz)	with	a	videocamera	attached	to	a	computer,	
and	analysed	using	the	software	package	PC-Image.	Cerebellum	Purkinje	cell	
numbers	were	counted	along	5-6	different	1.7	mm	long	lobule	stretches	per	
section	and	in	5	sections	for	each	mouse.	Numbers	were	averaged	and	expres-
sed	as	the	number	of	Purkinje	cells	per	mm	lobule	stretch	per	mouse,	and	per	
genotype.	Digitised	images	of	phospho-ERK1/2-antibody	stained	brain	sections	
were	analysed	by	outlining	the	clearly	phospho-ERK1/2-positive	areas	of	the	
cerebellum	Purkinje	cells	(mostly	at	the	basal	side)	and	recording	the	corres-
ponding	optical	density	and	area	values.	A	total	of	50-70	Purkinje	cells	was	
measured	for	each	mouse	with	density	values	ranging	between	100	–	243		
(in	1-256	grey	level	mode).	Phospho-ERK1/2-positive	neurons	in	the	motor	
cortex,	striatum,	nucleus	accumbens	shell	and	lateral	globus	pallidus	were	
analysed	similarly,	using	35	cells	per	region	per	mouse,	with	three	mice		
per	genotype.	The	average	immunodensity	value	per	genotype	group	was	
expressed	as	phospho-ERK1/2	density/100	µm2.
Motor coordination and balance tests
All	tests	were	performed	on	age-,	sex-	and	weight-matched	animals.	Detailed	
protocols	are	provided	as	Supplemental	data.	The	rotarod	and	the	rope	grip	
tests	were	performed	as	described	in	Kolkman	et	al.	[25]	and	Peled-Kamar		
et	al.	[26],	respectively,	with	minor	modifications	(see	supplemental	data	for	
details).	In	the	single	bar	and	parallel	bars	tests	[27]	mice	transversed	hori-
zontally	suspended	rods	towards	their	home	cage.	Two	trials	per	test	were	per-
	formed	and	“traverse	time”	(in	sec)	and	number	of	times	a	hindpaw	slipped	
from	the	rod	were	registered.	In	addition,	for	the	single	bar	test	also	the	number	
of	mice	falling	off	was	recorded	per	genotype	group.	Gait	assessment	[28]		
was	done	by	analysing	the	hind-limb	walking	pattern	of	individual	mice	that	
walked	through	a	small	alley,	using	the	animal’s	hind	feet	print	pattern	as	re-
corded	on	photographic	paper.	From	at	least	three	footprint	pairs	the	following	
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parameters	were	measured	(in	mm):	distance	length	from	left	to	right	foot	
(LTRF)	and	from	right	to	left	foot	(RTLF)	[24].	Aberrations	from	the	normally	
equal	distances	between	the	footprints	were	calculated	(100-(LTRF/RTLF)*100%)	
and	expressed	as	“%	foot	mismatch”.
Basal activity and explorative behaviour
Basal	nocturnal	activity	(i.e.	from	15:00	h	until	9:00	h	the	next	morning)	was	
monitored	for	individual	mice	using	an	activity	cage	(36	x	24	x	25	cm)	equipped	
with	three	photoelectric	cells	2	cm	above	the	grid	floor	[25].	The	activity	data		
of	the	mice	were	recorded	per	min,	summed	per	hour,	and	presented	as	total	
activity	counts	per	hour	for	each	genotype	group.	Explorative	behaviour	of	
individual	mice	in	a	square	open	field	(48	x	48	x	40	cm,	with	white	Plexiglas	
walls)	was	videotaped	for	30	min	and	subsequently	analysed	in	three	blocks		
of	10	min	for	the	duration	(in	sec)	of	walking,	wall	leaning,	rearing,	sitting	and	
grooming	[25].	In	addition,	the	accumulative	total	walking	distance	in	the	30	
min	period	was	calculated	by	applying	a	computer-assisted	walking	pattern	
analysis	of	the	video-taped	sessions	[25].
Statistical analysis
All	data	are	presented	as	means	±	S.E.M.	per	genotype	group,	and	the	statistical	
analyses	involved	Student’s	t-test	except	for	data	presented	in	Figures	6C	and	
6F	(Chi-square	test)	and	Figure	6H	(ANOVA	repeated	measures).	All	tests	were	
performed	using	the	SPSS	11.0	statistical	software	package.	Statistical	signifi-
cance	was	set	at	p	<0.05.
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Generation of Ptprr-/- mice
The	structure	of	mouse	gene	Ptprr,	having	three	distinct	transcription	start	
sites	that	are	some	150	kilobasepairs	(kbp)	apart	[19],	impelled	us	to	devise		
a	replacement-type	gene	targeting	strategy	involving	deletion	of	exon	6		
(Fig.	1A).	Following	homologous	recombination	in	mouse	embryonic	stem		
cells	the	exon	6	deletion	will	shift	the	reading	frame	in	any	residual	transcript	
coming	from	the	Ptprr	promoters	despite	the	presence	of	the	antiparallel	
selection	marker	transcription	unit,	thus	precluding	the	formation	of	cataly-
tically	active	or	MAPK-binding	PTPRR	mutant	proteins	from	the	targeted	
locus.	Presence	of	the	wildtype	and	mutant	Ptprr	alleles	in	resulting	animals	
and	their	offspring	was	monitored	by	Southern	blotting	(Fig.	1B)	and	PCR	
analysis	of	genomic	DNA.	Allele	distribution	in	the	offspring	(n=100)	of	the	
heterozygous	crosses	was	according	to	Mendelian	law	(data	not	shown)		
and	size	and	gross	morphology	of	heterozygous	and	Ptprr-/-	animals	was		
indistinguishable	from	that	of	their	wildtype	littermates.	Subsequent		
breeding	steps	also	demonstrated	no	overt	effects	on	fertility.	
PTPRR messenger and protein isoforms are absent in Ptprr-/- mice
To	assess	the	effects	of	the	targeted	mutation	at	the	RNA	level,	total	RNA		
was	isolated	from	cerebral	and	cerebellar	brain	parts,	and	analysed	by		
Northern	blotting	(Fig.	1C).	Use	of	a	cDNA	probe	that	spans	exon	5	through	
	14	revealed	the	presence	of	the	4.1	kb	PTPBR7	transcipt	in	both	brain		
areas	of	wildtype	and	heterozygous	animals.	The	shorter	~3	kb	transcript		
that	is	detected	in	cerebellum	represents	PTP-SL	or	PTPPBSγ	mRNAs.		
These	transcripts	are	all	absent	in	RNA	samples	obtained	from	Ptprr-/-		
mice.	The	somewhat	smaller	RNA	product	observed	in	knockout	cerebellar	
RNA	was	found	to	represent	a	Ptprr-derived	transcript	that	lacks	exon	6-
derived	sequences	(data	not	shown).	If	translated	at	all,	this	messenger		
would	at	best	result	in	a	truncated	PTPRR	mutant	protein	lacking	the	KIM		
and	PTP	domain.
 • Results 
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To	investigate	the	phenotypic	consequences	on	the	protein	level,	PTPRR	iso-
forms	were	immunoprecipitated	from	mouse	brain	lysates	to	ensure	maximum	
sensitivity,	and	analysed	on	blot	using	immunotools	that	are	reactive	towards	
all	PTPRR	proteins.	As	expected	no	immunoreactivity	was	detected	in	Ptprr-/-
-derived	material	(Fig.	1D).	We	also	exploited	a	polyclonal	antibody	raised	
against	the	extracellular	domain	of	PTPBR7	([22];	a	kind	gift	of	drs.	R.	Pulido	
and	P.	Ríos,	Valencia,	Spain)	for	immunoprecipitation	and	immunoblot	detec-
tion	of	any	truncated	PTPRR	mutant	but,	apart	from	immunoglobulin	chain	
background	signals,	we	did	not	detect	immunoreactivity	in	Ptprr-/-	samples	
(supplemental	data)	firmly	establishing	that	these	mice	lack	PTPRR	phos-
phatase	activity	and	MAP	kinase-binding	potency.	Absence	of	PTPRR	protein	
had	no	effect	on	the	expression	levels	of	the	closest	homologous	PTP	family,	
STEP,	as	determined	by	immunoblot	analyses	of	brain	lysates	(data	not	shown)	
using	a	STEP-specific	antiserum	(kindly	provided	by	dr.	R.	Pulido,	Valencia,	
Spain).	
Unaltered brain and Purkinje cell morphology in Ptprr-/- mice
Haematoxylin-eosin	stained	brain	sections	demonstrated	a	normal	cortical	
and	hippocampal	layering	in	the	cerebrum	of	wildtype	and	Ptprr-/-	mice,		
and	cerebellum	granule	and	molecular	layers	also	had	a	normal	appearance		
(Fig.	2A-D).	Immunohistochemical	staining	with	antibody	5E4	[19]	confirmed	
that	PTPRR	is	predominantly	present	in	the	cerebellum	Purkinje	cells	of	wild-
type	mice		and	absent	in	the	Ptprr-/-	Purkinje	cell	layer	(Fig.	2E,F).		
Calbindin	immunostaining	did	not	reveal	any	difference	in	Purkinje	cell	body	
and	dendritic	tree	details	in	wildtype	and	Ptprr-/-	cerebellum	(Fig.	2G-J).	
Numbers	of	calbindin-positive	or	haematoxilin-eosin	stained	Purkinje	cells	
per	mm	lobule	stretch	in	the	cerebellum	were	found	to	be	52.5	±	6	in	wildtype	
(n=4)	and	49.0	±	9	in	Ptprr-/-	(n=4)	mice,	respectively.	Thus,	both	morphology	
and	number	of	Purkinje	cells	is	unaffected	in	mice	deficient	for	PTPRR	
proteins.
PTPRR deficiency results in ERK1/2 hyperphosphorylation
The	reported	interaction	of	PTPRR	isoforms	with	several	MAPKs	[9,	10,	13,	14]	
prompted	us	to	investigate	MAPK	activity	in	mouse	brain	lysates	through		
the	monitoring	of	MAPK	biphosphorylation	levels.	Equal	amounts	of	protein,	
from	tissue	lysates	obtained	from	Ptprr-/-	animals	or	wildtype	controls,		
were	size-separated	using	SDS-PAGE	and	blotted	onto	PVDF	membranes.	
Subsequently,	pairs	of	phosphospecific	MAPK	antibodies	and	total	MAPK	
Figure 1 • Ptprr targeted 
disruption.  
A) The structure of mouse gene Ptprr 
(upper) and the targeting strategy 
( lower) is depicted. Genomic DNA is 
represented by a grey horizontal  
bar and exons are depicted as verti-
cal bars with exon number or name 
indicated above. The three distinct 
transcription start sites [19] are 
represented by hooked arrows.  
The PTPBR7 transmembrane domain 
is encoded within exons 5 and 6,  
the KIM domain codons originate 
from exons 6 and 7, and the catalytic 
PTP domain coding region spans 
exons 8-14. DNA stretches used to 
obtain homologues recombination 
are boxed and named 5’- and 3’-arm, 
respectively. A neomycin resistance 
cassette (Neo) in the opposite trans-
criptional orientation replaces exon 
6 in the targeting construct, which  
at the 5’ end also harbours the 
diphtheria toxin cassette (DT) for 
negative selection purposes. Two-
headed arrows indicate BamHI 
restriction fragments detected by 
diagnostic probes 5’p and 3’p  
on Southern blots.  
B) Southern analysis of BamHI-diges-
ted genomic DNA from liver of wild-
type (+/+), heterozygous (+/-), and 
Ptprr-/- (-/-) mice. Hybridisation 
with the 5’ ( left) and 3’ (right) dia-
gnostic probes revealed the wildtype 
8.6-kbp fragment and a mutant 2.0- 
or 6.9-kbp fragment, respectively.  
C) Northern analysis of total RNA ex-
tracted from cerebrum (cbr) or cere-
bellum (cbl) of wildtype, heterozy-
gous, or Ptprr-/- mice using a probe 
that detects exons 5-14.  
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D) Western blot analysis of proteins, 
immunoprecipitated by monoclonal 
antibody 6A6 from brain extracts of 
wildtype, heterozygous, and Ptprr-/- 
mice, using rabbit α-SL antiserum. 
Upper bands of around 75, 70 and 
65 kDa in size represent PTPBR7-
derived processed proteins; the 65 
kDa species may also contain PTP-
SL; and the smaller immunoreactive 
proteins correspond to PTPPBSγ 
isoforms [19].
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Figure 2 • Normal brain and cere-
bellum Purkinje cell morphology in 
Ptprr-/- mice. Haematoxilin/eosin 
stained sagittal brain sections 
displaying similar cortex, striatum, 
corpus callosum, fimbria fornix and 
hippocampus layering and morpho-
logy in wildtype (A) and Ptprr-/- (B) 
mice are shown. Cerebellum cortex 
granular, Purkinje and molecular 
layers in wildtype (C) and Ptprr-/- 
(D) mice are similar as well. 
Immunostaining for PTPRR revealed 
specific staining of Purkinje cells in 
wildtype (E), but not Ptprr-/- (F), 
mice. Purkinje cell staining with cal-
bindin (28 kD) antibody demonstra-
ted very similar cell numbers and 
branching morphology in both wild-
type (G,I) and Ptprr-/- (H,J) mice. 
Bars represent 500 (A,B), 425 (C,D), 
50 (E-H) and 40 (I,J) μm, respectively.
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Figure 3 • Altered MAPK phos-
phorylation levels in Ptprr-/- 
mouse brain. 
Degree of ERK1/2 (A), p38 (B) and 
JNK1/2 (C) biphosphorylation in 
cerebellum and cerebrum of wildtype 
(+/+, white bars) and Ptprr-/- (-/-, 
black bars) mice as determined by 
Western analyses of tissue lysates 
from individual mice (n=7 for each 
tissue and genotype group) using 
phospho-specific antibodies. Repre-
sentative examples (three out of the 
seven for each tissue and genotype 
group) of phosphorylated ERK1/p44 
and ERK2/p42 (pERK) and total 
ERK1/2 (totERK) immunofluorescent 
signals are depicted above the cor-
responding bars. Phosphorylated 
ERK1/2, p38 and JNK1/2 signals 
were normalized to total ERK1/2, 
p38 and JNK1/2 levels, respectively, 
and plotted as relative phospory-
lation levels. Results are the mean  
± SEM of 7 samples per group and 
are representative of at least 3 inde-
pendent experiments (*p <0.0001, 
**p <0.01).
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antisera	were	used	in	combination	with	fluorescent	second	antibodies	for	
quantitative	detection.	Ratio-imaging	of	biphosphorylated	and	total	ERK1/2	
levels	(Fig.	3A)	disclosed	a	highly	significant	hyperphosphorylation	(p	<	0.0001)	
of	these	MAP	kinases	in	both	cerebellum	and	cerebrum	tissue	lysates	of	
Ptprr-/-	animals	(n=7)	as	compared	to	wildtypes	(n=7).	No	differences	were	
apparent	in	ERK1/2	total	protein	levels	between	wildtype	and	PTPRR	deficient	
samples.	Importantly,	the	use	of	an	antibody	immunoreactive	towards	phospho-
threonine-containing	ERK1/2	did	not	reveal	any	significant	differences	between	
the	two	genotype	groups	(data	not	shown),	demonstrating	that	it	is	the	level		
of	tyrosine	phosphorylation	that	is	altered	and	is	causing	ERK	hyperactivation	
in	PTPRR	deficient	brain	material.	It	is	mainly	ERK2	that	is	hyperactivated	in	
cerebellum	of	PTPRR	deficient	mice,	whereas	ERK2	and	to	a	lesser	extend	
ERK1	both	display	increased	phosphorylation	ratios	in	cerebrum	(data	not	
shown).	Although	PTPRR	proteins	can	bind	to	p38	[12]	no	alteration	in	phos-
	phorylation	levels	was	discernible	for	this	MAPK	(Fig.	3B).	Surprisingly,		
a	slight	but	significant	reduction	in	phosphorylation	levels	for	the	stress-	
related	c-Jun	kinases	JNK1/2	was	obtained	in	lysates	from	Ptprr-/-	cerebel-
lum	(Fig.	3C),	despite	the	lack	of	a	direct	interaction	with	PTPRR	isoforms		
[12].	To	pinpoint	the	increased	levels	of	phospho-ERK1/2	at	the	histological	
level,	we	analysed	brain	sections	immunostained	for	phospho-ERK1/2		
(Fig.	4	and	data	not	shown).	In	cerebrum,	phospho-ERK1/2-positive	neurons	
were	most	notable	in	motor	cortex,	striatum,	nucleus	accumbens	shell		
and	lateral	globus	pallidus	areas,	but	densitometric	analyses	did	not	reveal	
significant	differences	between	wildtype	and	PTPRR	deficient	animals.		
In	cerebellum,	phospho-ERK1/2-positive	staining	was	visible	in	wildtype		
Purkinje	cells	and	mostly	confined	to	the	basal	portion	of	the	cytoplasm		
including	the	axon	hillock	region	(Fig.	4A),	which	is	in	line	with	published	data	
[29].	The	phospho-ERK1/2	immunostaining	of	Purkinje	cells	in	Ptprr-/-	mice	
demonstrated	a	similar	localization	but	at	a	higher	intensity	(Fig.	4B).	
Measurements	of	the	phospho-ERK1/2	densities	revealed	values	of	Purkinje	
cell	staining	in	wildtypes	(n=3)	ranging	between	148-176,	and	in	Ptprr-/-	mice	
(n=3)	between	195-243.	Thus,	the	absence	of	PTPRR	isoforms	results	in	a	
significant,	37%	increase	in	phospho-ERK1/2	density	levels	in	Purkinje	cells	
(Fig.	4C;	p	<0.023),	firmly	corroborating	a	physiological	link	between	PTPRR		
and	ERK1/2	signalling.
29 • Zsarnovszky A, Belcher SM: 
Spatial, temporal, and cellular 
distribution of the activated 
extracellular signal regulated 
kinases 1 and 2 in the 
developing and mature rat 
cerebellum. Brain Res Dev Brain 
Res 2004, 150(2):199-209.
A
lt
e
re
d
 M
A
P
 k
in
a
se
 p
h
o
sp
h
o
ry
la
ti
o
n
 a
n
d
 i
m
p
a
ir
e
d
 m
o
to
r 
co
o
rd
in
a
ti
o
n
 i
n
 P
TP
R
R
 d
e
fi
ci
e
n
t 
m
ic
e
Figure 4. ERK1/2 
hyperphosphorylation in Ptprr-/- 
cerebellum Purkinje cells. 
Immunostaining for biphosphory-
lated, active ERK1/2, confined  
to the basal portion and the axon 
hillock of wildtype (A) and Ptprr-/- 
(B) Purkinje cells. Bars represent  
50 μm in A1 and B1, and 20 μm in  
A2 and B2 (for A2-A5 and B2-B5).  
C) Quantification of phospho-ERK1/2 
staining density demonstrated a sig-
nificant increase of 37% in Ptprr-/- 
Purkinje cells (-/-) as compared to 
wildtype (+/+) specimen (n=3;  *p 
<0.023). 
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PTPRR affects ERK1/2 signalling downstream of MEK
The	observed	hyperphosphorylated	state	of	ERK1/2	in	Ptprr-/-	brain	parts	
triggered	us	to	investigate	the	phosphorylation	levels	of	the	upstream	MAPK	
kinases	MEK1/2	and	of	potential	downstream	ERK1/2	targets,	such	as	the	
transcription	factors	Elk-1	and	c-myc.	Antibodies	directed	against	phosphory-
lated	and	total	MEK1/2	protein	demonstrated	equal	MEK1/2	phosphorylation	
levels	upon	immunoblot	analysis	of	wildtype	and	knockout	brain	lysates		
(Fig.	5A).	An	Elk-1	phospho/total	antibody	combination	revealed	higher	phospho-
Elk-1	levels	in	Ptprr-/-	cerebellum	when	compared	to	wildtype	samples,	and		
in	PTPRR	deficient	cerebrum	this	Elk-1	hyperphosphorylation	reached	signi-
ficance	(Fig.	5B;	p<0.02).	In	contrast,	c-myc	phosphorylation	levels	were	not	
affected	in	Ptprr-/-	brain	lysates	(data	not	shown).	We	also	screened	for	effects	
of	PTPRR	depletion	on	the	PI(3)K-Akt	signalling	pathway.	Phospho-specific	
Akt	and	p90RSK	antibodies	did	not	provide	reliable	signals	on	blot	(data	not	
shown)	but	S6	ribosomal	protein	phosphorylation	levels	were	found	to	be	unaf-
fected	in	PTPRR	deficient	animals	(Fig.	5C).	Thus,	alterations	in	phospho-
signalling	relays	in	our	PTPRR	deficient	mice	appear	specific	for	the	MAPK	
signalling	circuitry	downstream	of	MEK1/2,	and	warrant	further	studies	towards	
possible	functional	repercussions.
Dysfunction in balance and motor coordination in Ptprr-/- mice  
Given	the	predominant	expression	of	PTPRR	in	Purkinje	cells	[19]	and	the	
observed	hyperphosphorylation	of	ERK1/2	in	PTPRR	deficient	cerebellum	
(Figs.	3,4),	we	performed	several	different	motor	function	tests	to	assess	
whether	fine	motor	movement	and	balance	function	is	impaired	in	Ptprr-/-	
mice.	On	the	accelerating	rotarod	Ptprr-/-	mice	were	falling	off	much	earlier,	
at	much	lower	rod	turning	speeds,	as	their	littermate	controls	(Fig.	6A)	indica-	
ting	reduced	motor	coordination	and	balance	skills.	A	similar	trend	was	
obvious	in	the	rope	grip	test	(Fig.	6B,C).	While	most	wildtype	animals	could	
hang	onto	the	rope	for	almost	120	sec	(with	only	5	falls	out	of	a	total	of		
27	trials),	Ptprr-/-	mice	lost	their	grip	already	after	some	90	sec	(15	falls	in		
27	trials).	
	 Fine	motor	movement	and	balance	were	also	tested	by	letting	mice	walk	
towards	their	home	cage	over	suspended	60	cm	long	parallel	bars,	or	over		
the	more	difficult	60	cm	long	single	bar.	The	time	to	traverse	the	parallel	bars,	
or	the	single	bar,	was	not	significantly	different	between	wildtype	(14	±	2	s	and	
16	±	3	s,	resp.)	and	Ptprr-/-	(20	±	4	s	and	20	±	3	s,	resp.)	mice.	However,	Ptprr-/-	
mice	made	significantly	more	slips	(Fig.	6D,E),	and	7	out	of	11	Ptprr-/-	mice	
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Figure 5 • PTPRR effects on 
ERK1/2 signalling pathways  
are downstream of MEK.  
MEK1/2 (A), Elk-1 (B) and S6 
ribosomal protein (C) phosphory- 
lation levels were analysed using 
phospho-specific antibodies on  
blots containing cerebellum or ce-
rebrum tissue lysates of indivi- 
dual wildtype (+/+, white bars)  
and Ptprr-/- mice (-/-, black bars). 
Results, representative for 3 
independent experiments, were 
normalized to total MEK, Elk, or 
tubulin protein levels, respectively, 
and are presented as the mean  
± SEM of 6 samples per group (*p 
<0.02).
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were	falling	off	the	single	bar	as	compared	to	2	out	of	12	wildtype	mice		
(Fig.	6F).	We	next	performed	hindlimb	gait	analyses	to	picture	any	possible	
uneven	walking.	Wildtype	animals	plant	both	their	feet	at	a	regular	and		
equal	distance	while	walking	through	a	narrow	alley,	with	only	a	small	percen-
tage	of	foot	mismatch	(6	±	0.6	%).	Ptprr-/-mice,	however,	demonstrated	a	clear	
aberration	(25	±	6	%	foot	mismatch)	indicating	that	they	move	somewhat	
asymmetrically	as	if	they	are	limping	with	the	right	or	left	foot	(Fig.	6G).
	
Novel-environment exploration behaviour is not affected in Ptprr-/- mice
Two	additional	tests	were	performed	to	monitor	possible	effects	of	PTPRR	
deficiency	on	behaviour.	General	basal	locomotion	activity	of	the	animals	was	
measured	overnight	using	a	so-called	Activity	Cage	that	contains	motility	
sensors.	In	the	period	from	18:00	h	until	09:00	h	the	Ptprr-/-	mice	were	far	
less	active	than	wildtype	littermates,	which	showed	a	normal	increased	
activity	in	the	nocturnal	period	(Fig.	6H).	Specific	exploration	behaviour	was	
observed	in	detail	during	a	30	min-period	using	an	Open	Field	set-up.		
Walking,	rearing,	wall	leaning,	grooming	and	sitting	activities	were	scored	for	
individual	mice	(n=9	per	genotype	group,	Table	1),	but	no	significant	differences	
in	any	of	the	parameters	were	observed	between	wildtype	and	Ptprr-/-	mice.	
Also,	the	total	cumulative	distance	walked	in	30	min	was		not	significantly	
different	between	wildtype	and	Ptprr-/-	animals	(59.4	±	7	m	versus	44.3	±	8	m,	
resp.).	Thus,	although	the	PTPRR	deficient	animals	are	less	active	than	wild-
type	mice	in	a	familiar	surrounding,	novel-environment	induced	exploration	
behaviour	appears	unaltered	in	Ptprr-/-	mice.
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Figure 6 • Motor coordination and 
balance defects in Ptprr-/- mice.  
A) Rotarod. The time wildtype (+/+, 
white bars) and Ptprr-/- (-/-, black 
bars) mice remained on the acce-
lerating rotarod, as measured during 
3 trials, is depicted as mean ± SEM 
(*p < 0.015).  
B) Rope grip test. The time wildtype 
and Ptprr-/- mice (n=9 per group) 
were holding onto a horizontally 
tightly suspended rope, measured 
during 3 trials, is depicted as mean  
± SEM (*p <0.031).  
C) The percentage of mice falling  
off during the 3 Rope grip trials is 
shown for both genotypes (Chi-
square test, *p <0.01). Parallel bars. 
The mean ± SEM number of slips that 
mice show while traversing parallel 
bars (D, *p <0.04) or a single bar  
(E, *p <0.05) during 2 trials is indi-
cated for both genotypes.  
F) The percentage of mice falling  
off the single bar during the 2 trials 
is shown for each group (Chi-square 
test, *p <0.02).  
G) Hindlimb gait. Aberrations in 
hindfoot placing of Ptprr-/- (-/-) 
mice and wildtype controls (+/+) 
that were walking through an alley 
are depicted as mean “% foot mis-
match” ± SEM (*p <0.002).  
H) Activity cage. General basal 
activity of wildtype (+/+, open 
circles) and Ptprr-/- (-/-, filled 
squares) mice (n=8 per group) was 
measured overnight for fifteen hours 
continuously, and is expressed as 
mean total counts per 60 minutes ± 
SEM. (Anova repeated measures, 
F(1,14) = 13.831; *p <0.002). For A), 
D), E), F), G): wildtype, n=12;  
Ptprr-/-, n=11.
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In	this	study	we	demonstrate	that	adult	mice	that	lack	PTPRR	proteins	
(PTPBR7,	PTP-SL,	PTPPBSγ-42	and	PTPPBSγ-37;	[19])	display	altered	MAPK	
phosphorylation	levels	in	neuronal	tissues,	reduced	basal	locomotive	activity	
and	specific	motor	coordination	deficits.	These	impairments	include	fine	
motor	movement	dysfunction,	reduced	neuromuscular	grip	strength,	and	
diminished	balance	skills,	all	features	that	are	reminiscent	of	those	seen		
in	ataxic	syndrome	mouse	models.	Novel-environment	induced	exploration	
behaviour	is	not	affected	in	Ptprr-/-	mice.	This	suggests	that	mostly	cerebel-	
lar	functions	are	impaired,	and	is	in	line	with	the	predominant	expression		
of	PTPRR	in	adult	cerebellum	Purkinje	cells.	The	total	number	of	Purkinje	
cells	or	their	extent	of	dendritic	branching,	however,	is	unaltered	in	Ptprr-/-	
mice.	In	addition,	20	months	old	Ptprr-/-	mice	still	showed	the	ataxia	features	
but	no	histological	signs	of	neurodegeneration	(CEEMvdZ,	personal	obser-
vations).
	 Multiple	ataxia	mouse	models	display	histological	aberrations	(such	as	
loss	of	cerebellar	granule	cells	or	Purkinje	cells)	that	provide	an	explanation	
for	cerebellum	dysfunction.	Mutant	mice	that	display	ataxic	behaviour	but	
have	apparently	normal	cerebellar	layering,	Purkinje	cell	numbers	and	den-
dritic	spine	morphology,	however,	are	limited	to	junctophilin	3	[30],	carbonic	
anhydrase-related	protein	VIII	[31],	calbindin	and	calretinin	[32]	deficient	
animals.	The	cause	of	ataxia	in	these	mice	may	converge	on	calcium	homeo-
stasis	related	with	Purkinje	cell	physiology.	In	line	with	this,	the	human	condi-
tions	episodic	ataxia	2,	familial	hemiplegic	migraine	1	and	spinocerebellar	
ataxia	6,	all	result	from	mutations	in	the	pore-forming	subunit	of	P/Q-type	
voltage-gated	calcium	channels	[33].	Several	other	ataxia	syndromes	are	
directly	linked	to	alterations	in	the	neuronal	phosphoproteome.	Familial	
spinocerebellar	ataxia	types	SCA12	and	SCA14,	for	example,	are	caused		
by	mutations	in	genes	encoding	the	phosphatase	PP2A	regulatory	subunit	
PR55/Bβ	[34]	and	the	kinase	PKCγ	[35,	36],	respectively.	Perhaps	these	muta-
tions	lead	to	altered	phosphorylation	levels	of	cerebellum	calcium	channels	
 • Discussion 30 • Nishi M, Hashimoto K, 
Kuriyama K, Komazaki S, Kano M, 
Shibata S, Takeshima H: Motor 
discoordination in mutant mice 
lacking junctophilin type 3. 
Biochem Biophys Res Commun 2002, 
292(2):318-324.
31 • Jiao Y, Yan J, Zhao Y, 
Donahue LR, Beamer WG, Li X, 
Roe BA, Ledoux MS, Gu W: 
Carbonic anhydrase-related 
protein VIII deficiency is 
associated with a distinctive 
lifelong gait disorder in waddles 
mice. Genetics 2005, 171(3):1239-
1246.
32 • Cheron G, Gall D, Servais L, 
Dan B, Maex R, Schiffmann SN: 
Inactivation of calcium-binding 
protein genes induces 160 Hz 
oscillations in the cerebellar 
cortex of alert mice. J Neurosci 
2004, 24(2):434-441.
33 • Pietrobon D: Function and 
dysfunction of synaptic calcium 
channels: insights from mouse 
models. Curr Opin Neurobiol 2005, 
15(3):257-265.
34 • Holmes SE, O’Hearn EE, 
McInnis MG, Gorelick-Feldman 
DA, Kleiderlein JJ, Callahan C, 
Kwak NG, Ingersoll -Ashworth RG, 
Sherr M, Sumner AJ: Expansion 
of a novel CAG trinucleotide 
repeat in the 5’ region of 
PPP2R2B is associated with 
SCA12. Nat Genet 1999, 23(4):391-
392.
35 • van de Warrenburg BP, 
Verbeek DS, Piersma SJ, 
Hennekam FA, Pearson PL, 
Knoers NV, Kremer HP, Sinke RJ: 
Identification of a novel SCA14 
mutation in a Dutch autosomal 
dominant cerebellar ataxia 
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and	receptors	that	function	in	synaptic	connectivity	and	plasticity,	thereby	
changing	their	membrane	localisation	and	activity	[37,	38].	Although	this	
mostly	concerns	serine/threonine	phosphorylation,	the	phosphotyrosine-
specific	PTPRR	isoforms	may	indirectly	contribute	to	this	via	the	action		
of	their	substrates	ERK1	and	ERK2.	MAPK	signalling	cascades	are	indeed	
acknowledged	as	key	processes	in	synaptic	plasticity	[2,	3],	and	aberrant	
ERK1/2	signalling	activity	has	been	witnessed	in	several	neuropathologies	[4].	
	 The	elevated	phospho-ERK1/2	levels	in	Ptprr-/-	mice	may	in	turn	also		
have	a	more	indirect	effect	on	locomotion,	through	changes	in	the	transcrip-
tome	of	affected	cells.	Indeed,	we	observed	hyperphosphorylation	of	the	
transcription	factor	Elk-1	in	cerebrum	and	it	seems	reasonable	to	assume	that	
in	cerebellar	neurons	altered	phosphorylation	levels	of	as	yet	undefined	nuclear	
ERK1/2	substrates	may	lead	to	multiple	changes	at	the	protein	level	as	well.	
Perhaps	such	secondary	effects	should	even	be	held	responsible	for	the	
unexpected	down-tuning	of	JNK1/2	activity	in	Ptprr-/-	cerebellum	and	perhaps	
neutralizes	any	effects	on	p38	activity.	Alternatively,	the	absence	of	changes		
in	p38	phosphorylation	levels	in	our	knockout	mice	could	be	taken	as	evidence	
that	under	physiological	conditions	PTPRR	isoforms	do	not	interact	with	nor	
dephosphorylate	this	MAPK.
	 In	the	cerebellum	of	Ptprr-/-	mice,	increased	phospho-ERK1/2	immuno-
staining	was	detected	predominantly	at	the	basal	portions	of	the	Purkinje	cell	
soma,	including	the	axon	hillock	region.	This	is	the	region	where	inhibitory	
basket	cell	afferents	regulate	Purkinje	cell	firing	via	synaptic	transmission,	
and	subtle	irregularities	in	Purkinje	cell	pacemaking	are	sufficient	to	cause	
cerebellar	dysfunction	and	ataxia	[39].	Our	immunoblot	analyses	indicate	
ERK1/2	hyperphosphorylation	in	other	brain	regions	as	well,	in	line	with	the	
broad	expression	pattern	of	the	Ptprr	gene	[19,	21],	which	coins	the	question	
whether	phenotypic	consequences	in	addition	to	locomotion	disturbance	may	
be	uncovered.	One	should	take	into	account,	however,	that	not	only	PTPRR	
proteins	but	also	multiple	other	KIM-domain-containing	phosphatases,	
including	the	phosphotyrosine-specific	STEP	and	HePTP/LC-PTP	and	a	large	
collection	of	dual-specificity	phosphatases,	are	offering	ways	to	regulate	
MAPK	activity	levels	[8,	40].	Also	genetic	analyses	in	Drosophila	demonstrated	
that	DSPs	and	PTPs	may	cooperate	and	perform	partially	redundant	functions	
as	ERK	phosphatases	in	a	cell	type	specific	way	[41].	The	closely	homologous	
striatum-enriched	phosphatase	(STEP)	family	of	PTPs	may	well	be	capable	of	
taking	over	part	of	the	signalling	functions	of	PTPRR	isoforms	in	certain	brain	
areas,	although	the	binding	preferences	of	these	two	MAP	kinase	phospha-
family. Neurology 2003, 
61(12):1760-1765.
36 • Yabe I, Sasaki H, Chen DH, 
Raskind WH, Bird TD, Yamashita I, 
Tsuji S, Kikuchi S, Tashiro K: 
Spinocerebellar ataxia type 14 
caused by a mutation in protein 
kinase C gamma. Arch Neurol 
2003, 60(12):1749-1751.
37 • Catterall WA: Structure and 
regulation of voltage-gated Ca2+ 
channels. Annu Rev Cell Dev Biol 
2000, 16:521-555.
38 • Nakanishi S: Synaptic 
mechanisms of the cerebellar 
cortical network. Trends Neurosci 
2005, 28(2):93-100.
39 • Walter JT, Alvina K, Womack 
MD, Chevez C, Khodakhah K: 
Decreases in the precision of 
Purkinje cell pacemaking cause 
cerebellar dysfunction and 
ataxia. Nat Neurosci 2006, 
9(3):389-397.
40 • Tárrega C, Ríos P, Cejudo-
Marin R, Blanco-Aparicio C, van 
den Berk L, Schepens J, Hendriks 
W, Tabernero L, Pulido R: ERK2 
shows a restrictive and locally 
selective mechanism of 
recognition by its tyrosine phos-
phatase inactivators not shared 
by its activator MEK1. J Biol Chem 
2005, 280(45):37885-37894.
41 • Rintelen F, Hafen E, Nairz K: 
The Drosophila dual-specificity 
ERK phosphatase DMKP3 
cooperates with the ERK 
tyrosine phosphatase PTP-ER. 
Development 2003, 130(15):3479-
3490.
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tase	families	towards	ERK1/2	differ	to	some	extent	[9,	14,	40].	It	is	unlikely	
that	HePTP/LC-PTP	is	compensating	in	some	cells	for	PTPRR	since	this	PTP	
is	not	expressed	in	neuronal	tissue	but	rather	restricted	to	the	haematopoi-
etic	system	[42,	43].	
	 The	current	study	firmly	establishes	the	ERK1/2	MAP	kinases	as	physio-
logically	relevant	PTPRR	substrates.	To	what	extent	the	four	PTPRR	isoforms	
individually	contribute	to	this	remains	to	be	established.	Its	broad	neuronal	
expression,	including	during	early	mouse	development	[21],	and	its	potential	
to	receive	extracellular	signals	make	the	receptor-type	isoform	PTPBR7	a	
tempting	candidate	to	account	for	many	of	the	effects.	However,	highest	
PTPRR	protein	levels	are	found	in	Purkinje	cells	[19]	that	are	intimately	connec-
	ted	with	fine	motor	coordination,	but	here	the	predominant	transcript	encodes	
the	vesicle-associated	PTP-SL	isoform	[21].	Clearly,	additional	experiments	
are	needed	to	further	disclose	signalling	specificity	within	this	PTP	family.
Acknowledgements
We	like	to	thank	C.	Verbaas	and	colleagues	at	the	Central	Animal	Facility		
of	the	Radboud	University	Nijmegen	for	performing	blastocyst	injections	and	
embryo	transfers,	and	for	housing	the	mice.	L.	Lubbers	and	M.	Verheij	are	
thanked	for	their	assistance	with	the	activity	cage	and	walking	pattern	analy-	
ses,	I.	Otte-Holler	for	assisting	in	the	use	of	the	LICOR	Odyssey	Fluorescence	
Imager,	and	R.	Bindels	for	providing	the	anti-28kD-calbindin	antiserum.	
Special	thanks	go	to	the	members	of	the	EU	Research	Training	Network	on	
Neuronal	Protein	Tyrosine	Phosphatases,	especially	J.	den	Hertog	(Utrecht,		
The	Netherlands)	and	R.	Pulido	and	P.	Rios	(Valencia,	Spain)	for	valuable	
discussions	and	provision	of	immunotools,	and	A.W.	Stoker	(London,	UK)		
for	critical	reading	of	the	manuscript.	This	work	was	supported	in	part	by	
grants	from	the	Radboud	University	Nijmegen	Medical	Centre	(III.120201)	and	
the	EU	(HPRN-CT-2000-00085)	to	W.H.
	
42 • Adachi M, Sekiya M, Isobe 
M, Kumura Y, Ogita Z, Hinoda Y, 
Imai K, Yachi A: Molecular 
cloning and chromosomal 
mapping of a human protein-
tyrosine phosphatase LC-PTP. 
Biochem Biophys Res Commun 1992, 
186(3):1607-1615.
43 • Zanke B, Squire J, Griesser 
H, Henry M, Suzuki H, Patterson 
B, Minden M, Mak TW: A 
hematopoietic protein tyrosine 
phosphatase (HePTP) gene that 
is amplified and overexpressed 
in myeloid malignancies maps to 
chromosome 1q32.1. Leukemia 
1994, 8(2):236-244.
A
lt
e
re
d
 M
A
P
 k
in
a
se
 p
h
o
sp
h
o
ry
la
ti
o
n
 a
n
d
 i
m
p
a
ir
e
d
 m
o
to
r 
co
o
rd
in
a
ti
o
n
 i
n
 P
TP
R
R
 d
e
fi
ci
e
n
t 
m
ic
e
Construction details of Ptprr targeting vector 
Required	Ptprr	gene	fragments	were	obtained	from	mouse	129/Ola	genomic	
DNA	by	PCR	amplification	using	high	fidelity	polymerase,	followed	by	digestion	
with	appropriate	restriction	enzymes.	All	primer	sequences	are	given	in	the	
supplementary	Table	S1	below.	
PCR product (size in bp) 5’primer 3’primer
Fragment intron 5 (2075) cgttgagtttatgtgtactgcgtg cgggatcccgacatgagggcttctgtgag
Fragment intron 6 (8570) cgttgagtttatgtgtactgcgtg ctttcattctacgtgtatttgcctg
5’ diagnostic probe (349) cgttgagtttatgtgtactgcgtg cagaataacatcgaagaagagtctg
3’ diagnostic probe (1272) cctggcttgcattacttcatc ctttcattctacgtgtatttgcctg
Wildtype Ptprr allele (524) gctcaacccaactggaaatac agggtccacaaccacgttca
Mutant Ptprr allele (402) gctcaacccaactggaaatac ctatcgccttcttgacgagtt
A	3.0-kbp	HindIII-XhoI	fragment	from	intron	6	of	the	Ptprr	gene	was	subcloned	
into	HindIII-XhoI	digested	pBluescript	KS+,	creating	pBS-intron6.	A	1.7-kbp	
BglII-BamHI	fragment	from	intron	5	of	the	mouse	gene	Ptprr	was	subcloned	
into	BamHI-digested	pBluescript	KS+,	rendering	pBS-intron5.	Next,	the	
neomycin	phosphotransferase	(Neo)	selection	cassette	from	a	pMC1Neo-PolyA	
derivative	was	cloned	as	an	EcoRV	-	BamHI	fragment	in	between	the	EcoRV	and	
BamHI	sites	in	pBS-intron5.	Using	the	unique	NotI	and	EcoRV	sites,	the	intron5-
Neo	insert	was	then	excised	and	cloned	into	pBS-intron6,	resulting	in		
plasmid	pBS-intron5-neo-intron6.	Finally,	a	8.8-kbp	NotI	fragment	containing	
the	Diptheria	toxin	expression	cassette	was	isolated	from	the	pKOSelect-DT	
vector	and	inserted	into	the	unique	NotI	site	in	pBS-intron5-neo-intron6.		
The	construct	was	linearised	using	the	unique	AspEI	site,	and	introduction		
into	E14	(129/Ola)	mouse	ES	cells	by	electroporation.	Screening	for	homo-
logous	recombination	in	resulting	G418	resistant	clones	and	subsequent	injec	-
 • Supplemental Materials and Methods Supplementary Table S1
Primers used for genotyping of cells 
and mice. Underlined sequence is  
a BamHI restriction site. Fragment 
intron 5 has been BglII-BamHI diges-
ted resulting in a 1725bp fragment. 
Fragment intron 6 has been HindIII-
XhoI digested resulting in a 3050bp 
fragment.
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tion	into	C57BL/6	blastocysts,	embryo	transfer	and	breeding	with	chimaeric	
males	was	done	as	described	[44].
Genotyping of cells and mice
Genomic	DNA	was	extracted	from	ES	cells	or	mouse	liver	and	analysed	by	
Southern	blot	analysis	as	described	[45].	Screening	was	performed	using	349	
bp	and	1.3	kbp	genomic	fragments	as	5’	and	3’	diagnostic	probes,	respectively,	
on	BamHI	digested	DNA.	The	fragments	were	generated	by	PCR	from	regions	
outside	the	targeting	vector	area	in	mouse	129	ES	cell	DNA.	Routine	genotyping	
of	animals	was	done	by	duplex	PCR	on	DNA	obtained	from	toe	clips	or	tail	
biopsies	using	primers	that	resulted	in	524	and	402	bp	fragments	for	the	wild-
	type	and	the	mutant	Ptprr	alleles,	respectively.	All	primer	sequences	are	
included	in	the	supplementary	Table	S1	below.
Rotarod
Mice	were	individually	placed	on	a	rotarod	while	the	rotation	speed	of	the		
rod	was	gradually	increased	from	0	to	38	rpm	during	a	300	sec	time	interval.		
The	time	(in	sec)	each	mouse	was	able	to	stay	on	the	rod	was	measured.	
Following	one	test	trial	to	get	used	to	the	apparatus,	mice	were	subjected		
to	three	300	sec	trials	with	an	inter-trial	time	of	1	h.
Rope Grip test
Each	mouse	was	allowed	to	grip	with	their	front	legs	a	5-mm	thick	horizontal	
tight	rope	(60	cm	long),	placed	70	cm	above	the	ground	and	with	home	cages	
placed	on	either	end-side.	Mice	were	holding	onto	the	rope	very	tightly,	and	
some	would	also	walk	short	distances	along	the	rope	while	hanging	upside	
down.	Mice	performed	three	trials	and	the	parameters	measured	were:	hanging	
(in	sec),	walking	(in	sec),	and	total	time	(in	sec)	the	mouse	could	hold	onto	the	
rope,	with	a	maximum	time	of	120	sec.	The	average	value	of	the	three	trials	per	
mouse	was	used	to	calculate	the	mean	value	per	parameter	per	genotype	group.	
For	each	genotype	group,	also	the	number	of	mice	falling	off	the	rope	(not	being	
able	to	hold	onto	the	rope	for	the	maximum	time	of	120	sec)	was	registered.
Parallel and single bars
In	the	parallel	bars	test	two	suspended	parallel	white	plastified	iron	rods	(60	
cm	long,	1	cm	diameter	each)	with	an	inter-rod	distance	of	3	cm	were	diagonally	
placed	on	top	of	an	open	white	Plexiglass	box.	The	home	cage	was	placed	
underneath	the	end	of	the	rods.	Each	mouse	performed	two	trials	and	the	time	
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(in	sec)	needed	to	traverse	the	rods	was	recorded.	In	addition,	the	number	of	
times	a	mouse	dropped	a	hind	paw	below	the	rod	was	registered	as	“number		
of	slips”.	For	both	“traverse	time”	and	“number	of	slips”,	the	average	value		
of	the	two	trials	per	mouse	was	used	to	calculate	the	mean	value	per	genotype	
group.	A	more	difficult	motor	coordination	and	balance	task	was	devised	by	
removing	one	of	the	two	bars,	leaving	a	single	suspended	white	plastified	iron	
rod	(60	cm	long,	1	cm	diameter)	diagonally	placed	on	top	of	the	open	white	
Plexiglass	box.	Again,	“traverse	time”	and	“number	of	slips”	were	recorded	
and	average	values	of	two	trials	per	mouse	were	used	to	calculate	the	mean	
value	per	genotype	group.	In	addition,	the	number	of	mice	falling	off	the	single	
rod	was	recorded	per	genotype	group.
Gait assessment
The	hind-limb	walking	pattern	of	individual	mice	was	monitored	by	allowing	
them	to	walk	through	an	alley	(40	cm	long,	3.5	cm	wide,	and	walls	of	7	cm	
height)	that	lead	into	a	dark	goal	box.	Following	a	practice	run,	a	strip	of	photo-
graphic	paper	(Kodak,	Polymax	II	RC	semi-matt)	was	placed	on	the	bottom		
of	the	walking	alley	and,	after	dipping	the	animal’s	hind	feet	in	photographic	
paper	developer	fluid	(Kodak,	Polymax	RT),	the	animal	was	placed	at	the	
beginning	of	the	alley	for	its	walk	towards	and	into	the	dark	box.	From	at	least	
three	footprint	pairs	on	the	photographic	paper	the	following	parameters		
were	measured	(in	mm):	distance	length	from	left	to	right	foot	(LTRF)	and	from	
right	to	left	foot	(RTLF)	[24].	Aberrations	from	the	normally	equal	distances	
between	the	footprints	were	calculated	(100-(LTRF/RTLF)*100%)	and	expressed	
as	“%	foot	mismatch”.
Figure S1 • Analysis of proteins, 
immunoprecipitated from extracts  
of wildtype, heterozygous, or 
knockout mouse brain by a poly-
clonal antibody raised against the 
extracellular domain of PTPBR7,  
on Western blots using monoclonal 
antibody 6A6. 
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Dimerisation of receptor-type protein tyrosine phosphatases (RPTPs) 
represents an appealing mechanism to regulate their enzymatic activity. 
Studies thus far mostly concern the dimerisation behaviour of RPTPs 
possessing two tandemly oriented catalytic PTP domains. Mouse gene 
Ptprr encodes four different protein isoforms (i.e. PTPBR7, PTP-SL  
and PTPPBSγ-42/37) that contain a single PTP domain. Using selective 
membrane permeabilisation we here demonstrate that PTP-SL, like 
PTPBR7, is a single membrane-spanning RPTP. Furthermore, these 
two receptor-type PTPs constitutively formed homo- and heteromeric 
complexes as witnessed in chemical cross-linking and co-immuno-
precipitation experiments, in sharp contrast to the cytosolic PTPPBSγ-42 
and PTPPBSγ-37 PTPRR isoforms. This multimerisation occurs inde-
pendently of the PTP domain and requires the transmembrane domain 
and/or the proximal hydrophobic region. Using overexpression of a 
PTPBR7 mutant that essentially lacks the intracellular PTP domain-
containing segment, a monomer-mimicking state was forced upon full-
length PTPBR7 immunoprecipitates. This resulted in a significant 
increase in the enzymatic activity of the PTPRR PTP domain, which 
strengthens the notion that multimerisation represents a general 
mechanism to tone down RPTP catalytic activity. 
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Signal	transduction	via	receptor	tyrosine	kinases	(RTKs)	emanates	from	the	
binding	of	a	ligand	to	the	RTK	extracellular	domain,	which	induces	subse-
quently	receptor	dimerisation,	auto-activation	via	phosphorylation	of	intra-
cellular	tyrosine	residues,	and	recruitment	and	activation	of	downstream	
signalling	proteins	[1].	In	contrast,	for	most	receptor-type	protein	tyrosine	
phosphatases	(RPTPs)	the	mechanisms	controlling	their	enzymatic	activity	
remain	to	be	disclosed	[2].	Potential	reversible	mechanisms	include	PTP	
inacti	vation	by	reactive	oxygen	species,	through	oxidation	of	the	catalytic	site	
cysteine	[3],	and	phosphorylation	itself,	as	demonstrated	by	the	increased	
activity	of	PTP1B	following	its	tyrosine-phosphorylation	by	the	insulin	receptor	
[4].	Intracellular	cleavage	of	RPTPs	that	results	in	the	release	of	the	catalytic	
domain	in	the	cytoplasm,	on	the	other	hand,	represents	an	irreversible	way	to	
abrogate	dephosphorylation	of	membrane-associated	substrates	[5],	and	
perhaps	the	extracellular	proteolytic	cleavage	or	ectodomain	‘shedding’	that		
is	observed	for	multiple	RPTPs	should	be	added	to	this	list	[6-8].
	 The	discovery	of	receptor-type	PTPs	led	to	the	suggestion	that,	in	analogy	
with	RTKs,	these	RPTPs	may	be	regulated	via	ligand-induced	multimerisation	
[2].	Unfortunately,	potential	ligand	proteins	have	only	been	identified	for	a	lim-
ited	number	of	RPTPs,	and	thus	far	ligand-dependent	dimerisation	and	
consequent	inactivation	has	only	been	demonstrated	for	RPTPζ	[9,	10].	
Nevertheless,	for	multiple	RPTPs,	including	CD45,	RPTPα	and	DEP-1,	the	arti-
ficial	induction	of	dimerisation	clearly	affected	their	enzymatic	activity	[11-13].	
Intriguingly,	for	quite	a	number	of	RPTPs	it	was	found	that	they	constitutively	
form	homo-	and	hetero-dimers	in	cells,	presumably	in	the	absence	of	ligands	
[14,	15].	Current	knowledge	about	the	regulation	of	RPTP	activity	by	dimerisation	
mostly	comes	from	studies	on	RPTPs	that	contain	two	tandemly	oriented	phos-
	phatase	domains;	a	catalytic,	membrane-proximal	domain	(D1)	and	a	regula-
tory,	membrane-distal	domain	(D2)	[16].	Interactions	between	these	various	
PTP	domains	appeared	key	determinants	in	the	outcome	regarding	activity		
[15,	17,	18].	A	minority	of	RPTPs	contains,	like	all	non-transmembrane	PTPs,	
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only	a	single	phosphatase	domain	that	is	either	active	(DEP-1,	Glepp1,	PTPBR7,	
PTPOST,	RPTPβ,	Sap-1,	STEP61)	or	inactive	(IA2	and	IA2β)		[19].	Sap-1	was	
found	to	be	able	to	form	dimers,	but	this	is	independent	of	its	single	catalytic	
PTP	domain	and	rather	occurs	through	extracellular	disulfide	bond	formation.	
Intriguingly,	this	multimerisation	led	to	a	net	decrease	in	activity	[20].
	 PTPBR7	is	one	of	the	RPTPs	with	a	single	catalytic	domain	but,	in	contrast	
to	Sap-1,	it	does	not	contain	extracellular	cysteines	following	cleavage	of	its	
signal	peptide.	In	the	current	study	we	investigated	whether	mouse	PTPBR7	
and	its	family	members	PTP-SL,	PTPPBSγ-42	and	PTPPBSγ-37	also	may	be	
regulated	via	multimerisation.	These	four	PTPRR	isoforms	are	all	encoded	by	
a	single-copy	gene,	Ptprr,	but	differ	in	their	amino-terminal	sequence	and,		
as	a	consequence,	subcellular	localisation	[21].	PTPBR7	is	mainly	localised		
on	the	plasma	membrane,	PTPPBSγ-42	and	PTPPBSγ-37	are	in	the	cytosol,	
and	PTP-SL	is	distributed	at	vesicular	structures	and	the	Golgi	apparatus.		
All	PTPRR	isoforms	can	specifically	bind	to	the	extracellular	signal-regulated	
kinases	1	and	2	(ERK1/2)	via	a	so-called	kinase	interacting	motif	(KIM),	and	in	
vitro	[22]	and	in	vivo	[23]	studies	established	tyrosine-phosphorylated	ERK1/2	
as	bona	fide	PTPRR	substrates.	We	now	demonstrate	that	PTP-SL,	like	PTPBR7,	
is	a	receptor-type	PTP.	PTPBR7	and	PTP-SL,	as	opposed	to	the	cytosolic	
PTPPBSγ	isoforms,	were	found	to	form	homo-	and	hetero-dimers	constituti-
vely.	The	multimerisation	attenuated	PTPRR	phosphatase	activity,	in	favour		
of	the	model	in	which	RPTP	dimerisation	negatively	regulates	PTP	signalling.
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Expression constructs
Plasmids	pSG5/PTPBR7,	pSG8/PTPBR7-VSV,	pSG8/PTP-SL-VSV	[24],	pMyc-
ERK2	[25]	and	pBICD1-HA	[26]	have	been	described	elsewhere.	Plasmid	pSG8/
PTPBR7-C/S-VSV	encoding	a	catalytically	inactive	Cys-to-Ser	mutant	was	
generated	by	site-directed	mutagenesis	of	Cys-578	(numbering	corresponds	
to	amino	acid	position	in	PTPBR7;	acc.	nr.	BAA06696)	using	the	QuickChange	
protocol	(Stratagene,	La	Jolla,	USA).	Cloning	of	a	SfiI-AgeI	fragment	from	
pSG5/PTPPBSγ	[21]	into	SfiI-AgeI	digested	pSG8/PTPBR7-VSV	generated	the	
plasmid	pSG8/PTPPBSγ-VSV.	In	these	pSG8-based	constructs,	a	unique	BglII	
restriction	site	in	fact	separates	the	PTPRR	isoform	reading	frame	and	the	C-
terminal	VSV-tag.	A	primer	duplex	encoding	a	HA-tag	followed	by	a	stop-codon	
was	inserted	in	this	BglII	site	for	all	variants,	resulting	in	plasmids	encoding	
full-length	HA-tagged	PTPRR	isoforms.	PTPBR7	and	PTP-SL	mutant	expres-
sion	constructs	were	generated	by	cloning	a	NotI	digested	PCR	fragment	
(spanning	the	amino	acids	as	described	in	fig.	4A	and	5A)	into	the	pSG8-VSV	
vector	[27].	Mutants	lacking	the	hydrophobic	region	(HR)	that	spans	residues	
128-154	in	PTPBR7	and	7-33	in	PTP-SL,	respectively,	were	generated	by	intro-
	ducing	a	HindIII	site	on	either	side	of	the	HR-encoding	region	by	site-directed	
mutagenesis.	Subsequently,	digestion	with	HindIII	and	religation	of	the	plas-
mids	resulted	in	∆HR	deletion	mutants.	Plasmid	pSG8/PTPBR7-H-HA	was	
obtained	by	insertion	of	a	primer	duplex	encoding	a	C-terminal	HA-tag	into		
the	unique	NheI	site	of	pSG8/PTPBR7-H-VSV.	Expression	constructs	generated	
by	PCR	were	verified	by	sequence	analysis.
Generation of PTP-SL-specific antiserum 
To	generate	the	polyclonal	α-PTP-SL-specific	antiserum	a	segment	of	mouse	
PTP-SL	cDNA	encoding	amino	acids	32-105	(numbering	according	to	Acc.No.	
CAF06526)	was	obtained	by	PCR	and	cloned	into	pGEX-4T.	The	resulting	plas-
mid	was	introduced	into	E.coli	strain	DH5α	and	GST	fusion	protein	was	induced	
and	isolated	as	described	[28].	Rabbits	were	immunised	with	purified	fusion	
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protein	following	standards	protocols.	Resulting	rabbit	polyclonal	α-PTP-SL-
specific	antiserum	was	characterised	on	immunoblots	of	lysates	from	trans-
fected	HeLa	cells	expressing	individual	full-length	PTPRR	isoforms	(see	below).	
Blots	were	incubated	simultaneously	with	rabbit	polyclonal	α-PTP-SL-specific	
antiserum	and	mouse	monoclonal	antibody	6A6	[21]	in	a	1:5000	and	1:1000	dilu-
tion,	respectively.	Secondary	antibodies	conjugated	to	fluorescent	dyes	were	
used	for	dual	detection	on	an	Odyssey	infrared	imaging	system	(LI-COR)	[29].
Cell culture
COS-1	(ATCC	nr:	CRL-1650)	and	HeLa	cells	(ATCC	nr:	CCL-2)	were	cultured	in	
Dulbecco’s	Modified	Eagle’s	Medium	(DMEM,	Gibco	BRL,	Gaithersburg,	MD)	
supplemented	with	10%	fetal	calf	serum	(FCS)	and	grown	in	a	humidified	
atmosphere	at	37ºC	with	5%	CO2.	COS-1	cells	were	seeded	at	a	density	of	
750,000	(10-cm	dish),	300,000	(6-cm	dish)	or	140,000	(six-wells	plate)	cells		
per	well	one	day	before	being	transiently	transfected	using	DEAE-dextran	[25].	
HeLa	cells	were	seeded,	at	a	density	of	50,000	cells	per	well,	on	glass	cover-
slips	in	a	12-wells	plate	one	day	prior	to	transient	transfection	using	poly-
ethylene-imine	(PEI,	MW	~25.000,	Polysciences	Inc.).	In	brief,	for	each	well		
3.0	µl	PEI	(1	µg/µl)	was	added	to	a	mixture	of	50	µl	Optimem	(Gibco	BRL)	and		
1	µg	DNA,	and	after	immediately	vortexing	the	transfection	mixture	was	in-
cubated	at	RT	for	10	min.	Medium	in	the	wells	was	replaced	with	450	µl	fresh	
culture	medium	before	addition	of	the	transfection	mixture	to	the	cells.	Two-
three	hours	later,	1	ml	fresh	culture	medium	was	added	to	the	cells	and	in-
cubation	continued	at	37ºC	with	5%	CO2.	HeLa	cells	seeded	in	a	6-wells	plate	
at	a	density	of	150,000	cells	per	well	were	transfected	with	9	µl	PEI	(1	µg/µl)		
in	a	mixture	of	150	µl	Optimem	and	3	µg	of	DNA	as	described	above.
Chemical cross-linking	
Transfected	COS-1	cells	in	a	6-cm	dish	were	washed	three	times	with	ice-	
cold	PBS	and	subjected	to	protein	cross-linking	for	1h	using	BS3	(Pierce	
Biotechnology,	Rockford,	USA)	[30].	Cells	were	then	washed	twice	with	ice-
cold	PBS	and	treated	with	50	mM	Tris-HCl	in	PBS	to	quench	residual	BS3.		
Cells	were	harvested	in	100	µl	lysis	buffer	(50	mM	Tris-HCl,	pH	8.0;	150	mM	
NaCl;	1%	Triton	X-100;	1	mM	PMSF)	supplemented	with	a	protease	inhibitor	
cocktail	(Roche	Diagnostics	GmbH,	Mannheim,	Germany)	and	incubated	on		
ice	for	30	min.	Lysates	were	cleared	by	centrifugation	and	subjected	to	SDS-
PAGE.	Cross-linked	proteins	were	detected	by	immunoblot	analysis	using	
monoclonal	antibody	6A6	[21].	
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Immunofluorescence microscopy 
Twenty	four	hours	after	transfection	HeLa	cells	were	washed	once	with	PBS,	
fixed	for	30	min	with	1%	paraformaldehyde	in	0.1	M	PB	buffer	(61	mM	Na2HPO4,	
23	mM	NaH2PO4,	pH	7.4)	and	subsequently	selectively	permeabilised	according	
to	Man	et	al.	[31].	After	blocking	of	aspecific	sites	with	10%	FCS	in	PBS,	cells	
were	incubated	in	PBS	with	a	1:200	dilution	of	mouse	monoclonal	α-VSV	anti-
body	(P5D4)	[32]	and	a	1:5000	dilution	of	either	rabbit	polyclonal	α-BR7	anti-
serum	[8]	or	rabbit	polyclonal	α-PTP-SL-specific	antiserum.	Control	samples	
were	incubated	with	a	1:100	dilution	of	rabbit	α-PDI	antiserum	(#SPA-890,	
StressGen	Biotechnologies	Corp.)	or	a	1:1000	dilution	of	rabbit	α-Lamp-1	anti-
serum	[33].	Following	three	washes	with	PBS,	cells	were	incubated	with	
Alexa488-conjugated	goat-anti-mouse	and	Alexa568-conjugated	goat-anti-
rabbit	antibodies	(1:500	dilutions	in	PBS;	Molecular	probes).	Following	three	
washes	with	PBS	and	methanol	dehydration,	cover	slips	were	mounted	on		
glass	slides	using	Mowiol	(Sigma-Aldrich),	and	images	were	collected	using	
confocal	laser	scanning	microscopy	(MRC1024,	Bio-rad).	
Co-immunoprecipitation and immunoblot analyses 
Transfected	COS-1	cells	on	10-cm	dishes	were	washed	with	ice-cold	PBS,	
harvested	in	500	µl	lysis	buffer	and	cleared	by	centrifugation	as	described	
above.	Supernatants	were	precleared	with	protein	A-sepharose	CL-4B	beads	
(GE	Healthcare)	before	overnight	incubation	at	4°C	with	beads	preloaded		
with	mouse	monoclonal	α-HA	antibody	(12CA5)	[34].	Beads	were	then		
washed	six	times	with	ice-cold	1%	Triton	X-100	in	PBS.	Immunoprecipitated	
proteins	were	taken	up	in	sample	buffer,	subjected	to	SDS-PAGE	and	blotted		
onto	PVDF	membranes	by	electrotransfer.	Tagged	proteins	were	detected	
using	rabbit	polyclonal	α-HA	(sc-805,	Santa	Cruz	Biotechnologies)	and	
affinity-purified	rabbit	polyclonal	α-VSV	(ITK	Diagnostics	BV)	antibodies,	
diluted	1:1000	and	1:10,000	respectively.	Immunoreactive	bands	were	visu-
alised	as	described	[25].	
Protein tyrosine phosphatase activity assays
COS-1	cells	grown	in	6-well	plates	were	co-transfected	with	pMyc-ERK2	and	
pSG8/PTPBR7-VSV	and/or	pSG8/PTPBR7-T-VSV.	Twenty-four	hours	later		
cells	were	serum-deprived	overnight.	The	next	day	cells	were	stimulated	with	
20ng/ml	epidermal	growth	factor	(EGF)	for	five	min	before	being	harvested		
in	ice-cold	lysis	buffer	[29].	Total	lysates	were	cleared	by	centrifugation	and	
Myc-ERK2	was	immunoprecipitated	from	the	lysates	using	monoclonal	
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antibody	9E10	[35].	Phospho-mycERK2	levels	were	determined	by	immunoblot	
analysis	as	described	previously	[23].	
	 Activity	assays	using	the	artificial	substrate	DifMUP	(Invitrogen,	Breda,	
The	Netherlands)	were	performed	as	follows.	COS-1	cells	grown	in	10cm	
dishes	were	transfected	with	pSG8/PTPBR7-VSV	and/or	pSG8/PTPBR7-T-VSV	
expression	constructs	and	twenty-four	hours	later	cells	were	harvested	and	
lysed	as	described	above.	VSV-tagged	full-length	PTPBR7	was	immunopre-
cipitated	from	the	lysates	using	monoclonal	antibody	6A6	[21]	and	half	of	it	was	
used	for	quantitative	immunoblot	analysis	on	an	Odyssey	infrared	imaging	
system	(LI-COR)	using	rabbit	polyclonal	α-VSV	antiserum	and	goat	anti-rabbit	
secondary	antibody	conjugated	to	AlexaFluor	680	(Molecular	Probes,	Eugene,	
OR,	USA).	The	remaining	half	of	the	PTPBR7-VSV-containing	beads	was	
washed	once	with	assay	buffer	(50	mM	Hepes	pH7.2;	1	mM	DTT;	0.1	%	BSA)	
before	being	taken	up	in	100µl	assay	buffer.	Reactions	were	initiated		
by	addition	of	100µl	assay	buffer	containing	200µM	DifMUP,	and	fluorescence	
emission	by	the	hydrolysed	product	(DifMU)	was	recorded	at	460	nm	on	a	
Wallac	Victor	2	fluorescence	plate	reader	(Perkin	Elmer)	at	regular	intervals	
over	a	3h	time	period.	Finally,	the	relative	PTP	activity	(arbitrary	units)	was	
calculated	for	each	sample	by	taking	the	slope	of	the	linear,	steady	state	part	
of	the	fluorescence-over-time	curves	and	subsequently	correcting	for	the	
amount	of	immunoprecipitated	PTPBR7-VSV	protein.	
	 Determination	of	the	normalised	PTP	activities	of	C-terminally	VSV-tagged	
PTPPBSγ,	wild-type	and	catalytically	inactive	PTPBR7	was	done	as	described	
above,	except	that	proteins	were	immunopurified	using	anti-VSV-G	monoclonal	
antibody	P5D4	and	subsequently	released	from	the	beads	by	a	30	min	incubation	
at	4ºC	in	the	presence	of	an	excess	VSV-G	epitope	peptide	(15	µg/ml;	Sigma-
Aldrich).	Resulting	supernatant	was	subsequently	used	in	activity	assays	and	
for	immunoblot	analyses.	Statistical	analyses	of	the	relative	PTP	activity	for	
PTPBR7	with	and	without	PTPBR7-T	(n=3)	and	for	PTPBR7	versus	PTPPBSγ	
(n=4)	involved	Student’s	t-test.
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PTP-SL is a transmembrane protein
Although	PTP-SL	contains	an	N-terminal	signal	peptide-like	sequence	[36],	
this	was	shown	to	be	non-functional	[24],	leaving	its	membrane	topology	
rather	enigmatic.	Therefore,	before	embarking	upon	the	associative	capacities	
of	the	PTPRR	isoforms,	we	first	determined	whether	PTP-SL	should	be	
regarded	a	transmembrane	PTP.	To	this	end,	we	generated	a	rabbit	polyclonal	
antiserum	directed	against	PTP-SL	residues	in	between	the	two	hydrophobic	
stretches	(Fig.	1A).	Specificity	of	this	α-PTP-SL-specific	antibody	was	demon-
strated	on	western	blots	using	total	lysates	from	transfected	HeLa	cells	expres-
	sing	the	various	PTPRR	isoforms.	Only	the	two	largest	PTPRR	isoforms,	PTPBR7	
and	PTP-SL,	are	detected	by	the	α-PTP-SL-specific	antiserum	(Fig.	1B).	
We	then	used	this	antiserum	in	an	indirect	cytoimmunofluorescence	assay	
with	selective	membrane	permeabilisation	by	digitonin	or	Triton	X-100	[31].	
Antibodies	directed	against	the	lumenal	ER	marker	protein	disulphide	
isomerase	(α-PDI)	[37]	or	against	the	cytosolic	part	of	the	lysosomes-
associated	membrane	protein-1	(α-Lamp-1)	[33]	confirmed	that	Triton	X-100	
permeabilised	all	cellular	membranes,	whereas	digitonin	only	permeated	the	
plasma	membrane	(Fig.	2).	PTP-SL-VSV-expressing	HeLa	cells	that	were	
treated	with	digitonin	displayed	α-VSV	antibody	reactivity	at	the	Golgi	apparatus	
and	vesicular	structures.	Use	of	the	α-PTP-SL-specific	antiserum,	however,	
resulted	in	a	similar	staining	pattern	only	when	cells	were	treated	with	Triton	
X-100	(Figure	2C).	These	data	are	in	line	with	a	single-pass	transmembrane	
topology	for	PTP-SL	in	which	the	N-terminus	resides	at	the	lumenal	side	and	
the	C-terminal	part,	that	contains	the	KIM	and	PTP	domain,	is	in	the	cytosol.
PTPBR7 and PTP-SL form multimers 
To	determine	whether	PTPBR7	forms	multimers	on	the	cell-surface,	the	non-
cell	permeable	chemical	cross-linker	BS3	was	used	on	transfected	COS-1	cells	
expressing	PTPBR7.	Cross-linking	the	other	PTPRR	isoforms,	PTP-SL	and	
PTPPBSγ,	was	not	considered	because	these	do	not	localise	on	the	cell-surface	
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Figure 1 • Characterisation of  
the α-SL-specific antiserum.  
A) Schematic representation of  
the different mouse PTPRR protein 
isoforms. Signal peptide (SP), 
hydrophobic regions (HR1, HR2), 
kinase-interacting motif (KIM), 
catalytic phosphotyrosine phos-
phatase domain (PTP) and the 
segments recognised by the α-BR7 
and α-SL-specific antisera and the 
monoclonal antibody 6A6 are 
indicated. HR2 functions as a ‘stop-
transfer signal’ in the receptor- 
type PTPBR7 isoform. Whether HR2 
also is a transmembrane-spanning 
region in PTP-SL has been addres- 
sed in the current study.  
B) Total lysates of HeLa cells 
transiently transfected with 
expression plasmids pSG5/PTPBR7, 
pSG5/PTP-SL or pSG5/PTPPBSγ 
were analysed on Western blot using 
monoclonal antibody 6A6 (left panel) 
and rabbit polyclonal α-PTP-SL-
specific antiserum (right panel). 
Rabbit polyclonal α-BR7 antiserum 
only detected the PTPBR7 isoform 
(data not shown). Please note that 
the PTPPBSγ mRNA codes for both 
PTPPBSγ-42 and PTPPBSγ-37 by vir-
tue of alternative translation start 
codons [21]. Molecular size markers 
are indicated on the left. 
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Figure 2 • PTP-SL is a trans-
membrane protein.  
A) HeLa cells selectively perme-
abilised with digitonin or Triton X-
100 were stained with α-PDI anti-
serum to detect endogenous ER 
lumenal protein disulphide 
isomerase ( left panels) or with  
α-Lamp-1 antiserum to detect  
a cytosolic epitope in lysosome-
associated membrane protein-1 
(right panels).  
B) HeLa cells expressing PTPBR7-
VSV were permeabilised with the 
indicated detergents and 
subsequently co-immunostained 
with mouse monoclonal α-VSV 
antibody and rabbit α-BR7 
antiserum. Anti-VSV staining always 
resulted in fluorescent signals at  
the plasma membrane, vesicular 
structures and the Golgi apparatus 
( left panels), as for the α-BR7 
antiserum on Triton X-100 permeabi-
lised cells ( lower middle panel). In 
digitonin treated cells α-BR7 reac-
tivity was only present on the plasma 
membrane (upper middle panel), 
confirming that PTPBR7 is a type I 
transmembrane protein [24].  
C) HeLa cells expressing PTP-SL-VSV 
were treated with the indicated 
detergents and then co-immuno-
stained with monoclonal α-VSV 
antibody and rabbit α-PTP-SL-
specific antiserum. For both perme-
abilisation conditions α-VSV staining 
revealed Golgi and vesicular 
structures ( left panels), while the α-
PTP-SL-specific signal as observed 
in Triton X-100 treated cells ( lower 
middle panel) is reduced to 
background levels (as observed in 
untransfected cells; arrowhead) in 
digitonin-treated cells. 
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Figure 3 • Homo- and hetero-
multimerisation of PTPRR 
isoforms.  
A) Intact COS-1 cells transiently 
transfected with pSG5/PTPBR7 
were treated with (+) or without  
(-) BS3 crosslinker, and lysed. 
Cleared lysates were subjected  
to 6% SDS-PAGE and immunoblot-
ted using monoclonal antibody 6A6. 
PTPBR7 monomers are indicated 
with an arrow, dimers with a filled 
arrowhead and multimers with an 
open arrowhead. Molecular size 
markers are indicated on the right.  
B) Schematic representation of  
the proteins used in the co-immuno-
precipitation experiments depicted 
in C). Coiled-coil domains (CC), 
signal peptide (SP), hydrophobic 
region (HR), transmembrane domain 
(TM), kinase-interacting motif (KIM), 
catalytic domain (PTP) and the C-
terminal HA or VSV epitope tags (E) 
are indicated.  
C) COS-1 cells were transiently 
transfected with HA- or VSV-tagged 
PTPRR expression plasmids in the 
indicated combinations. Upon 
immunoprecipitation (IP) of HA-
tagged proteins from cleared lysa-
tes (CL) using monoclonal antibody 
12CA5 (monoHA), co-precipitating 
proteins were detected using po-
lyclonal α-VSV antibody on immu-
noblots (IB). The IP procedure was 
verified on separate immunoblots 
using a polyclonal anti-HA anti-
serum. 
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[21].	Immunoblot	analyses	revealed	that	not	only	monomeric	PTPBR7	but	also	
species	at	the	expected	size	of	PTPBR7	dimers	and	higher	order	multimers,	
that	may	represent	complexes	between	PTPBR7	and	other	proteins,	were	
detectable	following	BS3	treatment	(Fig.	3A).	To	investigate	whether	PTPBR7	
may	indeed	homo-dimerise	and	perhaps	can	form	heteromeric	complexes	
with	other	PTPRR	isoforms,	immunoprecipitation	experiments	were	per-
formed	on	cell	lysates	containing	PTPRR	isoforms	that	were	differentially	
tagged	at	their	C-terminus	(Fig.	3B).	Intriguingly,	VSV-tagged	PTPBR7		
co-precipitated	with	HA-tagged	PTPBR7	and	PTP-SL,	both	transmembrane	
proteins,	but	not	with	the	cytosolic	PTPPBSγ	species	(Fig.	3C,	left	panels).	
Similarly,	PTP-SL-VSV	did	not	associate	with	HA-tagged	PTPPBSγ	but		
was	efficiently	precipitated	by	the	HA-tagged	transmembrane	isoforms		
(Fig.	3C,	middle	panels).	In	fact,	the	cytosolic	PTPPBSγ-42/37	did	not	display	
any	homo-	or	hetero-meric	interaction	in	this	assay	(Fig.	3C,	right	panels),	
implying	that	PTPRR	KIM	and	PTP	domains	do	not	suffice	for	this	interaction.
PTPRR hydrophobic regions are required for multimerisation
To	examine	which	protein	parts	are	mediating	the	association,	various	epitope-
tagged	PTPBR7	deletion	mutants	(Fig.	4A)	were	tested	for	their	ability	to		
co-precipitate	with	full-length	PTPBR7	and	PTP-SL.	Subcellular	localisation	
of	the	various	mutants	was	monitored	by	immunofluorescence	microscopy		
and	their	potential	secretion	into	the	medium	was	tested	through	immuno-
precipitation	and	Western	blotting	using	culture	supernatant	(data	not	shown).	
Deletion	of	353	(PTPBR7-T-VSV)	or	466	(PTPBR7-H-VSV)	C-terminal	residues	
did	not	affect	the	associative	capacity	(Fig.	4B),	even	though	the	PTPBR7-H-
VSV	mutant	had	lost	the	transmembrane	location	and	to	a	large	extent	was	
now	secreted	into	the	culture	medium	[24].	To	assess	a	possible	contribution	
of	the	hydrophobic	region	(HR)	that	is	contained	within	residues	128-154	in	
PTPBR7	and	7-33	in	PTP-SL,	respectively,	we	deleted	this	part	in	the	above	
mutants	and	tested	the	resulting	proteins	for	binding	to	full-length	PTPRR	
isoforms.	Mutant	PTPBR7-T-∆HR-VSV	did	not	reach	the	cell	surface	and	
resided	predominantly	in	the	Golgi	area	but	still	it	co-precipitated	with	
PTPBR7	and	PTP-SL,	and	not	with	PTPPBSγ-42/37	(data	not	shown).	Mutant	
PTPBR7-H-∆HR-VSV,	however,	lost	this	capability	(Fig.	4B,	right	panels),	
although	it	also	localised	in	the	Golgi	area	and	was	not	secreted	by	the	cells	
(data	not	shown).	This	suggests	that	either	one	of	the	hydrophobic	regions	
is	necessary	for	PTPRR	multimerisation.	
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Figure 4 • Mapping of the multi -
merisation domains in PTPBR7.  
A) Schematic representation of 
mutant PTPBR7 proteins used in  
the co-immunoprecipitation expe-
riments depicted in B). Nomen-
clature, encompassed or deleted (Δ) 
amino acid regions, and the position 
of signal peptide (SP), hydrophobic 
region (HR), transmembrane domain 
(TM), kinase-interacting motif (KIM), 
catalytic domain (PTP) and C-termi-
nal epitope tag (E) are indicated for 
each mutant. Schematic represen-
tations of epitope-tagged BICD1, 
PTP-SL and PTPPBSγ proteins were 
given in Figure 3B.  
B) Transfected COS-1 cells expres-
sing the indicated combinations of 
HA- or VSV-tagged proteins were 
lysed (CL). Upon immunoprecipita-
tion of HA-tagged proteins (IP: 
monoHA; upper panels), which was 
verified using a polyclonal anti-HA 
antiserum (IB: polyHA; upper 
panels), co-precipitating proteins 
were detected using poly α-VSV 
antiserum (IB: polyVSV; lowest 
panels). In a parallel experiment 
(data not shown) PTPBR7-T-ΔHR-VSV 
was co-precipitating with full- length 
HA-tagged PTPBR7 and PTP-SL  
but not with HA-tagged PTPPBSγ  
and BICD1, which served as negative 
control. Background signals due to 
non-specific binding of PTPBR7-H-
ΔHR-VSV are indicated by an asterisk. 
Molecular size markers are indicated 
for each panel on the left.
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To	substantiate	this,	we	also	examined	the	multimerisation	ability	of	PTP-SL	
deletion	mutants	(Fig.	5A).	Again,	deletion	of	353	C-terminal	residues	(PTP-
SL-T-VSV)	did	not	influence	the	subcellular	location	or	the	interaction	with	
PTPBR7	and	PTP-SL	(Fig.	5B	and	data	not	shown).	However,	further	deletion	
of	the	transmembrane	(TM)	segment,	leaving	essentially	the	first	hydrophobic	
segment	(PTP-SL-H-VSV),	abrogated	all	interactions	with	full-length	PTPRR	
isoforms	(Fig.	5B,	left	panels).	This	is	explained	by	the	fact	that	this	mutant	
localised	at	the	cytosolic	side	of	vesicular	structures,	as	determined	using	the	
selective	membrane	permeabilisation	protocol	(data	not	shown).	Importantly,	
removal	of	the	HR	region	from	PTP-SL-T-VSV	still	allowed	multimerisation	
with	PTPBR7	and	PTP-SL	(PTP-SL-T-∆HR-VSV;	Fig.	5B,	middle	panels),	under-
scoring	the	importance	of	a	proper	membrane	topology	for	the	interaction.	
Finally,	we	tested	whether	the	segment	containing	the	lumenal	HR	in	PTPBR7	
and	PTP-SL	can	mediate	multimerisation	on	its	own,	without	one	of	the	
partners	being	membrane-anchored,	by	performing	immunoprecipitation	
experiments	with	cells	co-expressing	VSV-	and	HA-tagged	PTPBR7-H	(	Fig	5B,	
right	panels).	The	differentially	tagged	PTPBR7-H	mutants	indeed	were	found	
to	dimerise,	corroborating	that	homo-	and	hetero-dimerisation	of	transmem-
brane	PTPRR	isoforms	requires	sequences	encompassing	the	hydrophobic	
region	and/or	the	transmembrane	segment.
Influence of multimerisation on PTPRR activity 
To	investigate	whether	PTPRR	phosphatase	activity	is	regulated	via	multi-
merisation	we	hypothesised	that	a	heterodimer	consisting	of	the	full-length	
PTPBR7	and	the	mutant	that	lacks	the	KIM	and	PTP	domain,	PTPBR7-T,	would	
mimick	an	RPTP	monomeric	state.	Changes	in	PTPBR7	specific	activity	upon	
co-expression	of	PTPBR7-T	might	thus	be	reflected	in	the	phosphorylation	
levels	of	co-transfected	myc-tagged	ERK2	following	epidermal	growth	factor	
(EGF)	stimulation	of	COS-1	cells.	As	expected,	PTPBR7	expression	resulted		
in	reduced	myc-ERK2	phosphorylation	levels	as	compared	to	mock-transfec-
ted	cells	(Fig.	6A	and	B).	Co-expression	of	PTPBR7	with	an	excess	of	PTPBR7-T	
further	reduced	these	phospho-ERK	levels.	However,	ectopic	expression		
of	PTPBR7-T	alone	unexpectedly	reduced	myc-ERK2	phosphorylation	levels		
as	well.	COS-1	cells	do	not	express	PTPRR	isoforms	endogenously,	so	we	
assumed	that	PTPBR7-T	influenced	the	activity	of	other,	endogenous	proteins	
involved	in	the	control	of	EGF	signalling.	This	prompted	us	to	determine	the	
enzymatic	activity	in	a	more	direct	way,	exploiting	difluoromethylumbelliferyl	
phosphate	(DifMUP)	[38]	as	an	artificial	substrate	on	PTPBR7	multimers	as	
38 • Welte S, Baringhaus KH, 
Schmider W, Muller G, Petry S, 
Tennagels N: 6,8-Difluoro-4-
methylumbiliferyl phosphate:  
a fluorogenic substrate for 
protein tyrosine phosphatases. 
Anal Biochem 2005, 338(1):32-38.
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Figure 5 • PTPRR binding domains 
in PTP-SL.  
A) Schematic representation of 
mutant PTP-SL proteins used in co-
immunoprecipitation experiments. 
Nomenclature, encompassed or 
deleted (Δ) amino acid regions, and 
the position of hydrophobic region 
(HR), transmembrane domain (TM), 
kinase-interacting motif (KIM), cata-
lytic domain (PTP) and C-terminal 
epitope tags (E) are indicated. Sche-
matic representations of epitope-
tagged PTPBR7 mutants and PTPPBSγ 
proteins were given in Figures 4A 
and 3B, respectively.  
B) COS-1 cells ectopically 
expressing the indicated HA- and 
VSV-tagged proteins were lysed 
(CL). Upon immunoprecipitation  
of HA-tagged proteins (IP: monoHA), 
which was verified on blot using 
polyclonal anti-HA antiserum (IB: 
polyHA; upper panels), co-precipita-
ting proteins were detected using 
polyclonal α-VSV antiserum (IB: 
polyVSV; lower panels). Specific and 
background signals are indicated by 
arrowheads and asterisks, respec-
tively. The BICD1 protein served as  
a negative control. Molecular size 
markers are indicated on the left.
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compared	to	monomer-mimicking	PTPBR7	-	PTPBR7-T	complexes	that	were	
immunopurified	from	transfected	COS-1	cells.	Applying	monoclonal	antibody	
6A6,	directed	against	amino	acids	348-413	of	PTPBR7	that	are	absent	in	
PTPBR7-T-VSV,	the	five-fold	excess	of	PTPBR7-T-VSV	over	PTPBR7-VSV	in	the	
lysates	led	to	immunoprecipitates	that	contained	a	‘BR7-over-T’	ratio	of	2.13:1	
(Fig.	6C).	Upon	normalisation	for	the	amount	of	precipitated	PTPBR7-VSV	this	
mixture	(of	PTPBR7/PTPBR7-T	heterodimers	and	homo-dimerised	or	
monomeric	PTPBR7)	displayed	a	specific	activity	that	was	significantly	greater	
than	that	of	PTPBR7	precipitates	(Fig.	6D;	p<0.009).	This	is	in	line	with	a	model	
in	which	enzymatic	activity	is	increased	upon	dissolution	of	multimers	of	
transmembrane	PTPRR	isoforms.	To	corroborate	this	finding,	we	compared	
the	in	vitro	phosphatase	activities	of	the	constitutively	dimerising	PTPBR7	and	
the	exclusively	monomeric	PTPPBSγ	isoforms,	again	using	DifMUP	as	a	
substrate.	Indeed,	the	normalised	activity	of	the	PTPRR	monomeric	isoforms	
was	two-fold	greater	than	that	of	the	dimerising	receptor-type	isoform	(Fig.	
6E;	p<0.002).	Taken	together,	our	results	point	to	an	attenuated	enzymatic	
activity	of	the	phosphatase	domain	in	the	constitutive	multimers	of	transmem-
brane	PTPRR	isoforms.
	
Figure 6 • Protein tyrosine phos-
phatase activity is reduced upon 
multimerisation.  
A) Transfected COS-1 cells expres-
sing Myc-ERK2 together with 
PTPBR7-VSV and/or PTPBR7-T-VSV 
were serum-starved overnight, 
stimulated with EGF and 
subsequently lysed. VSV-tagged 
protein levels ( IB: polyVSV) in  
the cleared lysate (CL) and phospho-
rylated (IB: pERK1/2) and total ( IB: 
polyMyc) Myc-ERK2 protein levels 
upon immuno-precipitation using 
antibody 9E10 (IP: monoMyc) were 
determined by immunoblot analysis.  
B) Quantitative representation of 
relative Myc-ERK2 phosphorylation 
levels as determined in A). Results 
are presented as mean values ± SEM 
(n=3, * p<0.005, ** p<0.045).  
C) Lysates from COS-1 cells 
expressing PTPBR7-VSV and/or 
PTPBR7-T-VSV were subjected to 
immuno-precipitation (IP) using 
antibody 6A6. Protein amounts  
in the cleared lysate (CL) and the 
immuno-precipitate were quantified 
by immunoblot analysis using poly-
clonal α-VSV antiserum (IB: polyVSV).  
D) Immunoprecipitates described  
in C) were used in a fluorescent in 
vitro phosphatase activity assay 
exploiting DifMUP as a substrate. 
The steady state enzymatic activities 
measured for the given protein com-
binations were normalised for the 
amount of precipitated PTPBR7-VSV, 
with the exception of the values  
for precipitates from cells solely 
transfected with the PTPBR7-T-VSV 
expression construct (BR7-T). 
Results (n=3) are presented as mean 
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values ± SEM (*p < 0.009).  
E) Lysates from COS-1 cells expres-
sing PTPBR7-VSV, PTPPBSγ-VSV or 
PTPBR7-C/S-VSV were subjected to 
immunoprecipitation (IP) using  
a monoclonal antibody against the 
VSV-G epitope tag. Proteins were 
released from the beads using VSV-G 
peptide and analysed on immuno-
blots and in fluorescent phosphatase 
activity measurements. Enzymatic 
activities were normalised for PTP 
protein content. Results (n=4) are 
presented as mean values ± SEM  
(*p < 0.002).
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In	this	study	the	concept	of	dimerisation	as	a	regulatory	mechanism	for	RPTP	
activity	was	tested	for	the	mouse	PTPRR	isoform	family.	Generation	of	a	
dedicated	antiserum	in	conjunction	with	selective	membrane	permeabilisation	
enabled	us	to	show	that	PTP-SL,	like	PTPBR7,	is	a	transmembrane-spanning	
protein.	These	two	RPTP	isoforms	formed	homo-	and	heteromeric	complexes,	
for	which	either	the	hydrophobic	segment	or	the	transmembrane	region		
is	required.	Unfortunately,	an	effect	of	the	PTPBR7	multimerisation	status	on	
its	catalytic	activity	towards	the	physiological	substrate	ERK1/2	could	not	be	
properly	assessed.	An	in	vitro	assay	exploiting	a	small-molecule	artificial	
substrate,	however,	indicated	a	significant	reduction	in	PTP	activity	upon	
multimerisation,	in	line	with	current	models	for	the	regulation	of	other	RPTPs.	
Originally	we	predicted	PTP-SL	to	be	a	type-I	transmembrane	protein	based	
on	the	presence	of	two	hydrophobic	regions	in	its	N-terminal	part	[36].	
However,	the	first	did	not	function	as	signal	peptide,	suggesting	PTP-SL	to		
be	a	membrane-associated	protein	[24].	Also	in	the	current	study	a	mutant	
essentially	consisting	of	the	HR	segment,	PTP-SL-H,	was	not	able	to	cross		
the	membrane.	The	HR	also	did	not	serve	as	transmembrane	anchor	since		
the	PTPBR7-H	mutant	was	secreted	into	the	medium.	Our	cell	permeabilisa-
tion	experiments	now	show	that	the	N-terminal	part	of	PTP-SL	is	located		
in	the	lumen	of	vesicular	structures	and	the	Golgi	apparatus,	whereas	the	
C-terminal	part	is	found	at	the	cytosolic	side,	demonstrating	that	PTP-SL	is		
a	transmembrane	protein.	Unlike	for	PTPBR7,	which	is	a	classical	type-I	
transmembrane	protein	that	is	co-translationally	targeted	to	the	ER	by	a	
cleavable	signal	peptide	and	anchored	in	the	lipid	bilayer	by	a	‘stop-transfer’	
transmembrane	domain,	the	N-terminus	of	PTP-SL	that	includes	the	HR	is	
probably	post-translationally	translocated	over	the	intracellular	membrane.	
The	TM	domain	would	then	serve	as	signal-anchor	sequence	to	initiate	trans-
location,	defining	PTP-SL	to	be	a	‘type-I	transmembrane	protein	without	
cleaved	signal’	or	‘type-III’	transmembrane	protein	[39].	
 • Discussion 39 • Spiess M: Heads or tails--
what determines the orientation 
of proteins in the membrane. 
FEBS Lett 1995, 369(1):76-79.
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Our	data	indicate	that	the	HR	segment	is	not	required	for	the	above	trans-
location	process	but	rather	serves	a	role	in	dimerisation.	Furthermore,	it	is	
required	for	the	proper	subcellular	localisation	of	the	two	receptor-type	
PTPRR	isoforms.	PTPBR7	is	predominantly	expressed	at	the	plasma	mem-
brane,	whereas	PTP-SL	is	localised	exclusively	on	intracellular	vesicles	and	
the	Golgi	apparatus	[21,	25].	Although	in	vivo	PTPBR7/PTP-SL	heterodimers	
most	likely	do	not	exist	in	view	of	the	distinct	spatiotemporal	expression	
patterns	of	PTPBR7	and	PTP-SL	[24],	co-transfection	studies	demonstrated		
an	overlapping	subcellular	localisation	in	the	Golgi	area	and	at	late	endosomal	
vesicles	(data	not	shown).	Surprisingly,	deletion	of	the	HR	sequence	essen-
tially	swapped	their	localisation	patterns.	PTP-SL-T-∆HR-VSV	was	found	also	
at	the	plasma	membrane,	whereas	PTPBR7-T-∆HR-VSV	no	longer	appeared		
at	the	cell	surface.	It	remains	as	yet	unclear	how	the	HR	on	the	one	hand	can	
facilitate	intracellular	retention	of	PTP-SL	and	on	the	other	hand	is	absolutely	
required	for	proper	cell	surface	routing	of	PTPBR7.	This	is	even	more	puzzling	
knowing	that	PTPBR7	is	subject	to	N-terminal	proteolytic	processing	at	the	
plasma	membrane	which	renders	a	cleaved	form,	PTPRR-65,	that	structurally	
resembles	PTP-SL	but	remains	localised	at	the	cell	surface	[8].
	 For	many	RPTPs	the	capacity	to	form	homo-	and	heterodimers	has	been	
documented.	Surprisingly,	the	protein	domains	that	mediate	the	binding	differ	
considerably	between	subfamilies.	First	examples	of	RPTP	dimerisation	
reflected	the	homotypic	association	of	RPTP	type	IIB	extracellular	segments	
on	opposing	cells	[40].	Crystallographic	studies	on	RPTPα triggered	the	notion	
that	PTP	domains	themselves	can	also	dimerise,	and	as	a	result	a	so-called	
‘wedge	structure’	in	the	one	molecule	blocks	the	catalytic	activity	of	the	other	
[17].	Many	examples	of	PTP	domain	–	PTP	domain	interactions	have	now	been	
reported,	including	intramolecular	ones	[41].	Contrary	to	most	RPTPs,	PTPBR7	
and	PTP-SL	contain	a	single	phosphatase	domain,	excluding	regulation	of	
activity	via	intramolecular	interactions	between	tandem	PTP	domains.	More-
over,	structural	and	chromatographic	data	indicated	that	the	PTPRR	phos-
phatase	domain	behaves	as	a	monomer	[42],	in	line	with	our	finding	that	the	
cytosolic	PTPPBSγ‘s	do	not	multimerise.	Also	the	single	PTP-like	domains		
of	IA-2	and	IA-2β	did	not	associate	with	the	PTPRR	PTP	segment	[15].	For	
multiple	RPTPs	the	TM	region	was	found	to	mediate	both	homotypic	and	
heterotypic	interactions	[14,	43,	44],	and	in	the	case	of	RPTPα	and	CD45	the	
weak	dimerisation	potential	displayed	by	their	ectodomains	may	well	add		
to	this	[14,	43].	In	a	comparative	study	the	homodimerisation	capacity	of	the	
PTPRR	TM	appeared	weaker	than	that	of	the	RPTPα	and	CD45	TM	[44],	
40 • Gebbink MF, Zondag GC, 
Wubbolts RW, Beijersbergen RL, 
van Etten I, Moolenaar WH:  
Cell-cell adhesion mediated by  
a receptor- like protein tyrosine 
phosphatase. J Biol Chem 1993, 
268(22):16101-16104.
41 • Blanchetot C, Tertoolen LG, 
Overvoorde J, den Hertog J :  
Intra- and intermolecular 
interactions between intracel-
lular domains of receptor protein-
tyrosine phosphatases. J Biol 
Chem 2002, 277(49):47263-47269.
42 • Szedlacsek SE, Aricescu AR, 
Fulga TA, Renault L, Scheidig AJ: 
Crystal structure of PTP-SL/
PTPBR7 catalytic domain: 
implications for MAP kinase 
regulation. J Mol Biol 2001, 
311(3):557-568.
43 • Xu Z, Weiss A: Negative 
regulation of CD45 by differen-
tial homodimerization of the 
alternatively spliced isoforms. 
Nat Immunol 2002, 3(8):764-771.
44 • Chin CN, Sachs JN, 
Engelman DM: Transmembrane 
homodimerization of receptor-
like protein tyrosine phospha-
tases. FEBS Lett 2005, 
579(17):3855-3858.
C
h
a
p
te
r 
4
10
perhaps	explaining	why	in	PTPBR7	and	PTP-SL	the	dimerisation	potential	of	
the	HR-containing	segment	is	also	exploited.	
	 The	KIM	domain	in	the	PTPRR	proteins	enables	their	association	with	
several	different	mitogen-activated	protein	kinases	(MAPKs),	including	ERK1	
and	ERK2,	which	leads	to	inactivation	of	the	MAPK	through	dephosphorylation	
of	their	regulatory	tyrosine	residue	[22,	45].	In	line	with	this,	significantly	
elevated	levels	of	phosphorylated	ERK	are	found	in	PTPRR	deficient	mouse	
brains	[23].	In	the	rat	phaeochromocytoma	cell	line	PC12,	however,	PTPRR	
isoforms	were	found	to	be	dispensable	for	ERK-dependent	signalling,	probably	
because	the	regulatory	serine	residue	in	the	KIM	domain	is	constitutively	
phosphorylated	in	these	cells	[29],	thereby	preventing	KIM-dependent	binding	
of	the	MAPKs	[46,	47].	In	the	current	study,	ectopic	expression	of	PTPBR7	
clearly	reduced	the	phosphorylation	levels	of	endogenous	(data	not	shown)	
and	ectopically	expressed	ERK	in	EGF-stimulated	cells.	However,	our	attempts	
to	alter	PTPBR7’s	specific	activity	towards	ERK	by	over-expression	of	a	
PTPBR7	mutant	that	lacks	the	KIM	and	PTP	domains	(PTPBR7-T),	which	by	
dimerising	with	the	wild	type	protein	should	mimick	an	increase	in	monomeric	
PTPBR7	in	the	cell,	could	not	be	interpreted	due	to	unexpected	effects	of		
the	PTPBR7-T	mutant	itself.	The	latter	may	be	explained	by	the	capacity	of	
PTPBR7-T	to	bind	to	other,	endogenous	RPTPs	(YN,	unpublished),	perhaps	
thereby	altering	their	activity.	In	our	in	vitro	phosphatase	assays	using	
PTPBR7-T	immunoprecipitates,	however,	no	significant	contribution	of		
co-purifying	COS	cell-endogenous	PTPs	was	apparent,	leaving	the	PTPBR7-T	
effect	on	ERK	phosphorylation	as	yet	enigmatic.	The	notion	that	PTPBR7:
PTPBR7-T	heterodimers	were	consistently	formed	during	the	above	experi-
ments	allowed	us	to	measure	PTP	activity	of	immunopurified	complexes	in	a	
direct	way	using	the	artificial	substrate	DifMUP.	This	disclosed	a	significant	
difference	in	normalised	relative	activity	(79.03	±	0.84	versus	89.93	±	2.06;	
arbitrary	units)	between	PTPBR7	and	PTPBR7:PTPBR7-T	immuno-complexes.	
Because	the	PTPBR7:PTPBR7-T	precipitate	still	contained	a	two-fold	excess	
of	PTPBR7,	its	normalised	activity	is	in	fact	confounded	by	the	portion	of	
PTPBR7	homodimers	and	possibly	monomers.	Direct	comparison	of	enzymatic	
activities	of	dimerising	(PTPBR7)	and	monomeric	(PTPPBSγ)	isoforms	also	
revealed	a	significantly	greater	activity	for	PTPRR	monomers.	Since	conceptu-
ally	an	on/off-type	of	regulation	by	dimerisation	is	the	most	straightforward,	
the	residual	activity	measured	in	the	PTPBR7	samples	would	be	explained	by	
assuming	that	about	half	of	the	PTPBR7	subunits	remained	monomeric.	
	 In	conclusion,	our	data	add	further	proof	to	a	model	in	which	RPTP	
45 • Muñoz JJ, Tárrega C, Blanco-
Aparicio C, Pulido R: Differential 
interaction of the tyrosine 
phosphatases PTP-SL, STEP and 
HePTP with the mitogen-
activated protein kinases 
ERK1/2 and p38alpha is 
determined by a kinase 
specificity sequence and 
influenced by reducing agents. 
Biochem J 2003, 372 
(Pt 1):193-201.
46 • Blanco-Aparicio C, Torres J, 
Pulido R: A novel regulatory 
mechanism of MAP kinases 
activation and nuclear 
translocation mediated by PKA 
and the PTP-SL tyrosine 
phosphatase. J Cell Biol 1999, 
147(6):1129-1136.
47 • Saxena M, Williams S, Tasken 
K, Mustelin T: Crosstalk between 
cAMP-dependent kinase and 
MAP kinase through a protein 
tyrosine phosphatase.  
Nat Cell Biol 1999, 1(5):305-311.
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dimerisation	results	in	the	attenuation	of	its	enzymatic	activity.	Oxidation-
induced	Sap-1	dimerisation	resulted	in	reduced	catalytic	activity	[20],	whereas	
antibody-induced	oligomerisation	of	DEP-1	was	shown	to	increase	activity	[13].	
Upon	treatment	of	cells	with	H2O2	we	noted	that	PTPBR7	multimerisation	was	
increased	in	a	dose-dependent	manner	(YN,	unpublished)	as	was	observed		
for	RPTPα	[48].	Putative	ligands	for	PTPBR7	(and	PTP-SL	for	that	matter)		
still	remain	to	be	identified.	Together	with	the	mapping	of	additional	PTPRR	
substrates	this	ultimately	will	allow	the	assessment	of	the	effect	of	multi-
merisation	on	PTPRR	activity	in	a	more	physiological	setting.
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Differentiation and survival of neuronal cell types relies on adequate 
neurotrophin signalling. The receptor tyrosine kinase TrkA belongs  
to the neurotrophin receptor family and specifically binds nerve growth 
factor, NGF. Activation of signalling pathways downstream of TrkA 
involves the autophosphorylation of several key tyrosine residues,  
the dephosphorylation of which implies involvement of protein tyrosine 
phosphatases, PTPs. Here, we demonstrate that the two transmem-
brane products encoded by the gene Ptprr (PTPBR7 and PTP-SL) are 
able to bind and dephosphorylate TrkA and its p41 cleaved fragment. 
This association is independent of the phosphatase domain, requires 
the presence of the hydrophobic segments, and does not occur with 
the highly related neurotrophin receptor TrkB. Strikingly, PTPBR7 and 
PTP-SL also promote the maturation and cell-surface expression of 
TrkA. These effects on binding, dephosphorylation and maturation  
of TrkA are not exerted by the cytosolic Ptprr gene products. These 
data put forward PTPBR7 and PTP-SL as versatile regulators of neuro-
trophin signalling events.
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Growth	factors	are	implicated	in	the	development	and	maintenance	of	the	
different	cell	populations	in	multicellular	organisms.	They	do	so	by	binding		
to	cell	surface	receptors,	so-called	receptor	tyrosine	kinases	(RTKs),	causing	
their	dimerisation	and	subsequent	auto-activation	through	tyrosine	phospho-	
rylation.	Timely	control	of	growth	factor	signalling	can	be	exerted	via	growth	
factor	availability,	receptor	levels	or	providence	of	downstream	signalling	com-
ponents.	In	addition,	proteins	that	neutralize	or	revert	the	effects	of	afore-
mentioned	signalling	components	are	controlling	determinants	as	well.	RTK	
signalling,	for	example,	is	counteracted	by	specific	protein	tyrosine	phospha-
tases	(PTPs)	that	revert	the	autophosphorylated	state	of	the	receptor	or	the	
phosphocontent	of	downstream	effectors	[1,	2].	On	the	other	hand,	PTPs	also	
can	act	as	positive	regulators	of	RTK	signalling	[3].	In	addition,	PTP	activity	
may	well	modulate	RTK	maturation	along	the	secretory	pathway	and	thus	
determine	growth	factor	receptor	levels	at	the	cell	surface	[4].	
	 Nerve	growth	factor	(NGF)	is	a	prototypical	neurotrophin	that	mediates	its	
effect	on	neuronal	populations	in	the	brain	through	binding	to	p75NTR,	the	
founding	member	of	the	tumour	necrosis	factor	family	of	receptors,	or	TrkA,	a	
member	of	the	tropomyosin-related	kinase	family	of	RTKs	[5].	TrkA	is	synthe-
sized	as	an	80-kDa	core	protein	that	is	immediately	glycosylated,	and	thereby	
converted	into	an	immature,	110-kDa	glycoprotein	(p110)	[6,	7].	Further	glyco-
sylation	occurs	in	the	Golgi	apparatus,	leading	to	the	140-kDa	mature	form	
(p140),	which	appears	at	the	cell	surface	[8,	9].	NGF-induced	dimerisation	and	
autophosphorylation	of	TrkA	starts	at	a	pair	of	adjacent	tyrosine	residues,	
Y680	and	Y681,	within	the	catalytic	domain	which	up-regulates	kinase	activity	
[10,	11].	Subsequent	phosphorylation	of	tyrosines	located	in	the	juxtamem-
brane	domain	(Y490)	and	the	carboxyl-terminal	region	(Y785)	results	in	
docking	sites	for	adaptor	proteins	that	relay	signals	towards	the	Ras,	PI3-K	
and	PLCγ	pathways	[12].	Interestingly,	the	N-glycosylation	of	TrkA	is	not	only	
required	for	the	appropriate	routing	and	stability	of	TrkA,	but	also	prevents	
ligand-independent	auto-activation	of	the	receptor	[6].	Proteolytic	shedding		
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of	TrkA	by	metalloproteases	leads	to	a	transmembrane	41-kDa	TrkA	variant	
that	is	constitutively	active	while	lacking	the	ligand-binding	ectodomain	[13-15].
	 Down-regulation	of	TrkA	activity	is	less	well	documented.	The	cytosolic	
PTP	Shp1	can	associate	with	and	dephosphorylate	TrkA	[16],	whereas	the	highly	
related	Shp2	is	implicated	in	fine	tuning	the	signalling	of	another	member	of	
the	Trk	family,	TrkB	[17].	Thus	far	two	receptor-type	PTPs	(RPTPs),	the	leuko-
cyte	common	antigen	related	receptor	LAR	and	the	homologous	RPTPσ,	are	
implicated	in	modulation	of	Trk	signalling.	RPTPσ	was	found	to	associate	with	
TrkA	and	inhibit	NGF-induced	neurite	outgrowth	[18].	LAR	appeared	a	positive	
regulator	of	TrkB	signalling	in	hippocampal	neurons	[19]	and	a	negative	
regulator	of	TrkA	signalling	in	neuroendocrine	PC12	cells	[20].	Both	activities	
are	exerted	through	association	with	the	Trk	complexes.	Interestingly,	NGF	
treatment	of	PC12	cells	results	in	upregulation	of	PTP	activity	[21]	and	a	two-
fold	increase	in	LAR	mRNA	levels	has	been	documented	[22].	Strikingly,	a	
nine-fold	induction	of	PCPTP1	mRNAs	eight	hours	after	NGF	administration		
to	PC12	cells	has	been	reported	[23],	which	may	point	to	a	regulatory	role	in	
NGF-induced	signalling	for	this	RPTP	as	well.	
	 PCPTP1	is	the	rat	orthologue	of	mouse	PTPBR7,	a	transmembrane	PTP	
that	belongs	to	the	protein	tyrosine	phosphatase	receptor-type	R	(PTPRR)	
family.	Mouse	PTPRR	isoforms	PTPBR7,	PTP-SL	and	PTPPBSγ-42/37	are	enco-
	ded	by	one	gene,	Ptprr,	have	distinct	subcellular	localizations,	are	differen-
tially	expressed	in	the	brain,	and	serve	as	physiological	MAPK	phosphatases	
[24-27].	In	the	current	study	we	investigated	the	potential	involvement	of	
PTPRR	proteins	in	TrkA-mediated	signalling.	We	demonstrate	that	the	PTPRR	
transmembrane	isoforms	PTPBR7	and	PTP-SL,	but	not	the	cytosolic	
PTPPBSγ-42/37	isoforms,	specifically	interact	with	TrkA	and	its	cleaved	
fragment	p41.	Concomitantly,	PTPBR7	and	PTP-SL	dephosphorylate	TrkA	on	
tyrosine	residues	relevant	for	signalling.	Furthermore,	they	promote	TrkA	
maturation,	increasing	TrkA	levels	at	the	cell	surface.	Thus,	transmembrane	
PTPRR	isoforms	may	modulate	TrkA-mediated	neurotrophin	signals	at	
multiple	levels	in	the	cell.
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Mammalian expression plasmids
Constructs	pSG8/PTPBR7-HA,	pSG8/PTP-SL-HA,	pSG8/PTPPBSγ-HA	and	
pSG8/PTPBR7-T-HA	have	been	described	previously	[28].	Plasmids	encoding	
catalytically	inactive	Cys-to-Ser	mutants	were	generated	by	site-directed	
mutagenesis	of	Cys-578	(numbering	corresponds	to	amino	acid	positions	in	
PTPBR7;	Acc.nr.	BAA06696)	using	the	QuickChange	protocol	(Stratagene,		
La	Jolla,	USA).	Rat	TrkA	and	TrkB	cDNAs	[18]	served	as	templates	for	PCR	
using	primer	EGFP-N	(5’-GAGGTCTATATAAGCAGA	GC-3’)	in	combination	with	
TrkA	(5’-AGACTCGAGGCCCAGAACGTCCAGGTAACT-3’)	or	TrkB	(5’-GCTCTCGAG	
GCCTAGGATGTCCAGGTAGAC-3’)	antisense	primers,	respectively,	with	added	
XhoI	sites	(underlined).	The	amplified	fragments	were	digested	with	EcoRI		
and	XhoI	and	subcloned	into	vector	pSG8-VSV	[29],	rendering	plasmids	pSG8/
TrkA-VSV	and	pSG8/TrkB-VSV.	Constructs	generated	by	PCR	were	verified	by	
sequence	analysis.
Cell culture
COS-1	cells	(ATCC	nr:	CRL-1650)	were	cultured	in	a	humidified	atmosphere		
at	37ºC	with	5%	CO2	using	Dulbecco’s	Modified	Eagle’s	Medium	(DMEM,	Gibco	
BRL,	Gaithersburg,	MD)	supplemented	with	10%	fetal	calf	serum	(FCS).	Cells	
were	seeded	at	a	density	of	750,000	cells	per	10-cm	dish	or	140,000	cells	per	
well	on	a	6-wells	plate,	respectively,	and	transient	transfection	on	the	next	day	
was	with	DEAE-dextran	[30].	Neuro-2A	cells	(ATCC	nr:	CCL-131)	were	cultured	
as	described	[31].	Two	million	cells	were	seeded	in	a	10-cm	dish	and	the	
following	day	transient	transfection	was	performed	using	lipofectamine-plus	
according	to	the	manufacturer’s	instruction	(Invitrogen	Life	Technologies,	
Breda,	The	Netherlands).
Co-immunoprecipitations and immunoblot analyses
COS-1	cells	on	a	10-cm	dish	were	harvested	24	h	after	transfection	and	the	
obtained	lysates	served	in	immunoprecipitation	and	immunoblot	experiments	
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following	established	protocols	[28].	HA-epitope	tagged	proteins	were	
precipitated	with	beads	preloaded	with	mouse	monoclonal	α-HA	antibody	
12CA5	[32].	Obtained	proteins	were	analysed	on	immunoblot	using	rabbit	
polyclonal	α-HA	(sc-805,	Santa	Cruz	Biotechnologies,	Santa	Cruz,	USA)		
and	affinity-purified	rabbit	polyclonal	α-VSV	(ITK	Diagnostics	BV,	Uithoorn,	
The	Netherlands)	antibodies,	diluted	1:1000	and	1:10,000	respectively.
Recombinant GST-fusion protein production
The	bacterial	expression	plasmid	pGEX-SL	has	been	described	previously	[33].	
A	catalytically	inactive,	DA/CS	double	mutant	version	of	this	plasmid	was	
generated	by	site-directed	mutagenesis	of	Asp-553	and	Cys-578	(numbering	
corresponds	to	amino	acid	positions	in	PTPBR7;	Acc.nr.	BAA06696)	using		
the	QuickChange	protocol	(Stratagene).	Plasmids	were	introduced	into	E.coli	
BL21(DE3)pLysS,	and	GST	fusion	proteins	were	induced	and	isolated	as	
described	[34].
In vitro TrkA tyrosine dephosphorylation assay
COS-1	cells	transiently	expressing	TrkA-VSV	were	treated	with	40µg/ml	
BpV(phen)	[35]	for	30	min,	washed	twice	with	ice	cold	PBS	and	lysed	[36].	
Subsequently,	TrkA-VSV	was	immunoprecipitated	with	the	anti-VSV	mouse	
monoclonal	antibody	P5D4	[37].	Following	extensive	washing	with	lysis	buffer,	
immunoprecipitated	proteins	were	washed	once	with	incubation	buffer		
(25	mM	HEPES	pH	7.5,	5	mM	EDTA,	10	mM	DTT	and	1%	Triton	X-100).	Immuno-
precipitates	were	then	rotated	for	1h	at	37°C	in	600µl	incubation	buffer	con-
taining	2µg	GST-SL	or	GST-SL-DA/CS	fusion	protein.	Beads	were	washed	once	
with	incubation	buffer	before	being	resuspended	in	30	µl	sample	buffer.	TrkA-
VSV	tyrosine	phosphorylation	levels	were	analysed	on	Western	blots	using	
monoclonal	α-phosphotyrosine	(PY20,	Santa	Cruz	Technologies)	and	poly-
clonal	α-VSV	antibodies	(ITK	Diagnostics	BV)	(in	a	1:1000	and	1:10,000	dilution,	
respectively)	in	conjunction	with	appropriate	goat	secondary	antibodies	conju-
gated	to	Alexa	Fluor	680	(Invitrogen,	Breda,	The	Netherlands)	or	IRDye800	
(Rockland	Immunochemicals,	Gilbertsville,	USA)	fluorescent	dyes	to	allow	
simultaneous	detection	on	an	Odyssey	infrared	imaging	system	(LI-COR	
biosciences,	Cambridge,	UK).		
In vivo TrkA tyrosine dephosphorylation assay
Cells,	transiently	expressing	TrkA-VSV	in	combination	with	either	wild	type	or	
catalytically	inactive	PTPRR	isoforms,	were	serum-starved	for	6h	before	being	
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stimulated	with	20ng/ml	NGF	for	20	min	and	scraped	in	lysis	buffer	[36].	
Following	immunoprecipitation	of	VSV-tagged	TrkA,	beads	were	washed	five	
times	with	lysis	buffer	and	resuspended	in	30	µl	sample	buffer.	Precipitated	
protein	was	analysed	on	Western	blots	using	mouse	monoclonal	α-VSV	anti-
body	simultaneously	with	rabbit	phosphoY490-TrkA	(#9141,	Cell	Signalling	
Technology,	Beverly,	USA)	or	phosphoY680/681-TrkA	(sc-7996,	Santa	Cruz	
Biotechnologies)	antibodies	at	a	1:1000	dilution.	Appropriate	fluorescent	
secondary	antibodies	(mentioned	above)	enabled	detection	and	quantification	
on	an	Odyssey	infrared	imaging	system	(LICOR	Biosciences).	Results	are	
expressed	as	the	ratio	of	the	phospho-TrkA	and	α-VSV	signal	intensities.	
Metabolic pulse-chase experiments
Twenty	four	hours	after	transfection,	COS-1	cells	were	metabolically	labelled	
with	Tran35S-label	(ICN	Radiochemicals,	Irvine,	USA)	as	described	previously	
[31]	and	chased	for	different	time	periods.	Subsequently,	cells	were	washed	
twice	with	ice-cold	PBS	and	lysed	[36].	Lysates	were	used	for	immunoprecipi-
tation	purposes	as	described	above.	Precipitated	proteins	were	subjected		
to	SDS-PAGE	and	electroblotting,	and	radiolabeled	proteins	were	detected		
and	quantified	using	a	Molecular	Imager	FX	(Biorad,	Veenendaal,		
The	Netherlands).
Deglycosylation experiments
TrkA-VSV	was	transiently	expressed	in	COS-1	cells	together	with	wild	type		
or	inactive	PTPBR7.	Protein	lysates	were	harvested	after	24h	and	following	
TrkA-VSV	immunoprecipitation	(as	described	above),	the	obtained	proteins	
were	digested	with	Endoglycosidase	H	(EndoH)	or	N-glycosidase	F	(PNGaseF)	
according	to	manufacturer’s	protocol	(Roche	Diagnostics	GmbH,	Mannheim,	
Germany).	Proteins	were	then	subjected	to	SDS-PAGE	and	analysed	on	
immunoblots	using	α-VSV	antibody.	
Cell surface biotinylation
Twenty-four	hours	after	transfection	with	combinations	of	TrkA-VSV,	PTPBR7-
WT,	PTPPBSγ-WT	and	PTPBR7-C/S	expression	constructs,	COS-1	cell	surface	
proteins	were	biotinylated	as	described	previously	[31].	After	harvesting		
of	cells,	TrkA-VSV	was	immunoprecipitated	and	analysed	by	dual	immunoblot	
detection	using	simultaneously	IRDye800-conjugated	streptavidin	and	α-VSV	
antibody	in	combination	with	Alexa	Fluor	680-labeled	goat	anti-rabbit	
antibodies	on	an	Odyssey	infrared	imaging	system	(LICOR	Biosciences).
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S-transferase (pGEX) fusion 
proteins. Anal Biochem 1993, 
210(1):179-187.
35 • Posner BI, Faure R, Burgess 
JW, Bevan AP, Lachance D, 
Zhang-Sun G, Fantus IG, Ng JB, 
Hall DA, Lum BS: Peroxovanadium 
compounds. A new class of 
potent phosphotyrosine 
phosphatase inhibitors which 
are insulin mimetics. J Biol Chem 
1994, 269(6):4596-4604.
36 • Noordman YE, Jansen PAM, 
Hendriks WJAJ: Tyrosine-specific 
MAPK phosphatases and the 
control of ERK signalling in PC12 
cells. J Mol Signaling 2006, 1:4.
37 • Kreis TE: Microinjected 
antibodies against the cytoplas-
mic domain of vesicular 
stomatitis virus glycoprotein 
block its transport to the cell 
surface. Embo J 1986, 5(5):931-941.
PTPBR7 and PTP-SL associate with the neurotrophin receptor TrkA
To	investigate	whether	brain-specific	PTPRR	proteins	are	also	capable	of	
associating	with	tyrosine	kinases	of	the	neurotrophin	receptor	family	we	tested	
for	co-immunoprecipitation	using	lysates	of	transiently	transfected	COS-1	
cells	expressing	C-terminally	VSV-tagged	versions	of	TrkA	or	TrkB	in	combi-
nation	with	HA-tagged	PTPRR	isoforms.	Receptor-type	isoforms	PTPBR7		
and	PTP-SL	specifically	associated	with	TrkA,	but	not	TrkB,	while	the	cytosolic	
PTPPBSγ	isoforms	did	not	bind	either	one	of	the	Trk	receptors	(Fig.	1,	lower	
panels).	Interestingly,	PTPBR7	and	PTP-SL	not	only	bound	mature	p140	TrkA	
and,	to	a	lesser	extent,	immature	p110	TrkA,	but	they	also	very	efficiently	
interacted	with	the	transmembrane	p41	TrkA	proteolytic	fragment	(Fig.	1,	
lower	panels).	
	 In	a	previous	study	we	reported	on	the	ability	of	PTPBR7	and	PTP-SL	to	
form	homo-	and	heterodimers	via	interactions	mediated	by	their	hydrophobic	
segments	[28].	To	map	the	region	involved	in	the	association	with	TrkA,	we	co-
expressed	TrkA	with	PTPBR7	or	PTP-SL	mutants	that	lack	the	intracellular	
segment.	These	PTPBR7-T	and	PTP-SL-T	mutants	[28]	still	associated	with	
TrkA	(data	not	shown),	indicating	that	the	KIM	and	PTP	domain	of	PTPBR7	and	
PTP-SL	are	dispensable	for	this	interaction	as	well.	
Phosphotyrosine-containing TrkA is dephosphorylated by PTPRR in vitro
To	test	whether	TrkA	may	represent	a	genuine	PTPRR	substrate,	we	precipi-
tated	TrkA-VSV	from	lysates	of	BpV(phen)-treated	COS-1	cells.	Subsequently,	
recombinant	GST-fusion	protein	containing	the	PTPRR	phosphatase	domain	
[33],	or	as	a	control	its	catalytically	inactive	version,	was	added.	The	p110	TrkA	
form	dominates	over	the	mature	p140	and	the	constitutively	active	p41	TrkA	
versions	in	the	BpV(phen)-treated	cell	lysates	(Fig.	2A,	right	panel).	Detectable	
tyrosine	phosphorylation	levels	were	obtained	for	all	three	TrkA	species		
upon	use	of	the	phosphotyrosine-specific	PY20	antibody	on	immunoblots.	
Addition	of	the	active	–	but	not	the	inactive	–	recombinant	PTPRR	catalytic	
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Figure 1 • Co-immunoprecipitation 
of TrkA with PTPBR7 and PTP-SL. 
A) Schematic representation of the 
proteins used in the experiments. 
Signal peptide (SP), leucine-rich 
repeat (LRR), immunoglobulin-like 
domain (Ig-like), transmembrane 
domain (TM), catalytic tyrosine 
kinase domain (PTK), hydrophobic 
region (HR), kinase-interacting  
motif (KIM), catalytic phosphotyro-
sine phosphatase domain (PTP) and 
C-terminal HA or VSV tags (T) are 
indicated.  
B) HA-tagged PTPRR isoforms were 
co-expressed with VSV-tagged TrkA 
(left panels) or TrkB (right panels)  
in COS-1 cells. Upon immunoprecipi-
tation of HA-tagged proteins (IP: 
12CA5), co-precipitating proteins 
were detected using α-VSV antibody 
(IB: polyVSV). Expression and preci-
pitation of HA-tagged proteins was 
verified on blots using a polyclonal 
anti-HA tag antiserum (IB: polyHA). 
Note that the p41 TrkA cleavage 
product ( indicated with an arrow  
in the lower left panel) is not detec-
ted in the cell lysate (CL). Size 
markers ( in kDa) are indicated on 
the left. 
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Figure 2 • In vitro tyrosine dephos- 
phorylation of TrkA by the PTPRR 
phosphatase domain. 
A) COS-1 cells expressing TrkA-VSV 
were treated with BpV(phen) before 
being lysed. Immuno-precipitated 
VSV-tagged proteins (IP: P5D4) were 
incubated with active (WT) or 
inactive (DA/CS) recombinant GST-
PTPRR phosphatase domain fusion 
proteins and then analysed on 
Western blots with monoclonal  
α-phosphotyrosine (IB: PY20) and 
polyclonal α-VSV antibodies. Arrows 
depict the tyrosine-phosphorylated 
and non-phosphorylated forms of 
p41 TrkA (p41) and the immature 
(p110) and mature (p140) full - length 
TrkA species. Size markers ( in kDa) 
are indicated in between the panels.  
B) Purified recombinant GST fusion 
proteins that were used in A), 
containing active (WT) or mutant 
(DA/CS) PTPRR phosphatase 
domain, were analysed on Western 
blot with rabbit polyclonal α-SL 
antibody. Size markers ( in kDa) are 
indicated on the left.
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Figure 3. Effects of PTPRR isoform 
expression on TrkA tyrosine phos-
phorylation. 
A) COS-1 cells expressing active 
(WT) or inactive (C/S) PTPRR 
isoforms in combination with VSV-
tagged TrkA were treated prior to 
lysis with NGF. Cell lysates (CL) were 
immunoblotted using anti-PTPRR 
monoclonal antibody 6A6. Immuno-
precipitated TrkA (IP: P5D4) was 
quantified on blot ( IB: α-VSV) and 
simultaneously site-specific phospho-
rylation levels were monitored using 
either pY680/681 or pY490 phospho-
specific antibodies. Arrows on the 
right indicate the positions of the 
various TrkA species. Size markers 
( in kDa) are indicated on the left. 
Ratio-imaging of immunoblot sig-
nals from three independent expe-
riments allowed the quantitative 
analysis of relative phosphorylation 
levels at positions Y490 (B-D) and 
Y680/681 (E-G) in the three distinct 
TrkA species: p140 (B, E), p110 (C, F) 
and p41 (D, G). All results are presen-
ted as mean values ± SEM (n=3) for 
the various PTPRR isoforms that 
were co-expressed with TrkA (indica-
ted below graphs C, F and G only). 
Asterisks in panels B) (* p<0.007), 
C) (* p<0.008), D) (* p<0.022; ** 
p<0.05), E) (* p<0.001; ** p<0.036) 
and G) (* p<0.032) reflect signi-
ficance levels as determined with 
Student’s t-test.
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domain	led	to	complete	dephosphorylation	of	all	TrkA	species	(Fig.	2A,	left	
panel).	Notably,	p41	TrkA	dephosphorylation	is	also	demonstrated	by	its	
increased	migration	on	SDS	protein	gels	(arrows	in	Fig.	2A).	
	
PTPRR isoforms dephosphorylate TrkA on residues Y490 and Y680/681
As	mentioned,	several	different	tyrosine	residues	in	the	cytoplasmic	portion		
of	TrkA	are	phosphorylated	upon	activation	by	NGF.	To	determine	whether	
there	is	an	in	vivo	preference	by	PTPRR	for	any	of	the	TrkA	phosphotyrosine	
sites	we	co-transfected	COS-1	cells	with	expression	constructs	for	TrkA-VSV	
and	wild	type	or	enzymatically	inactive	PTPRR	isoforms.	Following	NGF	
administration	and	TrkA	immunoprecipation	the	phosphotyrosine	levels	at	
residues	Y490	and	Y680/681	in	the	mature	(p140),	immature	(p110)	and	cleaved	
(p41)	TrkA	species	were	determined	on	immunoblots	using	phosphorylation	
site-specific	antibodies	(Fig.	3).	Co-expression	with	either	PTPBR7	or	PTP-SL	
reduced	the	phosphorylation	levels	on	positions	Y490	and	Y680/681	in	mature	
TrkA.	(Fig.	3B,	E).	Also	in	p41	TrkA	the	Y490	and	Y680/681	phosphorylation	
levels	were	significantly	lowered	upon	co-expression	of	PTPBR7	or	PTP-SL	
(Fig.	3D,	G).	In	contrast,	co-expression	of	PTPPBSγ	only	significantly	de-
creased	phosphorylation	levels	at	Y680\681	in	mature	TrkA	(Fig.	3E).	In	
immature	TrkA	(p110)	the	phospho-Y490	levels	also	go	down	upon	PTPBR7	or	
PTP-SL	co-expression,	but	only	in	the	case	of	PTPBR7	this	reached	signifi-
cance	(Fig.	3C).	Y680/681	phosphorylation	in	immature	TrkA,	on	the	contrary,	
was	not	affected	at	all	by	co-expression	of	PTPRR	isoforms	(Fig.	3F).	Impor-
tantly,	inactive	PTPRR	isoforms	did	not	reduce	relative	TrkA	phosphotyrosine	
levels.	Rather	a	substrate-trapping,	protective	effect	towards	phosphorylated	
TrkA	becomes	apparent	upon	co-expression	with	catalytically	dead	PTPRR	
mutants,	but	this	only	reached	significance	for	Y490	phosphorylation	levels		
in	p41	upon	co-expression	of	inactive	PTP-SL	(Fig.	3D).	
	 In	conclusion,	PTPBR7	and	PTP-SL	efficiently	dephosphorylate	positions	
Y490	and	Y680/681	in	p140	and	p41	TrkA	species.	Phosphorylation	levels	in	
immature	p110	TrkA,	however,	are	much	less	readily	reduced	by	the	PTPRR	
isoforms.	Finally,	the	moderate	but	nevertheless	significant	effect	of	PTPPBSγ	
on	Y680/681	phospholevels	in	mature	TrkA	might	be	a	result	of	the	high	
expression	levels	of	this	PTP	isoform.	
	
PTPBR7 and PTP-SL promote TrkA maturation
Strikingly,	we	noted	that	BpV(phen)	treatment	of	cells	resulted	in	a	markedly	
lower	amount	of	mature,	p140	TrkA	as	compared	to	untreated	cells	(comp.		
Figure 4 • PTPBR7 and PTP-SL 
promote TrkA maturation. 
A) TrkA-VSV, immunoprecipitated 
(IP: P5D4) from COS-1 cells co-
expressing wild type (WT) or inactive 
(C/S) PTPBR7, was treated with 
PNGaseF or EndoH and subsequently 
immunoblotted using polyclonal α-
VSV antibody (IB: polyVSV). TrkA 
species, including the 80 kDa core 
protein, are indicated by arrows on 
the right. 
B) Quantitation of the p140 TrkA 
steady state levels relative to that of 
p110 TrkA as determined in three 
independent immunoblot experiments 
like the one depicted in Figure 3A. 
Co-expressed PTPRR isoforms are 
indicated below the bars. Results are 
presented as mean values ± SEM 
(n=3, Student’s t-test, * p<0.007). 
C) COS-1 cells expressing VSV-tag-
ged TrkA alone (-), or TrkA together 
with wild type (BR7-WT) or in-active 
(BR7-C/S) PTPBR7, were cultured  
in the presence of [35S]methionine-
[35S]cysteine for 20min and subse-
quently chased with fresh medium 
for the indicated time periods before 
being lysed. Immunoprecipitated 
TrkA was subjected to SDS-PAGE and 
blotting, and radioactivity was 
detected using a Molecular Imager 
device. Arrows on the right indicate 
the positions of the p140 and p110 
TrkA species. 
D) Maturation of de novo synthe-
sized TrkA, as determined in (C), 
expressed in arbitrary units (a.u.) 
that reflect the ratio of p140 and 
p110 signals. 
E) TrkB-VSV and TrkA-VSV precursors 
(arrow) and mature proteins (arrow-
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head) were immunoprecipitated (IP: 
P5D4) from COS-1 cells co-expres-
sing wild type (WT) or inactive (C/S) 
PTPBR7. Detection on immunoblots 
was using polyclonal α-VSV anti-
body (IB: polyVSV). Expression of 
PTPBR7 proteins in the lysates (CL) 
is visualised on blots using mono-
clonal antibody 6A6. 
F) COS-1 cells expressing TrkA-VSV 
in combination with wild-type (WT) 
or inactive (C/S) PTPBR7, or with 
PTPPBSγ, were surface-biotinylated 
for 45 min at 4°C before being lysed. 
Immunoprecipitated TrkA-VSV (IP: 
P5D4) was analysed on blots using 
fluorescently labelled streptavidin 
(upper panel) and α-VSV antiserum 
(middle panel) allowing dual detec-
tion on an Odyssey infrared imager. 
Expression of PTPRR isoforms in cell 
lysates (CL) was verified on separate 
blots using polyclonal α-SL antibody 
( lower panel). Arrows on the right 
indicate the various TrkA species. 
Size markers ( in kDa) are indicated 
on the left. 
G) Neuro-2A cells expressing active 
(WT) or inactive (C/S) PTPBR7 in 
combination with VSV-tagged TrkA 
were treated prior to lysis with NGF. 
Cell lysates (CL) were immunoblot-
ted using anti-PTPRR monoclonal 
antibody 6A6. Immunoprecipitated 
TrkA (IP: P5D4) was quantified on 
blot ( IB: α-VSV) and simultaneously 
site-specific phosphorylation levels 
were monitored using either 
pY680/681 or pY490 phospho-
specific antibodies. Arrows on the 
right indicate the positions of the 
various TrkA species. Size markers 
( in kDa) are indicated on the left.
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Figs	1	and	2)	Furthermore,	over-expression	of	PTPBR7	and	PTP-SL	not	only	
resulted	in	TrkA	dephosphorylation	but	also	in	elevated	quantities	of	p140	TrkA	
(Fig.	3A)	reminiscent	of	the	phenomenon	observed	upon	co-expression	of		
the	PTP	Shp1	and	an	RTK	mutant,	FLT-3	ITD	[4].	Application	of	N-glycosidase	F	
(PNGaseF)	and	Endoglycosidase	H	(EndoH)	on	TrkA	immunoprecipitates	
confirmed	that	the	species	observed	on	immunoblots	reflected	the	distinct	
TrkA	maturation	stages	(Fig.	4A),	prompting	for	more	quantitative	studies	on	
the	effects	of	PTPRR	co-expression	on	the	steady-state	p140	/	p110	TrkA	ratio	
(Fig.	4B).	Strikingly,	inactive	PTPRR	isoforms	or	wild	type	PTPPBSγ	did	not	
alter	p140	/	p110	TrkA	ratios,	but	expression	of	catalytically	active	PTPBR7	or	
PTP-SL	resulted	in	a	six	to	seven-fold	higher	p140	/	p110	ratio	as	observed	in	
cells	transfected	with	TrkA	constructs	alone.	This	promoting	effect	on	the	
maturation	of	TrkA	was	corroborated	in	a	pulse-chase	metabolic	labelling	
experiment	(Fig.	4C).	Quantification	of	radioactive	signals	for	the	immuno-
precipitated	TrkA	species	confirmed	that	PTPBR7	promotes	TrkA	maturation		
(Fig.	4D)	and	that	this	effect	is	dependent	of	PTPBR7	enzyme	activity.	Impor-
tantly,	PTPBR7	co-expression	had	no	effect	on	TrkB	maturation	(Fig.	4E)		
nor	on	that	of	the	unrelated	glycoprotein	VSV-G	(data	not	shown),	indicating	
that	the	phenomenon	requires	specific	protein	binding	and	does	not	affect		
the	maturation	machinery	per	se.	The	augmented	TrkA	maturation	was	found	
to	result	in	a	clear	increase	of	TrkA	protein	levels	on	the	cell	membrane,	as	
revealed	by	cell-	surface	biotinylation	experiments	(Fig.	4F).	The	above	
findings	are	not	restricted	to	observations	in	COS-1	cells;	also	in	transfected	
mouse	neuroblastoma	(Neuro-2A)	cells	we	observed	TrkA-specific	binding		
and	dephosphorylation	as	well	as	a	maturation-promoting	effect	by	wild	type	
PTPBR7	(Fig.	4G).	Thus,	next	to	counteracting	NGF	signalling	through	direct	
dephosphorylation	of	TrkA	complexes,	receptor-type	PTPRR	isoforms	
augment	the	maturation	and	cell	surface	expression	of	TrkA.
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Thus	far	the	PTPRR	isoforms	PTPBR7,	PTP-SL	and	PTPPBSγ	have	been	
implicated	in	the	control	of	growth	factor	signalling	at	the	MAP	kinase	level	
because	their	kinase	interaction	motif	just	N-terminal	of	the	catalytic	PTP	
domain	enables	them	to	bind	and	dephosphorylate	ERK	and	p38	MAPKs	[38].	
In	line	with	this,	we	recently	demonstrated	elevated	ERK1/2	phosphorylation	
levels	in	brains	of	PTPRR	deficient	mice	[27].	However,	overexpression	or	
knockdown	of	PTPRR	members	in	rat	PC12	cells	remained	without	major	
consequences	for	MAPK	signalling	pathways	induced	by	EGF	and	NGF	[36].	
The	brain-specific	receptor-type	transmembrane	PTPRR	isoforms,	PTPBR7	
and	PTP-SL,	form	homo-	and	hetero-multimers	through	hydrophobic	seg-
ment-mediated	interactions	[28].	In	the	current	study	we	demonstrated	that	
PTPBR7	and	PTP-SL,	but	not	the	cytosolic	PTPPBSγ	variants,	associate	with	
and	dephosphorylate	neurotrophin	receptor	TrkA	species,	including	the	
constitutively	active	p41	variant.	This	association	is	specific	since	the	highly	
related	TrkB	is	not	bound	by	PTPRR	isoforms.	Intriguingly,	this	interaction		
of	PTPRR	transmembrane	forms	with	TrkA	positively	contributed	to	the	
maturation	and	stability,	and	thus	increased	cell	surface	expression,	of	the	
TrkA	receptor.
	 Multimerisation	of	PTPBR7	and	PTP-SL	is	mediated	independently	by		
the	transmembrane	domain	(TM)	and	a	hydrophobic	region	(HR)	located		
N-terminally	[28].	Association	of	these	RPTPs	with	TrkA	also	depends	on	the	
transmembrane	parts.	The	p41	TrkA	species	that	almost	completely	lacks		
the	extracellular	domain	[13]	associates	very	efficiently	with	PTPBR7	and	PTP-
SL	but	not	at	all	with	the	PTPPBSγ	isoforms	that	in	fact	correspond	to	the	
cytosolic	segments	of	PTPBR7	and	PTP-SL.	Furthermore,	PTPBR7	and	PTP-SL	
mutants	that	lack	the	cytosolic	part	still	bind	TrkA.	A	role	for	transmembrane	
(TM)	domains	in	TrkA	interactions	is	not	unprecedented.	For	example,	the	
interaction	between	TrkA	and	the	ankyrin-rich	membrane-spanning	(ARMS)	
protein,	that	is	involved	in	downstream	neurotrophin	signalling,	occurs	
through	the	respective	TM	domains	[39]	and	also	the	p75NTR	neurotrophin	
 • Discussion 38 • Pulido R, Zúñiga A, Ullrich A: 
PTP-SL and STEP protein tyrosine 
phosphatases regulate the 
activation of the extracellular 
signal-regulated kinases ERK1 
and ERK2 by association through 
a kinase interaction motif. Embo J 
1998, 17(24):7337-7350.
39 • Arévalo JC, Yano H, Teng KK, 
Chao MV: A unique pathway for 
sustained neurotrophin signal-
ling through an ankyrin-rich 
membrane-spanning protein. 
Embo J 2004, 23(12):2358-2368.
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receptor	TM	is	essential	for	p75NTR-TrkA	complex	formation	[40].	Recently,	
the	type	IIb	RPTPs,	LAR	and	RPTPσ,	were	also	found	to	associate	with	the	TrkA	
signalling	complex	and	for	RPTPσ	the	responsible	segment	was	mapped	to	its	
TM	[18,	20].	Future	experiments	should	reveal	whether	more	RPTPs	exploit	
their	transmembrane	segments	not	only	for	homotypic	clustering	[41],	but	also	
for	the	selection	of	receptor-type	substrates	through	transmembrane	associa-
tions.	It	also	remains	to	be	determined	whether	all	these	TrkA-associating	
proteins	bind	in	a	mutually	exclusive	manner	or	form	multiprotein	complexes	
with	TrkA.
	 The	preferential	binding	and	dephosphorylation	of	the	cleaved	TrkA	p41	
fragment	by	PTPBR7	and	PTP-SL	is	intriguing.	Cleavage	of	RTK	ectodomains	
may	serve	to	render	the	receptors	insensitive	for	ligand-induced	activation	
[13]	and	thus	down-regulate	RTK	signalling	[42].	However,	extracellular	
cleavage	of	TrkA	produces	a	constitutively	tyrosine-phosphorylated	and	signal-
ling	competent	fragment	[43]	and	perhaps	the	preferred	binding	of	PTPBR7	
and	PTP-SL	to	p41	TrkA	provides	an	effective	means	to	neutralize	this	
constitutively	active	tyrosine	kinase.
	 Following	activation	of	TrkA	at	the	plasma	membrane,	the	NGF-TrkA	
complex	is	rapidly	internalised	and	the	resulting	signalling	endosomes	are	
retrogradely	transported	to	the	cell	body	to	regulate	survival	and	differen-
tiation	[44].	PTPBR7	is	present	at	the	plasma	membrane	and	in	endosomal	
structures	[30]	and	therefore	may	dephosphorylate	TrkA	immediately	after	
activation	as	well	as	during	its	journey	through	the	endocytotic	pathway.		
In	contrast,	PTP-SL	is	excluded	from	the	plasma	membrane	and	early	endo-
somes	and	rather	resides	at	the	trans-Golgi	network	and	late	endosomes	[30].	
With	this	in	mind,	cells	expressing	PTP-SL	are	expected	to	be	more	sensitive		
to	NGF	as	compared	to	PTPBR7	expressing	cells.	The	conspicuous	develop-
mental	switch	in	Ptprr	promoter	use	that	results	in	the	replacement		
of	PTPBR7	transcripts	by	PTP-SL	messengers	in	the	postnatal	cerebellum		
of	mice	and	rat	[24]	may	reflect	such	a	putative	sensitivity	regulation.
	 The	TrkA	ectodomain	is	rapidly	co-translationally	glycosylated	within		
the	ER,	presumably	to	prevent	aberrant	autoactivation	of	the	cytosolic	kinase	
domain,	and	the	modifications	further	mature	in	the	Golgi	before	the	receptor	
is	directed	towards	the	cell-surface	[6].	Tyrosine	phosphorylation	indeed	
inhibits	maturation	of	RTKs;	the	highly	active	mutant	version	of	FGFR3,	inacti-
vation	[45].		Likewise,	constitutively	active	tumor-associated	FLT-3	mutants	
matured	poorly	as	compared	to	the	wild	type	RTK,	and	maturation	was	speeded	
up	upon	overexpression	of	several	non-receptor-type,	cytosolic	PTPs	[4].		
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This	effect	on	RTK	maturation	was	also	noted	for	PDGFβ-R,	c-Kit	and	Ros	but	
could	not	be	exerted	by	the	receptor-type	RPTPα	[4].	Our	results	provide	first	
evidence	that	receptor-type	PTPs,	i.e.	PTPBR7	and	PTP-SL,	can	also	promote	
RTK	maturation.	Moreover,	since	the	RPTP	effect	is	specific	for	TrkA	and	
depends	on	PTP	catalytic	activity,	this	suggests	a	substrate-specific	chaper-
one-like	role	for	RPTP	–	RTK	pairs	in	the	fine	tuning	of	growth	factor	signalling	
relays	at	the	cell	surface.	We	hypothesise	that	the	net	effect	of	increased	
PTPBR7/PTP-SL	levels	on	TrkA	signalling	may	be	improved	ligand	sensitivity	
paired	with	a	subdued	intracellular	response	window.	Elevated	receptor	
amounts	at	the	cell	surface	will	enable	the	cell	to	respond	to	lower	NGF	levels.	
The	subsequent	downstream	signalling,	in	turn,	will	be	attenuated	due	to		
the	counteracting	activity	of	increased	PTPRR	transmembrane	isoform	levels.	
Indeed,	net	phosphorylation	levels	in	cells	expressing	wildtype,	but		
not	catalytically	inactive,	PTPBR7	following	a	20’	NGF	stimulus	lags	behind	
that	of	control	cells,	despite	increased	TrkA	receptor	levels	(Fig.	3A).	This,		
in	combination	with	the	observed	preferential	affinity	for	constitutively	active	
p41	TrkA	fragment,	puts	forward	PTPBR7	and	PTP-SL	as	versatile	modulators	
of	TrkA-mediated	signalling	in	neuronal	cells.
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Since	the	purification	of	the	first	protein	tyrosine	phosphatase	(PTP)	almost	
two	decades	ago	[1]	a	wide	variety	of	different	PTPs	has	been	discovered.	Pre-
sence	of	a	well-conserved	signature	sequence	(HCXXXXXR,	encompassing	the	
catalytic	site	cysteine)	facilitated	PTP	identification	through	molecular	biolo-
gical	and	bioinformatics	means	[2].	Extensive	follow-up	studies	subsequently	
made	clear	that	PTPs	play	important	and	diverse	roles	in	various	intracellular	
signalling	pathways	[3].	The	family	of	PTP	genes	in	mammals	comprises	38	
genes	for	phosphotyrosine-specifc	(“classical”)	PTPs	and	61	genes	for	so-called	
“dual	specific	phosphatases”,	which	dephosphorylate	tyrosine-,	serine-,	threo-
nine-	and	even	lipid-phosphate	residues	[4].	The	complexity	of	the	mammalian	
“phosphatome”	is	even	more	complex	than	anticipated	on	the	basis	of	gene	
number,	because	a	substantial	portion	of	PTP	genes	encodes	multiple	protein	
isoforms	as	a	result	of	alternative	use	of	promoters,	splice	sites	and/or	trans-
lation	start	codons.	Combined	with	an	exceptionally	high	enzyme	activity	and	a	
notorious	substrate	ambiguity	displayed	in	vitro,	this	has	severely	confounded	
the	research	towards	the	specific	signalling	roles	of	individual	PTPs	[3,	4].	
	 At	the	start	of	the	study	described	in	this	thesis,	it	had	become	clear	that	
the	mouse	gene	Ptprr	encodes	no	less	than	four	different	phosphotyrosine-
specific	PTPs	which	differ	in	their	amino-terminal	part	and	display	distinct	
subcellular	localisations	in	neuronal	cells	[5,	6].	The	association	of	PTPRR	
proteins	with	β4-adaptin	[7]	and	the	notion	of	motile	PTPRR-bearing	vesicles	
in	cells	led	to	the	hypothesis	that	PTPRR	isoforms	may	perform	roles	in	cel-
lular	trafficking	[8].	Furthermore,	PTPRR	proteins	were	found	to	interact	with	
and	dephosphorylate	several	mitogen-activated	protein	kinases	(MAPKs)		
[9-13]	suggestive	of	a	role	in	the	regulation	of	growth	factor	signalling.		
The	studies	described	in	chapter	2-5	of	this	thesis	demonstrated	a	role	for	
PTPRR	isoforms	in	the	control	of	motor	coordination	and	MAPK	signalling		
in	vivo,	shed	light	on	the	potential	PTPRR	signalling	routes	and	disclosed	a	
regulatory	mechanism	acting	upon	the	receptor-type	PTPRR	isoforms.		
In	this	chapter	these	findings	will	be	discussed	in	a	broader	context.
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PTPRR protein behaviour
The	four	distinct	protein	tyrosine	phosphatase	isoforms	encoded	by	the		
single-copy	mouse	gene	Ptprr	are	named	PTPBR7,	PTP-SL,	PTPPBSγ-42	and	
PTPPBSγ-37	[6].	All	four	PTPRR	isoforms	harbour	a	so-called	kinase	inter-
action	motif	(KIM),	which	is	situated	just	proximal	of	their	C-terminal	enzymatic	
phosphotyrosine-specific	phosphatase	domain.	The	KIM	enables	PTPRR	
proteins	to	bind	and	subsequently	dephosphorylate	MAPKs	like	ERK1,	ERK2	
and	ERK5	[9,	10,	13,	14].	Analysis	of	the	PTPBR7	cDNA	sequence	made	clear	
that	the	corresponding	protein	had	the	typical	structural	features	of	a	type	I	
transmembrane	protein.	A	putative	signal	peptide	is	present	at	its	amino-
terminus	and	a	more	distal	transmembrane	or	‘stop	transfer’	domain	preced-
ed	the	KIM	and	PTP	domains	[15].	This	predicted	membrane	topology	was	
subsequently	demonstrated	experimentally	[5,	6,	16].	Originally,	also	PTP-SL	
was	predicted	to	be	a	type-I	transmembrane	protein	[17]	but	subsequent	
studies	revealed	the	lack	of	a	functional	signal	peptide,	leading	to	the	
suggestion	that	PTP-SL	rather	behaves	as	a	membrane-associated	protein	
[5].	Use	of	a	dedicated	antiserum	that	recognized	the	N-terminus	of	PTP-SL	
combined	with	a	selective	membrane	permeabilization	method	finally	allowed	
us	to	clarify	this	issue	(chapter	4).	The	membrane	topology	of	PTP-SL	is	
indistinguishable	from	that	of	PTPBR7,	i.e.	the	protein	resembles	type-I	trans-
membrane	proteins	with	the	C-terminus	at	the	cytosolic	side.	However,	
transport	of	the	N-terminal	part	over	the	membrane	does	not	occur	by	means	
of	a	cleavable	signal	peptide.	PTP-SL	should	therefore	be	classified	as	a	type-
III	transmembrane	protein	[18].	During	translation	of	these	type	of	trans-
membrane	proteins	the	TM	domain	serves	as	a	signal-anchor	sequence	to	
initiate	post-translational	translocation	of	the	N-terminus	over	the	intracel-
lular	membrane	[18].	Many	type-III	proteins	lack	a	sizeable	N-terminal	
domain,	facilitating	the	transfer	event.	An	example	of	this	type	of	protein	is	
cytochrome	p450,	which	has	just	a	few	aminoacids	to	translocate.	In	contrast,	
there	are	also	type-III	proteins	that	need	to	translocate	100	N-terminal	
residues	or	more.	Examples	of	this	class	of	proteins	are	neural-	and	thymus-
derived	activator	for	ErbB	kinases	(NTAK)	and	the	neuregulin	precursor	
protein	[19]),	which	behave	just	like	PTP-SL.	Again	other	type-III	proteins	are	
synaptotagmin	and	glycophorin	C	[20].
	 Thus,	PTPBR7	and	PTP-SL	are	both	single-transmembrane-spanning,	
receptor-type	proteins.	Due	to	their	distinct	N-terminal	parts,	however,	these	
proteins	have	very	different	subcellular	localisations;	PTPBR7	is	found	at		
the	cell	surface	and	in	endocytotic	vesicles	whereas	PTP-SL	is	not	present		
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at	the	cell	membrane	but	rather	decorates	the	trans-Golgi	network	and	late	
endocytic	vesicles	[5-8].	The	two	remaining	PTPRR	isoforms,	PTPPBSγ-42		
and	PTPPBSγ-37,	do	not	contain	any	particular	subcellular	targeting	signal	
and	hence	localise	throughout	the	cytosol.	
Complex formation of the receptor type PTPRR isoforms
A	decade	ago	a	crystallographic	study	revealed	a	dimer-like	structure	for		
the	catalytic	fragment	of	RPTPα	[21].	Subsequently,	dimerisation	of	the	full-
length	protein	in	living	cells	was	demonstrated	and	a	model	was	proposed	
in	which	PTP	activity	of	the	one	RPTPα		subunit	is	regulated	by	the	inhibitory	
wedge	present	in	the	other	subunit	[22,	23].	Although	the	dimerisation	capa-
city	has	now	been	demonstrated	for	several	other	RPTPs	as	well	[24-26],	
structural	studies	on	the	parts	containing	the	catalytic	domain	mostly	did	not	
support	PTP	domain	dimerisation	and	a	role	for	a	possible	regulatory	wedge	
was	not	disclosed	either.	Also	the	crystal	structure	of	the	PTPRR	phosphatase	
domain	pointed	out	that	this	moiety	functions	as	a	monomeric	structure	[27].	
Indeed	in	chapter	4	we	report	that	homo-	or	heterodimerisation	was	not	
observed	for	the	two	cytosolic	PTPRR	isoforms,	PTPPBSγ-42	and	PTPPBSγ-37.	
On	the	contrary,	the	two	receptor-type	isoforms	(PTPBR7	and	PTP-SL)	consti-
tutively	formed	homo-	and	heteromeric	complexes	(Figure	1).	This	multi-
merisation	does	not	require	the	cytosolic	domain	and	rather	is	mediated	by	
the	N-terminal	hydrophobic	region	and	the	transmembrane	domain.	The	
occurrence	of	heteromers	between	PTPBR7	and	PTP-SL	corroborates	in	an	
indirect	manner	the	ideas	about	the	transmembrane-spanning	topology	of	
PTP-SL.	Crystallographic	data	on	the	N-terminal	dimerisation	domains	within	
these	two	proteins	are	lacking	but	it	should	come	as	no	surprise	that	secon-	
dary	structure	prediction	programs	(i.e.	NNPredict)	indicate	an	α-helical	
structure	for	the	relevant	hydrophobic	segments	(data	not	shown).	The	hydro-	
phobic	region	(HR)	α-helix	in	the	ectodomain	segment	will	be	primed		
for	self-association	in	the	extracellular	hydrophilic	environment,	thereby	
contributing	to	the	dimerisation	of	the	transmembrane	α-helices	in	the	
hydrophobic	environment	of	the	lipid	bilayer.	Not	only	RPTPs	[28,	29]	but		
also	many	other	proteins	like	endosomal	SNARE	proteins	[30],	glycophorin	A	
[31]	and	EpoR	[32]	exploit	the	interactions	by	transmembrane	segments	as		
an	important	force	to	drive	multimerisation.
	 Ever	since	the	identification	of	receptor-type	PTPs	there	have	been	
speculations	about	the	possibility	to	regulate	PTP	activity	through	dimer	
formation,	i.e	in	a	manner	analogous	to	the	prevailing	ligand-induced	
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Figure 1 • Schematic depiction  
of the likely subcellular localisa-
tion of homo- and heteromeric 
PTPRR proteins. 
The hydrophobic region (HR), KIM 
sequence and catalytic PTP domain 
in each subunit are indicated. The 
transmembrane PTPBR7 and PTP-SL 
are predicted to exist as mono- 
mers and homo/heteromeric com-
plexes at the Golgi and vesicular 
structures from the endocytotic  
compartment. At the plasma mem-
brane and early endosomes only 
PTPBR7 homomers and monomers 
are expected. The non-transmem-
brane PTPPBSγ-42 and PTPPBSγ-37 
isoforms do not form multimers  
and reside in the cytosol (chapter 4). 
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mechanism	that	boosts	the	tyrosine	kinase	activity	of	growth	factor	receptors	
[33].	For	some	RPTPs	it	was	indeed	found	that	homodimerisation	was	of	in-
fluence	on	their	PTP	activity	[22,	24,	26,	34,	35].	Given	the	profound	lack	of	
knowledge	on	putative	ligands	that	could	bind	to	the	RPTP	ectodomains	and	
thereby	regulate	their	dimerisation,	these	studies	mostly	involved	protocols	
that	used	artificial	dimer-inducing	experimental	conditions.	Thus	far,	the		
only	physiological	case	deals	with	the	pleiotrophin-induced	dimerisation	of	
RPTPβ/ζ	[36].	All	data	obtained	so	far	support	a	model	in	which	RPTP	dimeri-
sation	reduces	enzymatic	activity.	The	receptor-type	PTPRR	isoforms	PTPBR7	
and	PTP-SL	constitutively	form	dimers	upon	ectopic	expression	in	various	cell	
systems.	In	chapter	4	we	exploited	a	truncated	PTPBR7	mutant,	predicted	to	
act	as	‘dominant-negative’	on	PTPRR	multimerisation,	to	address	the	ques-
tion	whether	PTPRR	activity	is	influenced	by	dimerisation.	This	led	to	the	detec-
tion	of	a	small	but	significant	increase	in	enzymatic	activity	upon	overexpression	
of	the	dimer-interfering	mutant,	in	full	support	of	the	above	model.	Obviously,	
identification	of	bona	fide	ligands	and	proper	substrates	for	PTPRR	isoforms	
will	allow	more	conclusive	experiments	in	a	physiologically	more	relevant	
setting.	The	occurrence	of	PTPBR7	as	a	dimer	on	the	cell	surface	may	well	be	
of	relevance	during	the	future	search	for	extracellular	PTPBR7	binding	proteins,	
especially	now	that	recently	heterophilic	ligands	for	RPTPσ	were	found	to		
bind	exclusively	to	dimerised	RPTPσ	extracellular	parts	[37].
	 Given	the	distinct	in	vivo	expression	patterns	of	PTPBR7	and	PTP-SL	[5,	6]	
it	is	likely	that	PTPBR7	/	PTP-SL	heteromultimers	will	form	less	frequent		
than	PTPBR7	or	PTP-SL	homomultimers	in	neuronal	cells.	In	adult	Purkinje	
cells,	for	example,	one	actually	expects	only	PTP-SL	homomers,	whereas	in	
other	brains	regions	mainly	PTPBR7	homomers	will	be	encountered.	Of	course,	
multimerisation	of	PTPRR	isoforms	with	other	transmembrane	proteins,	
including	RPTPs	should	also	be	taken	into	account.	For	example,	full	length	
RPTPα	and	LAR	were	found	to	heterodimerise	in	an	oxidative	stress	depen-
dent-manner	[38]	and	the	membrane-distal	PTP	domain	of	several	different	
RPTPs	can	interact	with	RPTPα	[39].	The	catalytically	inactive	RPTPs	IA-2		
and	IA-2β	can	form	heterodimers	with	RPTPα	and	RPTPε,	thereby	negatively	
regulating	PTP	activity	[25].	Initial	experiments	revealed	that	PTPBR7	is	well	
able	to	associate	with	IA2	and	RPTPσ	(data	not	shown)	but	effects	on	PTP	
activity	have	not	been	tested.	This	potential	inter-RPTP	complex	formation	
further	adds	to	the	complexity	of	the	regulation	of	reversible	tyrosine		
phosphorylation.
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Figure 2 • Illustration of the 
localisation of the different TrkA 
protein variants in the cell. 
The protein tyrosine kinase catalytic 
domain (PTK) is indicated for the 
immature (p110), mature (p140) and 
cleaved (p41) TrkA isoforms. Enzyma-
tically active PTPBR7 and PTP-SL aid 
in the maturation of TrkA, presuma-
bly by chaperoning the kinase on its 
route from the ER membrane through 
the Golgi apparatus towards the  
cell surface. Especially the p41 frag-
ment that is generated following 
cleavage (symbolized by a scissor) 
of TrkA at the cell surface strongly 
associates with PTPBR7 and, after 
translocation to late endosomes, 
PTP-SL (chapter 5). The cytosolic 
isoforms PTPPBSγ-42 and PTPPBSγ-37 
do not bind TrkA. As yet it is unclear 
whether PTPBR7 and PTP-SL bind to 
the activated TrkA dimer or that they 
rather associate with monomeric 
TrkA. For a schematic overview of 
the localisation of the different 
PTPRR isoforms we refer to Figure 1.
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Modulation of TrkA signalling by the PTPRR isoforms
In	addition	to	mediating	an	association	with	RPTPs,	the	PTPRR	transmembrane	
domain	may	also	facilitate	interactions	with	other	membrane-spanning	
proteins.	Indeed,	we	demonstrated	in	chapter	5	that	the	two	receptor-type	
PTPRR	isoforms	specifically	bind	to	TrkA,	the	neurotrophin	receptor	for		
nerve	growth	factor	(NGF),	by	means	of	an	interaction	between	the	respective	
transmembrane	domains.	Transmembrane	PTPRR	isoforms	associate	with	
immature	(p110)	as	well	as	mature	(p140)	TrkA	proteins,	but	highest	preference	
is	displayed	for	the	cleaved	p41	TrkA	fragment	that	lacks	the	ectodomain		
and	is	constitutively	active.	Also	RPTPσ	was	reported	to	bind	specifically	to		
the	neurotrophin	receptor	TrkA	via	its	transmembrane	domain	[40]	but	it		
is	currently	unclear	whether	this	preference	includes	the	constitutively	active	
p41	fragment.	In	Figure	2	the	subcellular	localisations	for	the	TrkA	protein	
variants	are	schematically	depicted.	Based	on	this	distribution	behaviour	and	
the	specific	distribution	of	the	PTPRR	isoforms	(Figure	1)	we	anticipate	that	
there	is	ample	opportunity	for	these	proteins	to	meet	during	the	TrkA	life	
cycle.	In	fact,	we	noted	that	the	PTPRR	–	TrkA	interaction	may	not	only	serve		
in	attenuating	NGF-induced	phosphotyrosine	signalling	at	the	cell	surface		
and	upon	receptor	internalisation,	but	also	has	a	role	in	receptor	maturation	
along	the	constitutive	secretory	route	(chapter	5).	
	 NGF-induced	TrkA	activation	involves	the	autophosphorylation	of	several	
key	tyrosine	residues	and	results	in	switching	on	downstream	signalling	
pathways	by	site-specific	binding	of	adaptor	proteins	to	phosphotyrosines	
residues	in	TrkA.	Autophosphorylation	of	tyrosine	residues	Y680	and	Y681	
within	the	catalytic	domain	potentiates	kinase	activity	[41,	42].	The	subsequent	
phosphorylation	of	Y490	and	Y785	enables	the	activation	of	the	PI3-K	and	
ERK1/2	cascades	and	the	PLCγ	pathway,	respectively	[43].	TrkA	dephosphory-
lation	implies	involvement	of	PTPs,	and	indeed	PTPBR7	and	PTP-SL	are	well	
capable	of	dephosphorylating	residues	Y680/Y681	and	Y490	in	the	p110,	p140	
and	p41	TrkA	variants.	A	role	for	PTPRR	isoforms	in	the	dephosphorylation		
of	pY785	could	not	be	established	because	the	required	phosphospecific	
antibodies	are	currently	lacking.	Importantly,	the	cellular	outcome	of	TrkA	
signalling	not	only	depends	on	the	tyrosine	residues	that	are	phosphorylated	
but	also	on	the	subcellular	location	of	the	activated	TrkA	receptors.	In	PC12	
cells,	for	example,	the	distinction	between	TrkA	signalling	towards	survival		
or	towards	differentiation	is	governed	by	receptor	endocytosis	[44].	Cells	
expressing	PTPBR7	thus	have	a	means	to	dephosphorylate	TrkA	already	at		
the	plasma	membrane,	whereas	PTP-SL	expressing	cells	may	rely	on	TrkA	
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endocytosis	to	enable	dephosphorylation	by	PTP-SL	on	late	endosomes.		
Thus,	in	PC12	cells,	PTP-SL	expression	would	be	expected	to	mainly	attenuate	
TrkA	differentiation	signals	whereas	PTPBR7	may	have	the	additional	capacity	
to	suppress	TrkA-mediated	survival	signals.	
	 But	to	view	PTPRR	proteins	exclusively	as	TrkA	counteractors	would	only	
render	an	oversimplified	picture	of	their	significance.	PTPBR7	and	PTP-SL	
have	the	potential	to	abrogate	NGF-induced	tyrosine	phoshorylation	at	two	
levels.	One	pathway	acts	through	dephosphorylation	of	both	the	receptor	and	
the	downstream	MAPKs.	In	another	pathway	these	PTPs	modulate	the	levels	
of	surface-exposed	TrkA	on	cells	(chapter	5).	This	latter	activity	depends	on	
PTPRR	localisation	and	enzyme	activity,	since	phosphatase-dead	or	cytosolic	
isoforms	did	not	show	the	promoting	effect	on	TrkA	maturation.	This	matura-
tion	effect	also	explains	why	enzymatically	inactive	versions	of	receptor	tyrosine	
kinases	(RTKs)	maturate	much	more	efficiently	than	constitutively	active	mu-
tants	[45,	46].	Obviously,	the	aberrant,	ligand-independent	receptor	phosphory-
lation	and	signalling	of	such	RTKs	on	the	ER,	Golgi	apparatus	and	transport	
vesicles	put	a	break	on	maturation	steps	like	f.i.	receptor	glycosylation	[47].	
Interestingly,	this	inhibitory	effect	can	be	reverted	by	co-expression	of	specific	
PTPs	[46].	In	analogy,	we	reason	that	premature	phosphorylation	of	TrkA	during	
its	journey	to	the	cell	surface	is	kept	to	a	minimum	by	the	enzymatic	activity	of	
PTPBR7	or	PTP-SL,	which	thus	act	as	chaperones	during	RTK	maturation.	
	 At	present,	it	is	difficult	to	predict	what	the	overall	effect	of	PTPBR7/PTP-SL	
action	on	TrkA	signalling	outcome	would	be	at	the	cell	level.	Our	current	belief	
is	that	PTPRR	proteins	enable	an	increased	sensitivity	of	cells	towards	NGF	
without	full-blown	increase	of	the	downstream	signalling	responses	and	their	
cellular	outcome.	This	belief	is	based	on	several	considerations	that	will	be	
outlined	below	and	are	depicted	schematically	in	Figure	3.	Under	standard	
conditions	a	model	cell,	e.g.	PC12,	will	contain	basal	levels	of	PTPRR	isoforms	
and	TrkA,	and	thus	have	a	background	level	of	active	(phospho-)TrkA	in	the	cell	
(Mock	curve	in	Figure	3).	NGF	administration	will	result	in	a	dose-dependent	
signalling	response,	in	which	the	decay	of	the	signal	is	related	to	the	balanced	
level	of	TrkA	and	PTPRR	proteins.	Upregulation	of	TrkA	levels	only,	by	ectopic	
expression	of	the	kinase	for	example,	is	expected	to	result	in	higher	back-
ground	levels	of	phosphorylated	receptor	(+TrkA	curve	in	Figure	3).	Moreover,	
following	NGF	addition	the	amount	of	activated	cellular	TrkA	will	now	be	
increased	as	compared	to	mock	cells	and,	in	view	of	the	altered	kinase/
phosphatase	balance,	will	display	a	longer	half-life.	On	the	contrary,	experi-
mental	upregulation	of	PTPRR	levels	in	the	cells	will	lead	to	a	concomitant	
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increase	in	TrkA	levels.	Thus	the	kinase/phosphatase	balance	may	well	remain	
intact	and	ensure	maintenance	of	the	basal	ligand-independent	background	
phospho-TrkA	signal.	Still,	as	a	result	of	the	increased	amount	of	TrkA	
receptors	at	the	cell	surface	due	to	the	increased	PTP	chaperoning	action,	
NGF	stimulation	would	now	result	in	higher	phospho-TrkA	levels	at	the	cell	
surface,	but	also	in	a	shortened	phospho-TrkA	decay	time	(+PTP	curve	in	
Figure	3).	In	other	words,	for	these	cells	much	less	NGF	is	required	to	produce	
a	phosphoTrkA	response	amplitude	as	obtained	in	the	mock	cells.
	 The	importance	of	NGF	concentration	in	the	determination	of	the	cellular	
response	was	recently	elegantly	demonstrated	in	PC12	cells.	Using	a	new	
approach	that	combined	siRNA-mediated	perturbations	of	signalling	net-
works,	single-cell	phosphorylation-state	recordings,	and	systems-biology	
modular	response	analyses	(MRA),	Philippe	Bastiaens’	team	uncovered	
secrets	of	EGF/NGF	-	ERK	signalling	pathways	in	PC12	cells	[48].	Apart	from	
negative	and	positive	feedback	loops	that	emanate	from	ERK	back	to	the	up-
stream	MAPK	kinase	kinase	Raf,	they	disclosed	a	switch-like,	bistable	
dynamics	of	the	NGF-induced	ERK	cascade.	Our	own	studies	in	PC12	cells	
(chapter	2)	were	performed	on	pools	of	stably	transfected,	hence	probably	
‘adapted’,	cells	and	involved	saturating	amounts	of	NGF	[49].	At	that		
time	we	thus	may	have	missed	a	potential	increased	sensitivity	towards	NGF	
resulting	from	enhanced	TrkA	levels	at	the	cell-surface.	Phospho-ERK	
signalling	experiments	in	PTPBR7-overexpressing	PC12	cells	using	limiting	
amounts	of	NGF	would	allow	us	to	address	this	issue.
Tyrosine phosphorylation in cellular trafficking
Although	the	process	of	tyrosine	phosphorylation	has	been	linked	to	the	
regulation	of	endocytotic	trafficking	[50,	51]	and	the	organization	of	the	Golgi	
complex	[52]	it	remains	thus	far	unclear	which	mechanism	underlies	the	
promoting	effect	of	PTPBR7	/	PTP-SL	on	TrkA	maturation.	It	is	of	note,	however,	
that	PTPRR	receptor-type	isoforms	are	distributed	throughout	the	different	
endocytotic	compartments	(Figure	1)	and	their	PTP	domain	can	bind	to		
β4-adaptin,	a	subunit	of	the	AP4	adaptor	complex	that	is	involved	in	vesicle	
transport	[7].	In	live	cell	imaging	studies	PTPRR-decorated	vesicles	demon-
strated	a	high	mobility,	travelling	both	to	and	from	the	Golgi	apparatus	[8].	
This	would	be	in	line	with	a	positive	effect	by	these	PTPs	on	the	anterograde	
transport	of	the	TrkA	receptor,	as	observed	in	chapter	5.	Only	for	a	few	PTPs		
a	role	in	cellular	trafficking	has	been	stipulated.	The	FERM	domain-containing	
cytosolic	enzyme	PTP-D1	is	involved	in	the	regulation	of	retrograde	Golgi	to		
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Figure 3 • Graphical display of a 
model for the influence of recep-
tor-type PTPRR isoforms on 
cellular phospho-TrkA dynamics. 
Curves representing the hypothetical 
levels of cellular TrkA phospory-
lation at different time points after 
treatment of cells with a fixed 
amount of NGF (arrow). Mock trans-
fected cells (Mock) with endogenous 
levels of PTPRR and TrkA proteins 
will display a “basal” phospho-TrkA 
signal that will be lower than cells 
overexpressing TrkA (+TrkA). Over-
expression of receptor-type PTPRR 
isoforms (+PTP) will minimally affect 
basal phospho-TrkA levels, because 
the rise in PTPs is paralleled by a 
rise in TrkA level at the cell surface. 
Consequently, NGF treatment ( indi-
cated by an arrow) of +PTP cells will 
lead to a rise in phospho-TrkA level 
that is higher than that obtained in 
Mock cells. This will also be the case 
in TrkA-overexpressing cells. The 
subsequent down-regulation of the 
phospho-TrkA signal, however, will 
be much quicker in PTP overexpres-
sing cells than that in TrkA overex-
pressors. Thus, the net effect of 
increased PTP levels and concomi-
tant TrkA upregulation is predicted 
to be a higher NGF sensitivity wit-
hout altered basal phospho-TrkA 
levels and a subdued downstream 
signalling in the cell.
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ER	membrane	flow	by	dephosphorylating	the	kinesin-like	protein	KIF1C	[53]	
and	the	retinaldehyde	binding	domain-containing	PTP-MEG2	triggers	secretory	
vesicle	biogenesis	in	granulocytes	by	dephosphorylating	the	N-ethylmaleimide-
sensitive	protein	NSF	[54].	Perhaps	PTPRR	proteins	could	influence	mem-
brane	trafficking	processes	via	their	capacity	to	bind	and	inactivate	MAPKs.		
It	has	been	reported	that	tyrosine-phosphorylated	ERK	transiently	associates	
with	the	Golgi	complex	in	the	late	G2	phase	of	the	cell	cycle	and	with	Golgi	
vesicles	throughout	mitosis.	This	may	well	involve	the	Golgi-specific	scaffold	
protein	Sef	[55,	56].	Importantly,	a	non-phosphorylatable	ERK	mutant	inhibited	
Golgi	fragmentation	during	mitosis,	whereas	a	tyrosine-phosphorylated	but	
catalytically	inactive	version	did	not	[52].	Thus,	PTP	activity	is	instrumental		
in	Golgi	membrane	fragmentation	and	PTP-SL’s	presence	at	the	trans-Golgi	
network	may	perhaps	relate	to	fission/fusion	processes	that	involve	these	
Golgi-associating	ERK	proteins.	
Regulation of MAPK signalling by PTPRR isoforms
Like	the	many	dual-specificity	MAPK	phosphatases,	the	phosphotyrosine-
specific	STEP,	HePTP	and	PTPRR	isoforms	contain	a	kinase-interaction	motif	
(KIM)	just	N-terminal	of	their	PTP	domain	that	determines	their	association	
with	MAPKs	[9,	12,	13].	To	study	the	impact	of	the	PTPRR	isoforms	on	MAPK	
signalling	in	a	physiological	context	we	made	use	of	one	of	the	few	cell	models	
that	endogenously	express	PTPRR	isoforms;	the	phaeochromocytoma-derived	
rat	cell	line	PC12.	These	cells	represent	the	paradigm	model	for	growth	factor	
specific	spatio-temporal	control	of	MAPK	signalling	[57].	EGF	administration	
to	these	cells	transiently	activates	ERK	in	the	cytosol	and	has	mitogenic	
consequences.	NGF	treatment,	on	the	other	hand,	induces	a	sustained	activa-
tion	and	subsequent	translocation	of	ERK	to	the	nucleus,	resulting	in	their	
differentiation	into	sympathetic	neurons.	PC12	cells	endogenously	express	
PCPTP1,	the	rat	ortholog	of	PTPBR7,	levels	of	which	are	transiently	up-regulated	
upon	NGF	treatment	[58].	In	chapter	2	we	demonstrated	that	PCPTP1	is	in	fact	
the	only	phosphotyrosine-specific	MAPK-PTP	expressed	in	these	cells	and	
that	changes	in	its	expression	level	did	not	markedly	alter	the	EGF	and	NGF-
induced	ERK	signalling	profiles.	This	suggests	that	not	PCPTP1	but	rather	
dual-specificity	MAPK	phosphatases	(MKPs)	and	serine/threonine	phospha-
tases	(PP)	must	be	the	relevant	modulators	of	ERK	signalling	in	PC12	cells.
The	recent	findings	regarding	the	NGF	concentration-dependent	bivalent	
signalling	mode	[48]	and	the	effects	of	PTPRR	expression	on	the	maturation	
and	cell	surface	levels	of	the	NGF	receptor	(chapter	5),	however,	urge	for	an	
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extension	of	the	study	described	in	chapter	2.	As	discussed	above,	it	might		
be	that	changes	in	PCPTP1	levels	in	fact	only	determine	the	sensitivity	of	the	
PC12	cells	towards	NGF.	Therefore,	future	experiments	should	exploit	a	variety	
of	different	growth	factor	concentrations	and	preferably	use	a	read-out	at		
the	single-cell	level,	such	as	the	application	of	fluorescently	labeled	phospho-
ERK	specific	antibodies	in	flow	cytometry.	In	parallel,	the	steady-state	TrkA	
(phospho)protein	levels	should	be	monitored	as	well,	but	this	may	be	confound-
ed	by	the	low	TrkA	expression	levels	and	poor	performance	of	antibodies	
(unpublished	data).	
	 At	least	one	other	factor	may	have	confounded	the	analysis	of	the	PTPRR	
impact	on	MAPK	signalling	in	our	PC12	cells.	The	potency	of	the	cAMP-depen-
dent	kinase	PKA	to	negatively	regulate	the	PTP	–	MAPK	interaction	through	
phosphorylation	of	an	essential	serine	residue	within	the	KIM	domain		
[11,	59,	60]	may	have	obscured	effects.	In	our	attempts	to	explain	the	finding	
that	ectopic	expression	of	PTPPBSγ	species	(the	cytosolic	PTPRR	isoforms)	
significantly	reduced	the	amplitude	of	transient	ERK	activity,	whereas	the	
sustained	ERK	activity	remained	totally	unaffected,	we	monitored	KIM	phos-
phorylation	levels	in	the	various	settings.	We	noted	a	considerable	basal	PKA	
activity	in	PC12	cells,	which	rendered	the	major	portion	of	PTPRR	proteins	
rather	impotent	towards	MAPK	association.	However,	because	both	EGF	and	
NGF	administration	resulted	in	reduced	PTPPBSγ	phosphorylation	levels,		
KIM	phosphorylation	cannot	explain	the	EGF-specific	effect	of	PTPPBSγ.	
	 In	chapter	3	we	investigated	the	physiological	function	of	the	PTPRR	
enzymes	by	means	of	the	generation	and	subsequent	analysis	of	Ptprr	knock-
out	mice.	PTPRR	deficient	animals	displayed	hyperactivated	ERK1/2	levels		
in	various	brain	parts.	The	activity	of	the	upstream	kinases,	MEK1/2,	was	not	
altered	in	the	PTPRR	deficient	tissues,	in	line	with	a	direct	effect	of	the	PTP		
at	the	level	of	the	MAPKs	ERK1	and	ERK2	[9,	14].	Still,	possible	indirect	effects	
-	like	the	PTPRR-dependent	activation	of	other	MAPK	phosphatases	-	cannot	
be	excluded.	In	this	light	it	is	of	note	that	in	cerebellum	the	PTPRR	deficiency	
resulted	in	a	significant	decrease	in	activity	of	the	MAPKs	JNK1	and	JNK2.		
In	vitro,	PTPRR	isoforms	do	not	bind	or	dephosphorylate	these	stress-related	
MAPKs,	and	even	if	they	could	do	so	in	vivo	the	PTPRR	deficiency	should		
then	lead	to	hyperphoshorylated	JNK1/2.	The	opposite	effect	was	seen,	thus	
our	findings	hint	at	indirect	effects	of	PTPRR	activity	on	MAPK	signalling,	
perhaps	involving	a	signalling	role	somewhere	upstream	in	the	JNK1/2	cascade.	
Alternatively,	the	effects	seen	may	also	reflect	alterations	in	RNA	and	protein	
levels	in	cells	due	to	the	transcriptional	events	downstream	of	ERK1/2.	Indeed,	
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activity	of	the	ERK	substrate	Elk-1,	a	transcription	factor,	was	found	to	be	signifi-
cantly	up-regulated	in	PTPRR-deficient	cerebrum.	In	cerebellum	this	difference	
did	not	reach	significance.	Because	Elk-1	also	is	a	substrate	of	JNK1/2	[61],	
perhaps	reduction	of	JNK1/2	activity	and	the	increase	of	ERK1/2	signalling	
balance	out	in	the	cerebellum,	leaving	phospho-Elk-1	levels	unchanged.	
	 Whatever	the	mechanism	involved,	the	above	findings	firmly	establish	
PTPRR	isoforms	as	physiological	regulators	of	MAPK	activity	[62].	They	
sharply	contrast,	though,	with	our	results	obtained	in	vitro	with	transfected	
PC12	cells	[49].	Of	course	this	may	relate	to	the	type	of	cells.	PC12	cells	
originate	from	a	neuroendocrine	tumour	of	the	medulla	of	the	adrenal	gland	
whereas	brain	cells	were	studied	in	the	mouse	model.	Moreover,	we	already	
mentioned	the	considerable	PKA	activity	in	PC12	cells,	which	may	severely	
hamper	KIM-dependent	PTPRR	actions,	and	indicated	that	in	retrospect	the	
saturating	amounts	of	growth	factors	might	have	blurred	effects	in	this	cell	
model.	Additionally,	extracellular	components	influencing	PTPRR	activity	-		
for	example	putative	ligands	that	interact	with	the	PTPBR7	ectodomain	–	
might	be	present	in	brain	material	but	may	be	absent	in	PC12	cultures.	The	
possible	ligand	dependency	of	PTPBR7	signalling	activity	becomes	even	more	
interesting	when	taking	into	account	that	monomeric	PTPBR7	PTP	domains	
are	significantly	more	active	than	those	present	in	homodimers	(chapter	4).	
Needless	to	say	that	proper	understanding	of	the	signalling	role	of	this	RPTP	
relies	on	the	identification	of	compounds	that	regulate	its	multimerisation	
status.	Analysis	of	proteins	that	associate	with	recombinant	PTPBR7	ectodo-
mains,	f.i.	by	mass	spectrometry,	represents	an	attractive	way	to	identify		
such	potential	ligands.	
	 Besides,	in	order	to	explain	the	indirect	effects	on	MAPK	cascades	observed	
in	vivo,	more	efforts	should	also	go	into	the	identification	of	new	PTPRR	targets.	
Strategies	to	accomplish	this	goal	may	involve	new	approaches	like	the	use	of	
substrate	trapping	mutants	[63],	in	combination	with	proteome-tailored	identi-
fication	methods	based	on	mass	spectrometry.	Our	initial	attempts	to	find	
additional	PTPRR	targets	in	PC12	cells	yielded	a	60	kDa	tyrosine-phosphory-
lated	protein	that	associated	with	a	PTPRR	substrate	trapping	mutant	(un-	
published	observations).	Since	the	highly	related	STEP	protein	can	associate	
with	the	60	kDa	Src	family	kinase	(SFK)	member	Fyn	[64]	we	exploited	SFK	
antibodies	in	an	immunoblot	analysis	of	the	substratetrapped	material.	This	
excluded	the	SFK	family	members	as	potential	PTPRR	binding	proteins	and	
leaves	the	identity	of	the	60kDa	PTPRR	binding	protein	to	be	determined.		
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In	addition	to	altered	brain	MAPK	signalling	the	PTPRR	knockout	mice	displayed	
a	mild	form	of	ataxia	characterized	by	defects	in	fine	motor	coordination	[62].	
Purkinje	cells,	which	are	the	major	PTPRR-expressing	cells,	generate	the	
primary	output	of	the	cerebellar	cortex	and	provide	signals	required	for	motor	
planning,	execution	and	coordination	in	their	rate	of	firing	and	pattern	of	activity	
[65].	Importantly,	no	aberrancies	in	brain	morphology	or	Purkinje	cell	numbers	
and	branching	could	be	detected	in	PTPRR	deficient	animals.	Multiple	mouse	
models	exist	that	display	ataxia-like	movement	[66]	but	the	subset	that	lacks	
obvious	changes	in	cerebellar	morphology	is	very	small.	Intriguingly,	the	
common	denominator	in	the	latter	group	of	mouse	models	is	an	abnormal	
calcium	homeostasis	[67-71].	It	will	therefore	be	highly	interesting	to	analyze	
whole-cell	Ca2+	currents	in	PTPRR	deficient	cerebellar	tissue	slices	and	
primary	cultures	of	Purkinje	and	granule	cells	in	order	to	verify	whether	
affected	synaptic	transmission	within	the	PTPRR	deficient	cerebellum	is	
causing	deficits	in	motor	coordination	and	balance.	In	the	case	that	aberrant	
Ca2+	channel	functioning	is	indeed	disclosed	in	PTPRR	deficient	mice,	a	next	
step	would	be	to	find	out	whether	this	is	due	to	direct	effects	on	channel	phos-
phorylation	levels	or	rather	reflects	an	altered	trafficking	towards	or	insertion	
into	the	plasma	membrane	of	these	channels,	reminiscent	of	PTPRR	effects	
on	TrkA	maturation.
	 It	has	been	demonstrated	that	the	MAPKs	ERK1/2	perform	an	important	
role	in	neuronal	plasticity	[72,	73]	and	that	they	can	phosphorylate	a	lot	of	dif-
ferent	proteins	comprising	nuclear	transcriptions	factor,	cytoskeleton	proteins,	
receptors	and	-	last	but	certainly	not	least	-	ion	channels	[74,	75].		
For	example,	ERK-dependent	phosphorylation	of	the	voltage-dependent	Kv4-
family	decreases	the	probability	of	channel	opening	which	results	in	a	reduced	
K+	current	and	depolarization	of	the	membrane	[76].	This	allows	augmented	
NMDA	receptor	activation	and	the	resulting	calcium	influx	is	sufficient	to	cause	
a	synaptic	long-term	potentiation	(LTP)	[72,	77].	Ultimately,	the	assessment		
of	altered	electrical	properties	(K+	currents,	Ca2+	fluxes	and	LTP)	of	PTPRR	
deficient	cells	and	tissues	would	allow	the	interconnection	between	the	elevated	
ERK1/2	activity	levels	and	the	defective	locomotion	control	that	we	reported	in	
chapter	3.	
	 As	briefly	eluded	to,	the	ERK	hyperactivity	that	results	from	PTPRR	
deficiency	will	have	bearing	for	the	cellular	transcriptome	in	view	of	its	
collection	of	transcription	factors	amongst	its	nuclear	targets.	It	may	be	of	
interest,	therefore,	to	exploit	oligo	microarray	analysis	and	determine	the	
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changes	in	cerebrum	and	cerebellum	gene	expression	profiles	that	result	from	
PTPRR	gene	inactivation.	Now	that	it	has	become	feasible	to	genetically	label	
specific	populations	of	neurons	in	the	mouse	brain,	one	may	even	consider	the	
isolation	of	such	subsets	of	fluorescently	labeled	neurons	and	-	through	amplifi-
cation	of	their	mRNA	and	probing	of	microarrays	-	derive	cell	type-specific	
expression	profiles	[78].	Of	course,	transcriptome	profiles	should	not	be	regarded	
as	representatives	of	protein	activity,	especially	in	view	of	the	plethora	of	post-	
translational	modifications	that	regulate	protein	action.	Therefore,	the	further	
development	of	microarrays	spotted	with	phospho-specific	antibodies	and	/	or	
recombinant	versions	of	specific	protein	binding	domains,	to	allow	the	assess-
ment	of	changes	in	proteome	phosphorylation	and	interaction	profiles,	are	
eagerly	awaited.		
	 Independently,	the	results	from	chapter	5	warrant	further	investigation	of	
possible	effects	on	neurotrophin	receptor	TrkA	signalling	by	the	PTPRR	trans-
membrane	isoforms	using	the	cell	and	mouse	models	described	in	chapters		
2-3.	Importantly,	since	TrkA	signalling	induces	downstream	signal	transduction	
pathways	in	addition	to	the	classical	MAPK	cascade,	such	as	the	PLCγ	and	PI3-K	
mediate	routes	[43],	one	should	also	keep	an	open	mind	towards	the	possible	
contributions	of	such	pathways	to	the	cerebellar	dysfunction	observed	in	PTPRR	
knockout	mice.	And	lastly,	since	our	current	mouse	model	carries	a	full	PTPRR	
null	allele,	and	thus	represents	a	composite	knockout	of	all	PTPRR	isoforms,	we	
are	in	fact	still	left	with	the	tantalizing	question	what	the	respective	contributions	
of	PTPBR7,	PTP-SL	and	PTPPBSγ-42/37	to	the	observed	phenotype	actually	are.	
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Adequate	cell-cell	communication	through	biochemical	signalling	is	an	abso-
lute	requirement	in	the	development	and	physiology	of	multicellular	organisms.	
Reversible	tyrosine	phosphorylation,	a	common	post-translational	mechanism	
to	control	enzymatic	or	binding	activity	of	proteins,	plays	an	important	role	in	
many	of	the	signal	transduction	pathways.	The	ultimate	cellular	outcome	of	
these	signalling	pathways	is	depending	on	the	spatial	and	temporal	control		
of	the	phosphotyrosine	content	in	proteins,	which	is	determined	by	the	balance	
in	activities	of	protein	tyrosine	kinases	(PTKs)	and	protein	tyrosine	phospha-
tases	(PTPs).	The	studies	described	in	this	thesis	focus	on	the	signalling	role	
of	the	protein	tyrosine	phosphatase	receptor-type	R	(PTPRR)	protein	family	
that	consists	out	of	four	different	isoforms	(i.e.	PTPBR7,	PTP-SL,	PTPPBSγ-42	
and	PTPPBSγ-37)	that	are	all	encoded	by	the	single-copy	mouse	gene	Ptprr.	
The	four	PTPRR	isoforms	differ	in	their	amino-terminal	part	and	display	
distinct	subcellular	localisations	in	neuronal	cells.	Highest	expression	levels	
are	found	in	cerebellar	Purkinje	cells.	Their	potential	to	bind	to	β4-adaptin	
suggested	a	possible	role	in	vesicle	transport	processes.	The	PTPRR	proteins	
were	also	found	to	interact	with	and	dephosphorylate	several	mitogen-activated	
protein	kinases	(MAPKs),	which	pointed	to	a	role	in	the	down-regulation		
of	growth	factor	signalling.	The	finding	that	a	PTPRR-encoding	transcript	is	
temporally	up-regulated	after	nerve	growth	factor	(NGF)-induced	sustained	
activation	of	the	MAPKs	extracellular	signal-regulated	kinase	(ERK)	1	and	
ERK2	in	rat	PC12	cells	prompted	us	to	study	the	role	of	PTPRR	in	the	spatial	
and	temporal	control	of	MAPK	signalling	in	this	paradigm	cell	model.	
	 In	chapter	2	we	show	that	the	rat	orthologue	of	PTPBR7,	PCPTP1,	is	the	only	
phosphotyrosine-specific	MAPK-phosphatase	that	is	endogenously	expressed	in	
PC12	cells.	Overexpression	or	RNAi-mediated	knock-down	of	PCPTP1/PTPBR7	in	
these	cells,	however,	left	the	temporal	profile	of	epidermal	growth	factor	(EGF)-	
and	NGF-induced	ERK1/2	activity	unchanged.	High-level	expression	of	the	
cytosolic	PTPRR	isoforms	PTPPBSγ-42	and	PTPPBSγ-37,	on	the	other	hand,	
resulted	in	a	slight	but	significant	reduction	of	EGF-induced	ERK1/2	activity.	
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This	led	us	conclude	that	in	PC12	cells	PCPTP1	has	a	modest	role	in	the	regula-
tion	of	ERK1/2	activity	and	that	MKPs,	which	can	(also)	dephosphorylate	serine/
threonine	residues,	must	serve	as	the	major	ERK1/2	inactivators	in	these	cells.
	 As	an	alternative	means	to	gain	insight	in	the	signalling	role	of	PTPRR	iso-
forms,	we	generated	PTPRR	deficient	mice	(chapter	3).	We	noted	that	MAPK	
phosphorylation	levels	were	significantly	altered	in	the	PTPRR	deficient	mouse	
brain,	whereas	morphology,	Purkinje	cell	number	or	dendritic	branching	was	
not	affected.	In	addition,	Ptprr-/-	mice	displayed	defects	in	motor	coordination	
and	balance	skills.	These	findings	establish	PTPRR	proteins	as	physiological	
regulators	of	MAP	kinase	activity	in	neuronal	tissue	and	as	contributors	to	loco-
motion	processing	in	the	brain.	
		 In	chapter	4,	we	describe	our	studies	on	multimerisation	as	a	possible	
mechanism	to	regulate	PTPRR	activity.	First,	we	determined	the	membrane	
topology	of	PTP-SL	using	selective	membrane	permeabilisation	combined	
with	immunofluorescent	detection.	PTP-SL	turned	out	to	be	a	type-III	trans-
membrane	protein	with	a	topology	identical	to	that	of	the	receptor-type	iso-
form	PTPBR7.	The	two	transmembrane	PTPRR	isoforms	constitutively	formed	
homo-	and	heteromeric	complexes,	while	the	cytosolic	PTPRR	species	
PTPPBSγ-42	and	PTPPBSγ-37	did	not.	The	association	was	mediated	by	the	
transmembrane	domain	and/or	the	hydrophobic	domain	present	in	both	PTPBR7	
and	PTP-SL,	and	did	not	require	the	PTP	domain.	Forcing	full-length	PTPBR7	
experimentally	in	a	monomer-mimicking	state	resulted	in	a	significant	in-
crease	in	enzymatic	PTP	activity.	This	strengthens	the	notion	that	multimerisa-
tion	represents	a	general	mechanism	to	attenuate	RPTP	catalytic	activity.	
	 The	identification	of	the	neurotrophic	receptor	TrkA	as	a	PTPRR	substrate	is	
described	in	chapter	5.	Receptor-type	PTPRR	isoforms	PTPBR7	and	PTP-SL	were	
found	to	associate	with	full-length	TrkA	and	especially	the	cleaved	form	of	TrkA,	
the	membrane-associated	p41	fragment.	This	interaction	is	specific	since	these	
PTPRR	isoforms	do	not	associate	with	the	highly	related	TrkB.	The	transmem-
brane	PTPRR	isoforms	not	only	bind	but	also	dephosphorylate	activated	TrkA	
molecules.	Interestingly,	PTPBR7	and	PTP-SL	also	promoted	TrkA	maturation	
into	its	fully	complex-glycosylated,	surface-exposed	form.	We	concluded	that	
PTPBR7	and	PTP-SL	may	fine-tune	neurotrophin	TrkA	signalling	at	various	levels.
	 In	chapter	6,	the	results	obtained	are	summarised	and	discussed	in	a	broader	
context.	A	hypothetical	model	addressing	the	influence	of	the	transmembrane	
PTPRR	isoforms	on	TrkA	signalling	is	put	forward.	Furthermore,	several	sugges-
tions	for	future	research	are	provided	in	order	to	further	the	insights	into	the	phy-
siological	roles	of	the	different	PTPRR	isoforms	in	cellular	signalling	networks.	
Adequate	communicatie	tussen	cellen	middels	biochemische	signalering	is	
absoluut	noodzakelijk	voor	de	ontwikkeling	en	de	fysiologie	van	multicellulaire	
organismen.	Reversibele	fosforylering	van	tyrosine	residuen,	een	veel	voor-
komende	post-translationele	modificatie	om	enzymatische	of	bindingsactiviteit	
van	eiwitten	te	beïnvloeden,	speelt	een	belangrijke	rol	in	deze	signaaltrans-
ductie	cascades.	De	uiteindelijke	cellulaire	respons	die	volgt	op	het	aan-
schakelen	van	deze	cascades	hangt	af	van	de	plaats,	levensduur	en	hoeveel-
heid	van	de	tyrosine-gefosforyleerde	eiwitten	in	de	cel,	en	dit	wordt	weer	
bepaald	door	de	balans	in	activiteit	van	eiwit-tyrosine-kinases	(PTKs)	en	eiwit-
tyrosine-fosfatases	(PTPs).	Het	onderzoek	beschreven	in	dit	proefschrift		
richt	zich	op	de	rol	van	de	eiwit-tyrosine-fosfatase	receptor-type	R	(PTPRR)	
eiwitfamilie	in	signaaltransductie	cascades.	De	PTPRR	familie	van	de	muis	
bestaat	uit	vier	verschillende	isovormen	(PTPBR7,	PTP-SL,	PTPPBSγ-42		
and	PTPPBSγ-37)	die	allemaal	worden	gecodeerd	door	één	en	hetzelfde	gen:		
Ptprr.	Ze	verschillen	in	hun	amino-terminale	uiteinde	en	daardoor	vertonen		
ze	onderscheidbare	subcellulaire	localisaties	in	neuronale	cellen.	De	hoogste	
eiwit-expressie-niveaus	worden	gevonden	in	de	Purkinje	cellen	van	de	kleine	
hersenen.	De	mogelijkheid	om	te	binden	aan	het	eiwit	β4-adaptine	suggereert	
een	rol	voor	deze	fosfatases	in	processen	gerelateerd	aan	het	blaasjestrans-
port	in	de	cel.	Ook	is	aangetoond	dat	PTPRR	eiwitten	kunnen	binden	aan	
zogenoemde	mitogen-activated	protein	kinases	(MAPKs)	en	deze	vervolgens	
kunnen	defosforyleren.	Dit	duidt	op	een	rol	voor	PTPRR	isovormen	in	groei-
factor-geïnduceerde	signaleringscascades.	
	 De	vinding	dat	na	aanhoudende	activatie	van	de	extracellular	signal-
regulated	kinase	1	(ERK1)	en	2	(ERK2)	MAPKs	in	rat	PC12	cellen,	middels	
stimulatie	met	NGF	(nerve	growth	factor),	een	PTPRR-coderende	mRNA	tijdelijk	
verhoogd	tot	expressie	komt	gaf	aanleiding	om	de	rol	van	de	PTPRR	eiwitten		
in	de	spatio-temporele	regulatie	van	MAPK	signalering	nader	te	bestuderen		
in	dit	celmodel.	In	hoofdstuk	2	laten	we	zien	dat	de	rat	ortholoog	van	PTPBR7,	
PCPTP1,	de	enige	fosfotyrosine-specifieke	MAPK-fosfatase	is	die	in	PC12	
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cellen	endogeen	tot	expressie	komt.	Zowel	overexpressie	als	RNAi-geme-
diëerde	reductie	van	PCPTP1/PTPBR7	liet	echter	het	tijdsafhankelijke	profiel	
van	epidermal	growth	factor	(EGF)	of	NGF	geïnduceerde	ERK1/2	activiteit	
onaangetast	in	deze	cellen.	Hoge	expressie	van	de	cytosolische	isovormen	
PTPPBSγ-42	en	PTPPBSγ-37	resulteerde	wel	in	een	(kleine	maar	significante)	
verlaging	van	de	EGF-geïnduceerde	ERK1/2	activiteit.	PCPTP1	speelt	dus	in	
PC12	cellen	een	zeer	bescheiden	rol	in	de	regulatie	van	ERK1/2	activiteit,	
hetgeen	impliceert	dat	MAPK-fosfatases	die	(ook)	serine/threonine	residuen	
kunnen	defosforyleren	als	belangrijkste	inactivatoren	van	ERK1/2	optreden		
in	deze	cellen.	
	 Om	op	een	andere	manier	verder	inzicht	te	verkrijgen	in	de	rol	van	de	
PTPRR	isovormen	in	signaaloverdracht	hebben	we	PTPRR	deficiënte	muizen	
gegenereerd	(chapter	3).	We	vonden	dat	de	MAPK	fosforylerings	niveaus	in		
de	hersenen	van	PTPRR	deficiënte	muizen	significant	verschilden	van	die	in	
controle-dieren,	terwijl	de	hersenmorfologie	en	de	aantallen	en	vorm	van	
Purkinje	cellen	niet	verschilden.	Bovendien	lieten	Ptprr-/-	muizen	defecten		
in	motor-coördinatie	en	evenwichtsstoornissen	zien.	Deze	bevindingen	
tonen	aan	dat	de	PTPRR	eiwitten	fysiologische	regulatoren	zijn	van	MAPK	
activiteit	in	neuronaal	weefsel	en	dat	ze	een	bijdrage	leveren	aan	de	mole-
culaire	processen	noodzakelijk	voor	een	goede	motoriek.
	 In	hoofdstuk	4,	beschrijven	we	onze	studie	naar	multimerisatie	als	mogelijk	
regulatie-mechanisme	voor	PTPRR	activiteit.	Als	eerste	werd	de	membraan-
topologie	van	PTP-SL	bepaald	met	behulp	van	selectieve	membraan-permea-
bilisatie	en	immuunfluorescentie-microscopie.	Hieruit	bleek	dat	PTP-SL		
een	type-III	transmembraan	eiwit	is	met	een	topologie	die	gelijk	is	aan	dat		
van	de	receptor-type	isovorm	PTPBR7.	Deze	twee	transmembrane	PTPRR	
eiwitten	konden	bovendien	constitutief	homo-	en	heteromere	complexen	
vormen,	terwijl	de	cytosolische	isovormen	PTPPBSγ-42	en	PTPPBSγ-37	
hiertoe	niet	in	staat	zijn.	Deze	complexering	is	onafhankelijk	van	het	fosfatase	
(PTP)	domein	en	wordt	gemediëerd	door	het	transmembraan-gedeelte	en/of	
het	hydrofobe	domein	dat	aanwezig	is	in	het	N-terminale	domein	van	zowel	
PTPBR7	als	PTP-SL.	Door	experimenteel	de	PTPBR7-complexen	in	een	
monomeer-achtige	toestand	te	dwingen	kon	een	significante	verhoging	van		
de	tyrosine-fosfatase-activiteit	worden	waargenomen.	Dit	alles	versterkt		
het	idee	dat	multimerisatie	een	algemeen	mechanisme	is	om	de	activiteit		
van	receptor-type	eiwit-tyrosine-fosfatases	(RPTPs)	af	te	zwakken.	
	 De	identificatie	van	de	neurotrofe	receptor	TrkA	als	een	PTPRR	substraat	
wordt	beschreven	in	hoofdstuk	5.	De	receptor-type	PTPRR	isovormen	PTPBR7	
en	PTP-SL	bleken	te	kunnen	associëren	met	de	PTK	TrkA	en	in	het	bijzonder	
met	een	gekliefde	vorm,	het	transmembrane	p41	TrkA	fragment.	Deze	interactie	
is	specifiek,	omdat	de	PTPRR	isovormen	niet	associëerden	met	de	sterk	gelij-
kende	TrkB	receptor.	De	transmembrane	PTPRR	isovormen	binden	niet	alleen	
aan	TrkA	maar	kunnen	deze	PTK	ook	defosforyleren.	Belangwekkend	is	ook	
dat	PTPBR7	en	PTP-SL	de	overgang	van	een	immatuur	naar	een	complex-
geglycosyleerde	en	celoppervlak	gelokaliseerde	vorm	(maturatie)	van	TrkA	
promoten.	Wij	concludeerden	dus	dat	PTPBR7	en	PTP-SL	de	mogelijkheid	
hebben	om	neurotrofe	TrkA	signalering	op	verschillende	manieren	te	reguleren.	
	 In	hoofdstuk	6	worden	de	resultaten	uit	dit	proefschrift	samengevat	en	
bediscussiëerd	in	een	bredere	context.	Een	hypothetisch	model	aangaande		
de	invloed	van	de	transmembrane	PTPRR	isovormen	op	TrkA	signalering	
wordt	uiteengezet.	Bovendien	worden	verscheidene	suggesties	voor	vervolg-
onderzoek	voorgesteld	om	zo	uiteindelijk	meer	inzicht	te	krijgen	in	de	fysio-
logische	rol	van	de	verschillende	PTPRR	isovormen	in	cellulaire	signaaltrans-
ductie-netwerken.
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acc.nr.	 accession	number
ARMS	 ankyrin-rich	membrane-spanning
BS3	 bis[sulfosuccinimidyl]	suberate
BSA	 bovine	serum	albumin
BMK1		 big	MAPK1
cAMP	 cyclic	adenosine	monophosphate
CC	 	 coiled-coil	domain
cDNA		 copy	deoxyribonucleic	acid
CL	 	 cleared	lysate
DEAE	 diethylaminoethyl
DMEM	 Dulbecco’s	Modified	Eagle	Medium
DTT	 dithiothreitol
DUSP	 dual-specificity	phosphatase
EDTA		 ethylenediaminetetraacetic	acid
EGF	 epidermal	growth	factor
eGFP		 enhanced	green	fluorescent	protein
ER	 	 endoplasmic	reticulum
ERK	 extracellular	signal-regulated	kinase
FCS	 fetal	calf	serum	
FGFR3	 fibroblast	growth	factor	receptor	3
FLT-3	 FMS-like	tyrosine	kinase
GST	 glutathione-S-transferase
HePTP	 hematopoietic	protein	tyrosine	phosphatase
HA			 haemagglutinin
HeLa		 Henrietta	Lack
HR		 hydrophobic	region
HS	 	 horse	serum
IB	 	 immunoblot
Ig	 	 immunoglobulin
IP		 	 immunoprecipitation
 • Abbreviations
A
b
b
re
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a
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o
n
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JNK		 c-Jun	N-terminal	kinase
kDa	 kilo	Dalton
KIM	 kinase	interaction	motif
KIS		 kinase	specificity	sequence
LAMP	 lysosomes-associated	membrane	protein
LAR		 leukocyte	antigen-related	protein	tyrosine	phosphatase
LC-PTP	 leukocyte-protein	tyrosine	phosphatase
LTRF		 left	to	right	foot
MAPK	 mitogen-activated	protein	kinase
MAPKK	 mitogen-activated	protein	kinase	kinase
MAPKKK		 mitogen-activated	protein	kinase	kinase	kinase
MEK	 meiotic	kinase
MKP	 MAP	kinase	phosphatase
mRNA		 messenger	RNA
NGF	 nerve	growth	factor
NMDA				 N-methyl-D-aspartate
PA	 	 polyacrylamide
PBS	 phosphate	buffered	saline
PC12	 phaeochromocytoma	clone	12
PCPTP1	 PC12	protein	tyrosine	phosphatase	1
PCPTP1-Ce	 PC12	protein	tyrosine	phosphatase	1-Cerebellum
PCR		 polymerase	chain	reaction
PDGF	 platelet-derived	growth	factor	
PDI	 protein	disulphide	isomerase
PEI		 polyethylene-imine
PHEM	 Pipes,	Hepes,	EGTA,	MgCl2
PI3-K		 phosphatidylinositol	3-kinase
PKA	 cAMP-dependent	kinase	
PLCγ	 phospholipase	Cγ
PMSF	 phenyl	methyl	sulfonyl	fluoride
PP			 protein	phosphatase
PTB		 phosphotyrosine	binding
PTP		 protein	tyrosine	phosphatase
PTPBR7	 protein	tyrosine	phosphatase	brain	clone	7
PTP-ER	 protein	tyrosine	phosphatase-ERK/enhancer	of	Ras1			
PTPN5	 protein	tyrosine	phosphatase	non-receptor	type	5
PTPN7	 protein	tyrosine	phosphatase	non-receptor	type	7
PTPPBS	 protein	tyrosine	phosphatase	PC12/BR7/SL
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PTPRR		 protein	tyrosine	phosphatase	receptor	type	R
PTP-SL	 protein	tyrosine	phosphatase	STEP-like
PVDF	 polyvinylidene	fluoride
RNA	 ribonucleic	acid
ROS		 reactive	oxygen	species
RPTP	 receptor-type	protein	tyrosine	phosphatase
RTK		 receptor	tyrosine	kinase
RTLF	 right	to	left	foot
RT-PCR		 reverse	transciptase-polymerase	chain	reaction
SDS-PAGE	 sodium	dodecyl	sulfate-poly	acrylamide	gel	electroforese
SH2		 Src	homology	2
SHP	 SH2	domain-containing	protein	tyrosine	phosphatase
siRNA	 short	interference	ribonucleic	acid	
SP	 	 signal	peptide
STAT	 signal	transducer	and	activator	of	transcription
STEP	 striatal-enriched	phosphatase
TBS-T	 tris	buffered	saline-tween
TM			 transmembrane
Trk		 tropomyosin-related	kinase
UTR	 untranslated	region
VSV	 vesicular	stomatitis	virus
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 • Dankwoord
Tijdens	het	schrijven	van	dit	dankwoord	is	het	alweer	ruim	een	jaar	geleden	
dat	ik	voor	het	laatst	met	de	pipet	in	de	hand	rond	liep	op	de	6de	verdieping.		
Ik	kijk	met	erg	veel	plezier	terug	op	deze	periode	echter	er	is	een	tijd	van	
komen	en	helaas	ook	weer	eentje	van	gaan	(om	er	eens	een	lekkere	cliché		
zin	tegenaan	te	gooien).	Voordat	ik	officieel	afscheid	neem	van	de	6de	ver-
dieping	op	21	februari	2008	zijn	er	uiteraard	nog	wel	een	heel	aantal	mensen	
die	ik	wil	bedanken	voor	hun	grote	dan	wel	kleine	bijdrage	aan	dit	boekje		
en	aan	deze	onvergetelijke	periode.	
	 Als	allereerste	zijn	dit	natuurlijk	Bé	en	Wiljan,	want	zonder	jullie	goed-
keuring	had	dit	project	überhaupt	geen	kans	van	slagen.	Wiljan,	bedankt	voor	
je	goede	begeleiding	en	de	vele	leermomenten,	want	daar	is	tenslotte	een	
promotie	toch	voor.	En	natuurlijk	bedankt	voor	het	opperen	van	nieuwe	ex-
perimenten,	het	meedenken	in	hoofdstukken	en	het	altijd	weer	hameren	op	
controles.	Ook	ben	ik	je	vrouw	Wilma	een	kleine	dank	verschuldigd	voor		
feit	dat	ze	jou	er	op	attendeerde	dat	ik	opzoek	was	naar	een	promotieplaats		
en	zodoende	bij	jou	op	gesprek	mocht	komen.	Bé,	je	gaf	mij	de	vrijheid	en		
de	mogelijkheid	om	het	promotieonderzoek	dat	beschreven	staat	in	dit	proef-
schrift	uit	te	voeren	op	de	afdeling	Celbiologie,	bedankt	hiervoor.	Dorien,	
gedurende	de	10	jaar	dat	we	samen	in	Nijmegen	woonden	hebben	we	praktisch	
al	ons	lief	en	leed	met	elkaar	gedeeld	en	werden	we	door	onze	mede-scheiko’s	
dan	ook	wel	vaak	‘Jut	en	Jul’	genoemd.	Helaas	door	mijn	‘schuld’	kunnen	we	
ons	‘12,5	jaar	in	Nijmegen’	jubileum	niet	meer	halen,	maar	toch	hoop	ik	dat	ik	
nog	vaak	bij	jou	en	Tom	langs	mag	komen	(en	op	jullie	bank	in	slaap	kan	val-
len).	Bedankt	voor	alles	wat	we	hebben	meegemaakt.	Je	bent	echt	een	super-
mens	en	ben	daarom	ook	blij	dat	jij	op	deze	speciale	dag	naast	me	staat	als	
paranimf.	En	zie	het	maar	als	een	generale	voor	de	jouwe…alleen	draaien	we	
dan	de	rollen	om	;-).	Jan	‘met	de	gouden	handjes’	S.,	bedankt	voor	alle	droge	
humor	die	je	bracht	in	onze	U-tjes,	het	absorberen	van	alle	kritiek	over	de	PTPs	
en	uiteraard	het	geven	van	de	‘gouden’	tips.	Je	bent	mijn	langste	PTP-maatje	
en	gelukkig	was	je	blij	verrast	toen	ik	je	vroeg	of	je	mijn	paranimf	wilde	zijn.	
15
Labmeiden	Femke,	Gönül,	Lieke,	Marloes	en	Susan…hoe	had	mijn	promotie	tijd	
er	in	godsnaam	uitgezien	zonder	jullie?	Vast	een	tijd	met	heel	wat	minder	
gefeest,	labmeiden-weekendjes	en	gezelligheid.	Femmie	feestbeest	op	en	top,	
altijd	goedgezind	en	een	keiharde	werker…jammer	dat	je	nu	zover	weg	woont,	
maar	je	doet	het	toch	maar	wel	even	als	enige	van	ons	allemaal.	Gönül,	ik		
heb	respect	voor	je	hoe	jij	in	het	leven	staat	en	de	manier	waarop	je	de	dingen	
tot	nu	toe	bereikt	hebt.	Ik	zie	er	naar	uit	dat	je	straks	mijn	bijna-buurvrouw	
wordt.	Liekje	elastiekje,	bedankt	voor	alle	gekkigheid,	het	luisterend	oor,	het	
geouwehoer	en	de	avonden	dat	we	samen	tot	de	laatste	uurtjes	door	gingen.	
Jij	bent	ook	mijn	SUPER-AIO	;-)	en	wens	je	veel	plezier	en	geluk	op	de	boerde-
rie.	Marloesje,	U-genoot	en	de	rust	zelve,	ik	vond	het	leuk	met	je	samen	in		
ons	u-tje	en	wens	je	veel	succes	en	plezier	met	je	nieuwe	baan.	Susannetje	
koekenpannetje,	bijna	tegelijk	zijn	we	komen	te	werken	bij	Celbio.	Jij	eerst	als	
analist,	maar	nu	druk	bezig	met	je	goedlopende	promotieonderzoek.	Ik	kan	
echt	genieten	van	jouw	directheid	en	je	altijd	vrolijke	humeur.	Succes	met	je	
‘skipping’	en	wees	trots	op	jezelf!!	Beste	Huibert	(zo	pak	ik	je	eens	even	terug	
voor	al	die	keren	dat	je	me	Yvette	noemde),	ook	al	was	het	op	het	lab	voor	jou	
ook	altijd	maar	een	6je….blijf	zoals	je	bent,	dan	vind	ik	je	een	dikke	9!!	En	
nogmaals	bedankt	voor	die	geniale	Indische	rijsttafel.	Studenten	Eveline	en	
Patrick,	bedankt	voor	jullie	bijdragen	aan	de	verschillende	hoofdstukken.		
Voor	mij	was	het	erg	leerzaam	en	hopelijk	heb	ik	jullie	nog	enige	wetenschap-
pelijke	kennis	kunnen	bij	brengen.	Eveline,	de	vele	gezellige	gesprekken	die	
we	hadden	en	de	ochtend	dat	we	uit	de	Carolus	kelder	kwamen	zal	ik	niet		
snel	vergeten.	Renato	(zonder	jouw	muis	geen	hoofdstuk	3)	en	Ineke,	bedankt	
voor	het	uitvoeren	van	de	muizen	experimenten	en	de	vruchtbare	samenwerk-
ing.	
	 Na	een	week	hard	werken	was	er	op	vrijdag	ook	vaak	altijd	even	een	mo-
ment	van	ontspanning.	Jan	K,	Bas,	Ad,	Jack,	Frank	en	enkele	reeds	genoemde	
personen,	bedankt	voor	de	‘diepgaande	gesprekken’	die	dan	werden	gehouden	
en	de	vele	zakjes	chips	die	we	weg	werkten.	En	natuurlijk	de	overige	(ex-)	
collega’s	Edwin,	Rene,	Helma,	Remco,	Mietske,	Rinske,	Rick,	Walther,	Mariska,	
Marieke,	Ralph,	FrankdeL,	Magda,	Marco,	Marianne,	Marjon	en	‘de	Boertjes’	
die	direct	dan	wel	indirect	een	steentje	hebben	bijgedragen	aan	het	voltooien	
van	dit	project.	Tillers	Alessandra,	Ben,	Joost	en	Suzanne	en	(ex-)Moldiertjes	
Eric,	Gerrit,	Rob,	Jos,	Dorien,	Karen,	Jessica,	Jeroen,	Marcel,	Nick,	Martine,	
François,	Bart	en	Gerard	bedankt	voor	de	goede	integratie	en	jullie	gezellig-
heid.	Wilma	en	Karel,	veel	te	vroeg	zijn	jullie	uit	het	leven	gegrepen,	maar		
in	mijn	gedachten	zijn	jullie	nog	steeds	aanwezig.	Alex,	ondanks	dat	onze		
wegen	zich	nu	hebben	gescheiden,	wil	ik	je	toch	bedanken	voor	de	steun	en		
het	vertrouwen	dat	je	me	gaf	gedurende	een	groot	gedeelte	van	mijn	promotie.	
Anna	&	Karin,	helaas	zien	we	elkaar	niet	meer	zo	vaak	als	vroeger	en	ook	al	
snapten	jullie	volgens	mij	maar	weinig	van	dat	promotiegedoe	toch	bedankt	
voor	jullie	onvoorwaardelijke	vriendschap!	Ik	wens	jullie	veel	geluk	toe	samen	
met	de	mannen	in	jullie	leven.	
	 Ook	mede	dankzij	de	steun	van	familie	is	mijn	promotie	succesvol	verlopen	
en	ik	wil	ze	hier	dan	ook	van	harte	voor	bedanken.	Annette,	Peter,	Alrik	en	
Inge,	bedankt	voor	de	warme	ontvangst	binnen	jullie	gezin	en	ik	hoop	samen	
met	Crispijn	nog	veel	met	jullie	te	kunnen	delen.	Grote	broers	Oscar	en	Edwin	
en	Riette,	Rijntje	en	Elrik,	bedankt	voor	het	vertrouwen	in	jullie	kleine	zus	en	
tante.	Ma	en	pa,	de	optelsom	van	de	fijne	jeugd	die	jullie	mij	gaven,	het	feit	dat	
jullie	er	altijd	voor	me	zijn	en	de	overerving	van	vaders	technische	en	moeders	
creatieve	genen	heeft	mij	gemaakt	tot	wie	ik	nu	ben	….duizend	maal	dank	
hiervoor.	
	 En	dan	last	but	definitely	not	least….Crispijn!	Bedankt	voor	het	super	mooie	
vormgeven	van	dit	boekje	en	onze	liefde….je	bent	geweldig!!	
	
Veel	liefs,
Yvet
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